## Thursday, July 8, 2021

### Scientific programme day by day

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11:00 - 12:00</strong></td>
<td>Industry Sponsored Satellite Symposia 1a, 1b &amp; 1c</td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>1: Opening</td>
</tr>
<tr>
<td></td>
<td>L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France</td>
</tr>
<tr>
<td><strong>12:30 - 13:45</strong></td>
<td>Scientific Session 1: Sophisticated strategies within reach</td>
</tr>
<tr>
<td></td>
<td>P. Irving, London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>S. Vermeire, Leuven, Belgium</td>
</tr>
<tr>
<td>12:30 - 12:45</td>
<td>2: Head to head trials</td>
</tr>
<tr>
<td></td>
<td>S. Ghosh, Cork, Ireland</td>
</tr>
<tr>
<td>12:45 - 12:55</td>
<td>3: OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial</td>
</tr>
<tr>
<td></td>
<td>A. Levine, Holon, Israel</td>
</tr>
<tr>
<td>12:55 - 13:10</td>
<td>4: Switching from IV to SC: Benefits beyond merely convenience?</td>
</tr>
<tr>
<td></td>
<td>S. Schreiber, Kiel, Germany</td>
</tr>
<tr>
<td>13:10 - 13:20</td>
<td>5: OP02: Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study</td>
</tr>
<tr>
<td></td>
<td>P. Irving, London, United Kingdom</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>6: OP03: Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab</td>
</tr>
<tr>
<td></td>
<td>N. Kennedy, Exeter, United Kingdom</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>7: Combining biologics: Pros and cons</td>
</tr>
<tr>
<td></td>
<td>D. Rubin, Chicago, United States</td>
</tr>
<tr>
<td><strong>13:45 - 14:00</strong></td>
<td>Break</td>
</tr>
<tr>
<td><strong>14:00 - 15:15</strong></td>
<td>Scientific Session 2: Safety first?</td>
</tr>
<tr>
<td></td>
<td>M. Adamina, Winterthur, Switzerland</td>
</tr>
<tr>
<td></td>
<td>L. Lopetuso, Rome, Italy</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>8: When do we really know the safety profile of a drug?</td>
</tr>
<tr>
<td></td>
<td>J. Rahier, Yvoir, Belgium</td>
</tr>
<tr>
<td>14:15 - 14:25</td>
<td>9: OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study</td>
</tr>
<tr>
<td></td>
<td>S. Schreiber, Kiel, Germany</td>
</tr>
</tbody>
</table>
10: Are we safer with biologics or small-molecules?
E. Louis, Liège, Belgium

11: OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study
N. Narula, Hamilton, Canada

12: OP06: 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry
R. Ungaro, New York, United States

13: Are surgical interventions really more harmful than medical treatment?
O. Faiz, Harrow, United Kingdom

15:30 - 16:35 **Scientific Session 3: Hot and (almost) happening**
J. Burisch, Hvidovre, Denmark
C. Maaser, Lüneburg, Germany

14: How machine learning will affect IBD treatment
S. Ennis, Southampton, United Kingdom

15: Artificial intelligence: A strategic alliance between the machine and the endoscopist
P. Bossuyt, Bonheiden, Belgium

16: OP07: Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative Colitis
B. Lo, Hvidovre, Denmark

17: OP08: Automatic detection of enteric ulcers and erosions in capsule endoscopy using a convolutional neural network
M. Saraiva, Porto, Portugal

18: How to set-up a virtual clinic?
M. Pierik, Maastricht, The Netherlands

16:45 - 17:45 **Digital Oral Presentations (Sessions 1-5)**

17:45 - 17:55 Break

17:55 - 18:55 **Industry Sponsored Satellite Symposia 2a, 2b & 2c**
### Scientific Programme day by day

**Friday, July 9, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:15 - 08:15</strong></td>
<td><em>Industry Sponsored Morning Satellite Symposia 3a, 3b &amp; 3c</em></td>
<td></td>
</tr>
</tbody>
</table>
| **08:30 - 09:20** | *Scientific Session 4.1.: Next generation diagnostics*                                               | T. Kucharzik, Lüneburg, Germany  
N. Yassin, Birmingham, United Kingdom                                                                 |
| **08:30 - 08:50** | 19: *What histology can tell us: Are we speaking the same language?*                               | R. Feakins, London, United Kingdom  
F. Magro Dias, Porto, Portugal                                                                                     |
| **08:50 - 09:00** | 20: *OP09: Patient-reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study* | B. Verstockt, Leuven, Belgium                                                                                      |
| **09:00 - 09:10** | 21: *OP10: Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labeling and gene expression profiling* | M. Iacucci, Birmingham, United Kingdom                                                                                |
| **09:10 - 09:20** | 22: *OP11: Longitudinal profiling of mucosal immune cell composition using multiplex immunohistochemistry identifies drug-and-response-specific patterns in Ulcerative Colitis* | V. Volk, Hannover, Germany                                                                                       |
| **09:20 - 09:30** | **Break**                                                                                           |                                                                                                              |
| **09:30 - 10:30** | *Scientific Session 4.2.: Next generation diagnostics*                                               | T. Kucharzik, Lüneburg, Germany  
N. Yassin, Birmingham, United Kingdom                                                                 |
<p>| <strong>09:30 - 09:45</strong> | 23: <em>Fluorescence in IBD surgery</em>                                                                     | M. Slooter, Amsterdam, The Netherlands                                                                             |
| <strong>09:45 - 09:55</strong> | 24: <em>OP12: Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn’s Disease patients stopping infliximab</em> | N. Pierre, Liège, Belgium                                                                                       |
| <strong>09:55 - 10:05</strong> | 25: <em>OP13: Mucosal organoids capture innate Lymphoid Cells (ILC) tissue-specific development and reveal that Inflammatory Bowel Disease-associated ILC modulate intestinal remodelling</em> | J. Neves, London, United Kingdom                                                                                   |
| <strong>10:05 - 10:15</strong> | 26: <em>OP14: Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD</em>                         | B. Verstockt, Leuven, Belgium                                                                                     |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 - 10:30</td>
<td>27: The future of radiology for IBD</td>
<td>A. Laghi, Rome, Italy</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 - 12:00</td>
<td>Scientific Session 5: The young and the old</td>
<td>T. Raine, Cambridge, United Kingdom, P. Van Rheenen, Groningen, The Netherlands</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>28: Lessons from paediatric IBD – early disease intervention, nutrition, genetic testing</td>
<td>J. Van Limbergen, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>11:00 - 11:10</td>
<td>29: OP15: Cyclic exclusive enteral nutrition to maintain longterm drug-free remission in Paediatric Crohn’s Disease: the CD HOPE study of the GETAID pédiatrique</td>
<td>B. Pigneur Arnaud, Paris, France</td>
</tr>
<tr>
<td>11:10 - 11:25</td>
<td>30: Drug safety in the elderly patients with IBD</td>
<td>T. Lobatón Ortega, Ghent, Belgium</td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td>31: OP16: Characterization of the Clinical Features and Outcomes of Paediatric Patients with Isolated Colonic Crohn’s Disease: A Multi-center Study from the Porto Group of ESPGHAN</td>
<td>D. Shouval, Petah Tiqwa, Israel</td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>32: OP17: Impact of phenotypic and genetic factors on Crohn’s Disease evolution in a cohort of 13,926 patients</td>
<td>Q. Zhang, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>33: Body image and sexuality</td>
<td>P. Tozer, London, United Kingdom</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:50</td>
<td>Industry Sponsored Lunch Satellite Symposia LS1, LS2, LS3 &amp; LS4</td>
<td></td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:15</td>
<td>Scientific Session 6: Bottoms behaving badly</td>
<td>A. Armuzzi, Rome, Italy, Z. Zelinkova, Bratislava, Slovakia</td>
</tr>
<tr>
<td>13:00 - 13:15</td>
<td>34: New surgical approaches for perianal disease</td>
<td>P. Kotze, Curitiba, Brazil</td>
</tr>
<tr>
<td>13:25 - 13:40</td>
<td>36: Looking beyond anti-TNF</td>
<td>S. Vavricka, Zurich, Switzerland</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>37: OP19: Disease course and treatment outcomes of early resected Crohn’s Disease patients: A Danish nationwide cohort study from 1997 to 2015</td>
<td>M. Zhao, Hvidovre, Denmark</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Presentation</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 13:50 - 14:00| **38: OP20:** Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemiBD study  
M. Chaparro, Madrid, Spain |
| 14:00 - 14:15| **39: When it is not IBD**  
G. Bouguen, Rennes, France |
| **14:15 - 14:30** | Break |
| **14:30 - 15:20** | **Scientific Session 7: Milestones in clinical care**  
R. Atreya, Erlangen, Germany  
P. Gionchetti, Bologna, Italy |
| 14:30 - 14:45| **40: Endoscopy or ultrasound for disease activity assessment?**  
M. Lacucci, Birmingham, United Kingdom  
M. Allocca, Rozzano, Italy |
| 14:45 - 15:05| **41: OP21:** Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study  
M. Allocca, Rozzano, Italy |
| 15:05 - 15:20| **42: OP22:** Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCT study  
L. Derikx, Edinburgh, United Kingdom |
| **15:20 - 15:35** | Break |
| **15:35 - 16:25** | **Scientific Session 8: IBD Horizons**  
B. Verstockt, Leuven, Belgium  
J. Torres, Loures, Portugal |
| 15:35 - 15:45| **44: OP23:** Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study  
S. Vermeire, Leuven, Belgium |
| 15:45 - 15:55| **45: OP24:** Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study  
S. Danese, Rozzano, Italy |
| 15:55 - 16:05| **46: OP25:** Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial  
I. Dotan, Petah Tikva, Israel |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:05 - 16:15 | **OP26**: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies  
S. Schreiber, Kiel, Germany |
| 16:15 - 16:25 | **OP27**: WITHDRAWN                                                       |
| 16:25 - 16:45 | **OP28**: The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study  
S. Danese, Rozzano, Italy |
| 16:45 - 17:45 | Digital Oral Presentations (Sessions 6-10)                              |
| 17:45 - 17:55 | **Break**                                                               |
| 17:55 - 18:55 | **Industry Sponsored Satellite Symposia 4a, 4b & 4c**                   |
### Scientific Programme day by day

#### Saturday, July 10, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td><strong>Industry Sponsored Satellite Symposia 5a &amp; 5b</strong></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:55</td>
<td><strong>Scientific Session 9: Basic Science: The microbiome as game changer in IBD?</strong></td>
<td>A. Kaser, Cambridge, United Kingdom</td>
</tr>
<tr>
<td></td>
<td><strong>50: Current knowledge: What is the problem with FMT therapy?</strong></td>
<td>M. Joossens, Ghent, Belgium</td>
</tr>
<tr>
<td>08:45 - 08:55</td>
<td><strong>51: OP29: Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome</strong></td>
<td>L. Bolte, Groningen, The Netherlands</td>
</tr>
<tr>
<td>08:55 - 09:05</td>
<td><strong>52: OP30: Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)</strong></td>
<td>C. Haifer, Sydney, Australia</td>
</tr>
<tr>
<td>09:05 - 09:20</td>
<td><strong>53: Precision editing of the gut microbiota</strong></td>
<td>S. Zeissig, Dresden, Germany</td>
</tr>
<tr>
<td>09:20 - 09:30</td>
<td><strong>54: OP31: RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn’s Disease</strong></td>
<td>B. Bressler, Vancouver, Canada</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td><strong>55: OP32: Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients</strong></td>
<td>C. Verburgt, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>09:40 - 09:55</td>
<td><strong>56: Remote control of immune and metabolic homeostasis by the gut microbiome and its potential impact on health</strong></td>
<td>M. Chamaillard, Lille, France</td>
</tr>
<tr>
<td>09:55 - 10:10</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>10:10 - 11:00</td>
<td><strong>Scientific Session 10.1.: CD and UC: Similar disease burden and treatment goals? Is it the organ or the disease process?</strong></td>
<td>I. Dotan, Petah Tikva, Israel</td>
</tr>
<tr>
<td></td>
<td><strong>57: Disease burden</strong></td>
<td>C. Le Berre, Nantes, France</td>
</tr>
<tr>
<td>10:10 - 10:25</td>
<td><strong>58: OP33: Oral ritucilatinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study</strong></td>
<td>W. Sandborn, La Jolla, United States</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Topic</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 10:35 - 10:50 | **59: Deep healing**  
M. Ferrante, Leuven, Belgium |
| 10:50 - 11:00 | **60: OP34: AJM300, an Oral Antagonist of a4-Integrin, as induction therapy for patients with moderately active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction study**  
M. Watanabe, Tokyo, Japan |
| 11:00 - 11:10 | **Break**                                                                   |
| 11:10 - 12:00 | **Scientific Session 10.2.: CD and UC: Similar disease burden and treatment goals?**  
*Is it the organ or the disease process?*  
I. Dotan, Petah Tikva, Israel  
A. Spinelli, Rozzano, Italy |
| 11:10 - 11:30 | **61: Can we cure IBD with surgery?**  
J. Colombel, New York, United States  
T. Pinkney, Birmingham, United Kingdom |
| 11:30 - 11:40 | **62: OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn’s Disease - Week 48 analysis of the STARDUST trial**  
S. Danese, Rozzano, Italy |
| 11:40 - 11:50 | **63: OP36: Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies**  
P. Bossuyt, Bonheiden, Belgium |
| 11:50 - 12:00 | **64: OP37: Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study**  
S. Danese, Rozzano, Italy |
| 12:00 - 13:00 | **Break**                                                                   |
| 12:10 - 12:50 | **Industry Sponsored Satellite Symposia LS5 & LS6**                          |
| 13:00 - 14:15 | **Scientific Session 11: Personalised medicine**  
U. Kopylov, Tel Aviv, Israel  
J. Gisbert, Madrid, Spain |
| 13:00 - 13:15 | **65: Stratified management for mild and severe IBD?**  
J. Halfvarson, Örebro, Sweden |
I. Al Bakir, London, United Kingdom |
| 13:25 - 13:40 | **67: Precision medicine to prevent disease complications**  
M. Scharl, Zurich, Switzerland |
### Saturday, July 10, 2021, cont.

*Scientific programme day by day*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11: Scientific Programme 68: OP39: The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel Disease</th>
</tr>
</thead>
</table>
A. Bourgonje, Groningen, The Netherlands |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11: Scientific Programme 69: OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial</th>
</tr>
</thead>
</table>
| 13:50 - 14:00 | 69: OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial  
S. Danese, Rozzano, Italy |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11: Scientific Programme 70: Personalised surgery in IBD</th>
</tr>
</thead>
</table>
| 14:00 - 14:15 | 70: Personalised surgery in IBD  
C. Buskens, Amsterdam, The Netherlands |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11: Scientific Programme 14:15 - 14:25 Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15 - 14:25</td>
<td>Break</td>
</tr>
</tbody>
</table>

| Time          | Session 12: ECCO Lecture 71: SARS-CoV-2 vaccination completed – end of pandemic?  
L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France  
B. Siegmund, Berlin, Germany |
|---------------|----------------------------------------------------------------------------------------------------------------------------------|
L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France  
B. Siegmund, Berlin, Germany |

| Time          | Session 12: ECCO Lecture 72: ECCO Lecture: IBD clinical trials: Where do we go from here?  
W. Sandborn, La Jolla, United States |
|---------------|----------------------------------------------------------------------------------------------------------------------------------|
W. Sandborn, La Jolla, United States |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11: Scientific Programme 15:00 - 15:15 The ECCO Film</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:15</td>
<td>The ECCO Film</td>
</tr>
</tbody>
</table>

---

*Note: The schedule may be subject to change.*
“IBD beyond 2020”

Thursday, February 13, 2020

Scientific programme day by day (as of January 15, 2020)
Plenary Hall, Hall D, Reed Messe Wien

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:00</td>
<td>Industry Sponsored Satellite Symposia 1a (Plenary Hall), 1b (Parallel Hall) &amp; 1c (Lehar 1-3)</td>
</tr>
<tr>
<td>12:15 - 12:20</td>
<td>1: Welcome</td>
</tr>
<tr>
<td></td>
<td>H. Tilg, Innsbruck, Austria</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>2: Opening</td>
</tr>
<tr>
<td></td>
<td>S. Danese, Milan, Italy</td>
</tr>
<tr>
<td>12:30 - 14:00</td>
<td>Scientific Session 1: Hot debates in IBD</td>
</tr>
<tr>
<td></td>
<td>W. Reinisch, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>N. Yassin, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>12:30 - 12:50</td>
<td>3: Is there still a place for anti-TNF in 2020?</td>
</tr>
<tr>
<td></td>
<td>T. Ahmad, Exeter, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>J. Lindsay, London, United Kingdom</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>4: OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study</td>
</tr>
<tr>
<td></td>
<td>J. Colombel, New York, United States</td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td>5: Early Crohn's: Surgery first and early medicine later?</td>
</tr>
<tr>
<td></td>
<td>A. Armuzzi, Rome, Italy</td>
</tr>
<tr>
<td></td>
<td>A. D’Hoore, Leuven, Belgium</td>
</tr>
<tr>
<td></td>
<td>D. Ley, Lille, France</td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>7: OP03: Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s Disease: Long-term follow up of the LIRIC trial</td>
</tr>
<tr>
<td></td>
<td>T. Stevens, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>13:40 - 14:00</td>
<td>8: Monitoring IBD: Can we abandon endoscopy?</td>
</tr>
<tr>
<td></td>
<td>C. Hedin, Stockholm, Sweden</td>
</tr>
<tr>
<td></td>
<td>E. Louis, Liège, Belgium</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 16:00</td>
<td><strong>Scientific Session 2: When location makes the difference</strong></td>
<td>J. Burisch, Hvidovre, Denmark</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Magro Dias, Porto, Portugal</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td><strong>9: Colonic versus small bowel CD: Same mechanism – same treatment?</strong></td>
<td>B. Siegmund, Berlin, Germany</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td><strong>10: OP04: Long-term outcomes after ileocolonic resection in Crohn's Disease according to severity of early endoscopic recurrence</strong></td>
<td>N. Hammoudi, Paris, France</td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td><strong>11: Proctitis – a lonely disease?</strong></td>
<td>T. Raine, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td><strong>12: OP05: Validation of the Lémann Index in Crohn's Disease</strong></td>
<td>B. Pariente, Lille, France</td>
</tr>
<tr>
<td>15:30 - 15:40</td>
<td><strong>13: OP06: Comparison between Crohn and celiac diseases small intestine transcriptomics and microbial data define similarities and divergent pathways linked to pathogenesis</strong></td>
<td>Y. Haberman Ziv, Tel Aviv, Israel</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td><strong>14: Surgery for enteric IBD – does location matter?</strong></td>
<td>C. Buskens, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>16:00 - 17:20</td>
<td><strong>Scientific Session 3: Reducing the burden of IBD</strong></td>
<td>N. Ding, Fitzroy, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Gisbert, Madrid, Spain</td>
</tr>
<tr>
<td>16:00 - 16:20</td>
<td><strong>15: Reducing infections with biologics and immunomodulators</strong></td>
<td>S. Ben-Horin, Ramat Gan, Israel</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td><strong>16: Reducing neoplastic complications of therapy</strong></td>
<td>L. Beaugerie, Paris, France</td>
</tr>
<tr>
<td>16:40 - 17:00</td>
<td><strong>17: OP07: The epidemiology of Inflammatory Bowel Diseases among immigrants to Denmark: A population-based cohort study</strong></td>
<td>M. Agrawal, New York, United States</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td><strong>18: OP08: Inflammatory Bowel Disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden</strong></td>
<td>J. Axelrad, New York, United States</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td><strong>19: Reducing postoperative complications</strong></td>
<td>K. Gecse, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td><strong>Digital Oral Presentations (Sessions 1-5)</strong></td>
<td>See pg. 14</td>
</tr>
<tr>
<td>18:45 - 19:45</td>
<td><strong>Industry Sponsored Satellite Symposia</strong></td>
<td>2a (Plenary Hall), 2b (Parallel Hall) &amp; 2c (Lehar 1-3)</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
# Scientific Programme day by day (as of January 15, 2020)

**Plenary Hall, Hall D, Reed Messe Wien**

## Friday, February 14, 2020

### 07:15 - 08:15

**Industry Sponsored Morning Satellite Symposia 3b (Parallel Hall) & 3c (Lehar 1-3)**

### 08:30 - 10:30

**Scientific Session 4: IBD out of the gut**

- **08:30 - 10:30**
  - **OP8: Immunomodulatory mechanisms of faecal microbiota transplantation is associated with clinical response in Ulcerative Colitis – early results from STOP-Colitis**
    - M. Quraishi, Birmingham, United Kingdom
  - **OP9: Immunomodulatory mechanisms of faecal microbiota transplantation is associated with clinical response in Ulcerative Colitis – early results from STOP-Colitis**
    - M. Quraishi, Birmingham, United Kingdom

### 08:30 - 09:00

- **08:30 - 09:00**
  - **20: Orofacial Crohn’s**
    - S. Sebastian, Hull, United Kingdom

### 09:00 - 09:10

- **09:00 - 09:10**
  - **21: OP09: Immunomodulatory mechanisms of faecal microbiota transplantation is associated with clinical response in Ulcerative Colitis – early results from STOP-Colitis**
    - M. Quraishi, Birmingham, United Kingdom

### 09:00 - 09:10

- **09:00 - 09:10**
  - **22: OP10: IgA coating of intestinal microbiota is associated with Inflammatory Bowel Disease in twin pairs discordant for Inflammatory Bowel Disease**
    - E. Brand, Utrecht, The Netherlands

### 09:10 - 09:20

- **09:10 - 09:20**
  - **23: OP11: Exposure to an inflammatory mix re-induces inflammation in organoids of Ulcerative Colitis patients, independent of the inflammatory state of the tissue of origin**
    - K. Arnauts, Leuven, Belgium

### 09:20 - 09:40

- **09:20 - 09:40**
  - **24: Perianal disease or hidradenitis suppurativa – does it matter?**
    - W. Reinisch, Vienna, Austria
    - H. Maier, Vienna, Austria

### 09:40 - 09:50

- **09:40 - 09:50**
  - **25: OP12: The incidence and disease course of Perianal Crohn’s Disease – A Danish nationwide cohort study**
    - M. Wewer, Copenhagen, Denmark

### 09:50 - 10:00

- **09:50 - 10:00**
  - **26: OP13: Glyco-fingerprint as a relevant risk factor on colitis-associated cancer**
    - A. Dias, Porto, Portugal

### 10:00 - 10:10

- **10:00 - 10:10**
  - **27: OP14: Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn’s Disease: A Scandinavian population-based cohort study**
    - O. Olen, Stockholm, Sweden

### 10:10 - 10:30

- **10:10 - 10:30**
  - **28: Managing fatigue in IBD**
    - A. Dignass, Frankfurt, Germany

### 10:30 - 11:00

**Coffee break**

---

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:30</td>
<td><strong>Scientific Session 5: Cartels in IBD – Part 1</strong></td>
<td>I. Dotan, Petah Tikva, Israel</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Irving, London, United Kingdom</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td><strong>29: IBD genetics consortium</strong></td>
<td>S. Vermeire, Leuven, Belgium</td>
</tr>
<tr>
<td>11:20 - 11:30</td>
<td><strong>30: OP15: Multi-omic data integration with network analysis reveal underlying molecular mechanisms driving Crohn’s Disease heterogeneity</strong></td>
<td>B. Verstockt, Leuven, Belgium</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td><strong>31: Prevention initiatives</strong></td>
<td>J. Colombel, New York, United States</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td><strong>32: OP16: Influence of early life factors on the development of intestinal microbiota of infants born to mothers with and without IBD</strong></td>
<td>J. Guedelha Sabino, Leuven, Belgium</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td><strong>33: OP17: Protein intakes and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)</strong></td>
<td>C. Dong, Saint-Mandé, France</td>
</tr>
<tr>
<td>12:10 - 12:20</td>
<td><strong>34: OP18: Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s Disease: The SuPREMe-CD Study</strong></td>
<td>G. Luglio, San Prisco, Italy</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td><strong>35: OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017</strong></td>
<td>C. Burgess, Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td><strong>Break / Guided Poster Session (Hall C)</strong></td>
<td>See pg. 16</td>
</tr>
</tbody>
</table>
**Friday, February 14, 2020, cont.**

*Scientific programme day by day (as of January 15, 2020)*

**Plenary Hall, Hall D, Reed Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13:30 - 15:00</strong></td>
<td><strong>Scientific Session 6: Cartels in IBD – Part 2</strong></td>
<td>F. Baert, Roeselare, Belgium; U. Kopylov, Tel Aviv, Israel</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td><strong>36: Microbiome consortium</strong></td>
<td>J. Raes, Leuven, Belgium</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>37: OP20: The gut microbiota during biological therapy for Inflammatory Bowel Disease</strong></td>
<td>C. Caenepeel, Kessel, Belgium</td>
</tr>
<tr>
<td>14:00 - 14:20</td>
<td><strong>38: TDM consortium</strong></td>
<td>K. Papamichail, Boston, United States</td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td><strong>39: OP21: Positivity thresholds of a total infliximab and adalimumab anti-drug antibody assay:</strong></td>
<td><em>The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service</em></td>
</tr>
<tr>
<td></td>
<td><em>N. Kennedy, Exeter, United Kingdom</em></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td><strong>40: OP22: Crohn’s Disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s Disease</strong></td>
<td>J. Van Limbergen, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td><strong>41: ECCO Quality Standards of Care</strong></td>
<td>G. Fiorino, Rozzano, Italy</td>
</tr>
<tr>
<td><strong>15:00 - 15:30</strong></td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EITHER:</strong></td>
<td><strong>Scientific Session 7: Milestones in clinical care</strong></td>
<td></td>
</tr>
<tr>
<td><strong>15:30 - 16:10</strong></td>
<td><strong>Plenary Hall, Hall D, Reed Messe Wien</strong></td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:37</td>
<td><strong>42: I-CARE</strong></td>
<td>L. Peyrin-Biroulet, Vandoeuvre-Lès-Nancy, France</td>
</tr>
<tr>
<td>15:47 - 15:54</td>
<td><strong>44: UR-CARE</strong></td>
<td>F. Baert, Roeselare, Belgium</td>
</tr>
<tr>
<td>15:54 - 16:04</td>
<td><strong>45: OP24: A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative Colitis</strong></td>
<td>S. Ben-Horin, Ramat Gan, Israel</td>
</tr>
<tr>
<td>16:04 - 16:10</td>
<td><strong>46: IBD Nurse Education Programme</strong></td>
<td>K. Kemp, Manchester, United Kingdom</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:10 - 16:20</td>
<td>47: OP25: Biologics before surgery for IBD – Are they associated with post-operative infectious outcomes? Results from the National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative S. Holubar, Cleveland, United States</td>
</tr>
<tr>
<td>16:20 - 16:30</td>
<td>48: OP26: The first real-life multicentre prospective validation study of the electronic chroendoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis M. Iacucci, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>49: OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension study M. Ferrante, Leuven, Belgium</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td>50: OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores K. Gottlieb, Indianapolis, United States</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>51: OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry M. Chaparro, Madrid, Spain</td>
</tr>
<tr>
<td>17:00 - 17:10</td>
<td>52: OP30: The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s Disease N. Seyed Tabib, Leuven, Belgium</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>15:30 - 17:10</td>
<td><strong>Scientific Session 9: Basic Science: Big Data research</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td><strong>53: Pits and pearls of Big Data in scientific research:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td><strong>54: OP31: Meta-omics reveals microbiome driven proteolysis as a contributing factor to severity of Ulcerative Colitis disease activity</strong></td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td><strong>55: OP32: Mincle signaling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn’s Disease</strong></td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td><strong>56: Integrating multi-omics in IBD</strong></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td><strong>57: OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosa</strong></td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td><strong>58: OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease</strong></td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td><strong>59: How Big Data changes medicine: Concrete examples for translating Big Data into daily clinical practice</strong></td>
</tr>
<tr>
<td>17:25 - 18:25</td>
<td><strong>Digital Oral Presentations (Sessions 6-10)</strong></td>
</tr>
<tr>
<td>18:40 - 19:40</td>
<td><strong>Industry Sponsored Satellite Symposia 4b (Parallel Hall), 4c (Lehar 1-3) &amp; 4d (Strauss 1-2)</strong></td>
</tr>
</tbody>
</table>

**OR = Oral presentation – Best abstracts**

---

**Friday, February 14, 2020, cont.**

*Scientific programme day by day (as of January 15, 2020)*

**Parallel Hall, Hall C, Reed Messe Wien**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Case</th>
</tr>
</thead>
</table>
| 08:30 - 10:20 | **Scientific Session 10: Multidisciplinary cases**  
D. Turner, Jerusalem, Israel  
M. Ferrante, Leuven, Belgium  
P. Michetti, Lausanne, Switzerland  
Y. Panis, Clichy, France |
| 08:30 - 08:40 | 60: **GRADE-ing Guidelines: ECCO CD Treatment**  
J. Torres, Loures, Portugal  
M. Adamina, Winterthur, Switzerland |
| 08:40 - 08:50 | 61: **ECCO ESPGHAN Guideline Pitch on Paediatric CD (update)**  
F. Ruemmele, Paris, France  
P. Van Rheenen, Groningen, The Netherlands |
| 08:50 - 09:00 | 62: **OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study**  
M. Zhao, Hvidovre, Denmark |
| 09:00 - 09:20 | 63: **Clinical Case: Medical CD**  
R. Panaccione, Calgary, Canada |
| 09:20 - 09:30 | 64: **OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease**  
R. Giri, Brisbane, Australia |
| 09:30 - 09:50 | 65: **Clinical Case: Surgical CD**  
P. Kotze, Curitiba, Brazil |
| 09:50 - 10:00 | 66: **OP37: Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response**  
B. Creyns, Leuven, Belgium |
| 10:00 - 10:20 | 67: **Clinical Case: Paediatric CD**  
D. Turner, Jerusalem, Israel |
| 10:20 - 10:50 | **Coffee break**                                      |
| 10:50 - 12:20 | **Scientific Session 11: What have we got outside our box of drugs?**  
| G. Doherty, Dublin, Ireland  
| J. Panes, Barcelona, Spain |
| 10:50 - 11:10 | **68: The multi-refractory paediatric patients: Out of the box therapeutic treatments**  
| D. Wilson, Edinburgh, United Kingdom |
| 11:10 - 11:20 | **69: OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s Disease – A multicenter randomized controlled trial**  
| M. Jongsma, Rotterdam, The Netherlands |
| 11:20 - 11:40 | **70: Drugs of the future: Update on developmental agents**  
| W. Sandborn, La Jolla, United States |
| 11:40 - 11:50 | **71: OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epithelium**  
| R. Mrsny, San Francisco, United States |
| 11:50 - 12:00 | **72: OP40: A core transferable microbiota in responders to faecal microbiota transplant for Ulcerative Colitis shape mucosal T-Cell immunity**  
| R. Longman, New York, United States |
| 12:00 - 12:20 | **73: Pathology guided surgery**  
| P. Borralho Nunes, Lisbon, Portugal  
| A. Spinelli, Rozzano, Italy |
| 12:20 - 12:50 | **Scientific Session 12: ECCO Lecture**  
| S. Danese, Milan, Italy  
| L. Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France  
| J. van der Woude, Rotterdam, The Netherlands |
| H. Clevers, Utrecht, The Netherlands |
| 12:50 - 13:05 | **75: Awards and Closing remarks**  
| S. Danese, Milan, Italy  
| J. van der Woude, Rotterdam, The Netherlands |
| 13:05 - 13:15 | **ECCO Film** |

**OP** = Oral presentation – Best abstracts
**Thursday, March 7, 2019**

*Scientific programme day by day (as of February 1, 2019)*  
*Plenary Hall, Hall A, Bella Center*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:00 - 12:00 | Industry sponsored satellite symposia 1a & 1b & 1c  
See pg. 106                                                    |
| 12:15 - 12:20 | 1: Welcome  
President of Dansk Selskab for Gastroenterologi og Hepatologi  
Henning Glerup, Silkeborg, Denmark                            |
| 12:20 - 12:30 | 2: Opening  
Silvio Danese, Milan, Italy                                    |
| 12:30 - 14:00 | **Scientific Session 1: Silencing IBD**  
Peter Irving, London, United Kingdom  
Britta Siegmund, Berlin, Germany                                |
| 12:30 - 12:50 | 3: Can we prevent IBD?  
Jean-Frédéric Colombel, New York, United States                 |
| 12:50 - 13:00 | 4: OP01: In-depth characterisation of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease  
S. Hu1, A. Vich Vila1, R. Gacesa1, V. Collij1, R. Xavier1, C. Stevens1, M. Daly1, C. Wijmenga1, H. van Dullemen1, G. Dijkstra1, M. Visschedijk1, E. Festen1, J. Fu1, A. Kurlshikov1, A. Zhernakova1, R. Weersma1  
1Universitair Medisch Centrum Groningen, Gastroenterology & Hepatology, Groningen, Netherlands, 2Massachusetts General Hospital, Molecular Biology, Boston, United States, 3Broad Institute, Boston, United States, 4Universitair Medisch Centrum Groningen, Genetics, Groningen, Netherlands, 5Universitair Medisch Centrum Groningen, Pediatrics, Groningen, Netherlands |
| 13:00 - 13:20 | 5: Can we cure IBD?  
Arthur Kaser, Cambridge, United Kingdom                         |
| 13:20 - 13:30 | 6: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s Disease  
C. Li, J. Kuemmerle  
Virginia Commonwealth University, Internal Medicine, Richmond, United States |
| 13:30 - 14:00 | 7: OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT  
J. Cosin-Roger1,2, D. Ortiz-Masia1, F. Canet1, A. Trescoli-Garcia1, S. Calatayud1, M. D. Barrachina1  
1University of Valencia, Pharmacology, Valencia, Spain, 2Hospital Dr Peset, Valencia, Spain, 3University of Valencia, Medicine, Valencia, Spain |
| 13:40 - 14:00 | 8: Are fibrotic complications reversible?  
Geert D’Haens, Amsterdam, The Netherlands  
Massimo Pinzani, London, United Kingdom                        |
| 14:00 - 14:30 | Coffee break                                                                     |

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 16:00</td>
<td><strong>Scientific Session 2: Complementary treatments: The good and the bad</strong></td>
</tr>
<tr>
<td></td>
<td>Shomron Ben-Horin, Tel Aviv, Israel</td>
</tr>
<tr>
<td></td>
<td>Pascal Juillerat, Bern, Switzerland</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td><strong>9: The crazy stuff – what your patients are taking and why?</strong></td>
</tr>
<tr>
<td></td>
<td>Fernando Gomollon Garcia, Zaragoza, Spain</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td><strong>10: OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response</strong></td>
</tr>
<tr>
<td></td>
<td>A. Dias¹, M. Pereira¹, A. Correia¹, I. Alves¹, V. Pinto¹, L. Azevedo¹, L. Maia¹, R. Marcos-Pinto¹, M. Vilanova¹, P. Lago¹, S. Pinho¹</td>
</tr>
<tr>
<td></td>
<td>Institute for Research and Innovation in Health (i3S), Immunology, Cancer &amp; GlycoMedicine, Porto, Portugal, Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, Porto Centre Hospital, Gastroenterology, Porto, Portugal</td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td><strong>11: ECCO Topical Review on complementary medicine</strong></td>
</tr>
<tr>
<td></td>
<td>Joana Torres, Lisbon, Portugal</td>
</tr>
<tr>
<td></td>
<td>Stephan Vavricka, Zurich, Switzerland</td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td><strong>12: OP05: Crohn’s Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn’s Disease: A prospective randomised controlled trial</strong></td>
</tr>
<tr>
<td></td>
<td>J. Van Limbergen¹,², E. Wine³, A. Assa⁴, R. Sigall Boneh⁵, R. Shaoul⁶, M. Kori⁷, S. Cohen⁸, S. Peleg⁹, H. Shamaly¹⁰, A. On¹¹, P. Milman¹², L. Abramas¹³, T. Ziv Baran¹³, S. Grant¹³, A. Levine¹³</td>
</tr>
<tr>
<td></td>
<td>¹Dalhousie University, Halifax, Canada, ²IWK Center, Halifax, Canada, ³University Alberta, Edmonton, Canada, ⁴Schneider Medical Center, Petach Tikva, Israel, ⁵Wolfson Medical Center, Holon, Israel, ⁶Meyer Hospital, Haifa, Israel, ⁷Kaplan Hospital, Rehovot, Israel, ⁸Dana childrens Hospital, Tel Aviv, Israel, ⁹HaEmek Hospital, Afula, Israel, ¹⁰French Hospital, Nazareth, Israel, ¹¹Poriah Hospital, Tiberias, Israel, ¹²Hadassah Hospital, Jerusalem, Israel, ¹³Tel Aviv University, Tel Aviv, Israel, ¹⁴Mount Saint Vincent University, Halifax, Canada</td>
</tr>
<tr>
<td>15:30 - 15:40</td>
<td><strong>13: OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression</strong></td>
</tr>
<tr>
<td></td>
<td>F. Humbel¹, P. Juillerat², M. Scharl¹, B. Misselwitz², P. Schreiner¹, A. Macpherson¹, G. Rogler¹, R. von Känel¹, B. Yilmaz¹, L. Biedermann¹,⁵</td>
</tr>
<tr>
<td></td>
<td>¹University Hospital Zurich, Department of Gastroenterology &amp; Hepatology, Zurich, Switzerland, ²Bern University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland, ³University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, ⁴University of Bern, Maurice Müller Laboratories, Bern, Switzerland, ⁵Equal, Contribution, Switzerland</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td><strong>14: Psychological support in IBD</strong></td>
</tr>
<tr>
<td></td>
<td>Yoram Inspector, London, United Kingdom</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
**Thursday, March 7, 2019, cont.**

*Scientific programme day by day (as of February 1, 2019)*

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>16:00 - 17:20</th>
<th>Scientific Session 3: Precision medicine: Lessons to learn and paths to the future</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:20</td>
<td>15: What is system biology? Dermot McGovern, Los Angeles, United States</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>16: Multi-omics profiling of IBD Jonas Halfvarson, Örebro, Sweden</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Digital Oral Presentations (Sessions 1-5) See pg. 41</td>
</tr>
<tr>
<td>18:45 - 19:45</td>
<td>Industry sponsored satellite symposia 2a &amp; 2b &amp; 2c See pg. 108</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
**Friday, March 8, 2019**

*Scientific programme day by day (as of February 1, 2019)*

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td>Industry sponsored satellite symposia 3b &amp; 3c</td>
<td>See pg. 109</td>
</tr>
<tr>
<td>08:30 - 10:30</td>
<td>Scientific Session 4: Best practice in UC</td>
<td>Andre D’Hoore, Leuven, Belgium Henit Yanai, Petah Tikva, Israel</td>
</tr>
<tr>
<td></td>
<td><strong>20:</strong> When do you start a biologic?</td>
<td>Simon Travis, Oxford, United Kingdom</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td><strong>21:</strong> OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis</td>
<td>L. Peyrin-Biroulet1, J. Panés2, M. Chiolean3, J. Zhang4, S. Vermeire5, V. Jairath6, A. Yarur7, C. Cabell8, S. Naik9, W. J. Sandborn10</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td><strong>22:</strong> OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis</td>
<td>J. Brooks1, 2, D. Modos3, P. Sudhakar4, 5, D. Fazekas4, 6, A. Zoufir4, A. Watson1, 7, M. Tremelling1, B. Verstockt3, S. Vermeire6, A. Bender1, S. Carding8, T. Korcsmáros9, 10</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td><strong>23:</strong> OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture</td>
<td>K. Arnauts2, 3, B. Verstockt1, 3, M. Vancamelbeke1, S. Vermeire1, 3, C. Verfaillie1, M. Ferrante1, 3</td>
</tr>
<tr>
<td>09:10 - 09:20</td>
<td><strong>24:</strong> Where is the exit?</td>
<td>Marc Ferrante, Leuven, Belgium</td>
</tr>
</tbody>
</table>
### Scientific Programme Day by Day (as of February 1, 2019)

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:40 - 09:50 | 25: **OP12:** Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake  
*R. Gropp*¹, H. Jodeleit¹, J. Caesar¹, C. Villarroel Aguilera¹, F. Beigel²,³, S. Breiteneicher³, J. Stallhofer³, M. Siebeck¹  
¹Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, ²Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, ³Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany |
| 09:50 - 10:00 | 26: **OP13:** Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study  
*K. Li*, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman  
Janssen Research & Development, LLC, Spring House, United States |
| 10:00 - 10:10 | 27: **OP14:** Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study  
*W. J. Sandborn*¹, S. Schreiber², S. D. Lee³, J. O. Lindsay⁴, X. Hebuterne³, W. Zhou³, F. Cataldi⁵, A. P. Lacerda⁶, B. Huang⁷, W. Xie⁷, E. V. Loftus Jr⁷  
¹University of California San Diego, La Jolla, United States, ²University Hospital Schleswig-Holstein, Kiel, Germany, ³University of Washington, Seattle, United States, ⁴Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁵Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, ⁶AbbVie Inc., North Chicago, United States, ⁷Mayo Clinic, Rochester, United States |
| 10:10 - 10:30 | 28: Precision surgery in UC  
Yves Panis, Clichy, France |

**10:30 - 11:00 Coffee break**

*OP = Oral presentation – Best abstracts*
### Scientific Session 5: IBD around the world

**Toshifumi Hibi**, Tokyo, Japan
**Giovanni Maconi**, Milan, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Organization(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>29: Vaccination and travelling with IBD: An update</strong></td>
<td>Jean-François Rahier, Yvoir, Belgium</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td><strong>30: OP15: Cost-analysis in a prospective European population-based inception cohort. Is there a cost-saving effect of biological therapy?</strong></td>
<td>J. Burisch1, H. Vardi2, D. Schwartz3, Z. Krznaric4, P. L. Lakatos5, M. Fumery6, L. Kupcinskas7, F. Magro8, E. Belousova9, P. Oksanen10, N. Arebi11, E. Langholz12, S. Turcan13, R. D’Inca14, V. Hernandez15, D. Valpiani16, Z. Vegg17, M. Giannotta17, K. H. Katsanos18, D. Duricova19, K. R. Nielsen20, H. A. L. Kievit21, P. Ellul22, R. Salupere23, A. Goldis24, I. Kaimakliotis25, N. Pedersen26, V. Andersen27, J. Halfvarson28, S. Sebastian29, J. F. Dahlerup30, P. Munkholm1, S. Odes1, Epi-IBD</td>
<td>1North Zealand University Hospital, Frederikssund, Denmark, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 3Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, 4University Hospital Center Zagreb, Zagreb, Croatia, 5Semmelweis University, Budapest, Hungary, 6Amiens University and Hospital, Amiens, France, 7Lithuanian University of Health Sciences, Kaunas, Lithuania, 8Hospital de São João, Porto, Portugal, 9Moscow Regional Research Clinical Institute, Moscow, Russian Federation, 10Tampere University Hospital, Tampere, Finland, 11Imperial College London, London, United Kingdom, 12Herlev University Hospital, Herlev, Denmark, 13State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, 14Azienda Ospedaliera di Padova, Padova, Italy, 15Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 16Soragna Hospital, Forlì, Italy, 17Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, 18University Hospital Hospital, Ioannina, Greece, 19Charles University, Prague, Czech Republic, 20National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 21Herning Hospital, Herning, Denmark, 22Mater Dei Hospital, Msida, Malta, 23Tartu University Hospital, Tartu, Estonia, 24University of Medicine ‘Víctor Babes’, Timisoara, Romania, 25American Gastroenterology Center, Nicosia, Cyprus, 26Slagelse Hospital, Department of medicine, Denmark, 27Regional Hospital of Viborg, Viborg, Denmark, 28Örebro University, Örebro, Sweden, 29Hull and East Yorkshire NHS Trust, Hull, United Kingdom, 30Aarhus University Hospital, Aarhus, Denmark</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>31: Management of IBD outside of Europe: The example of India</strong></td>
<td>Rupa Banerjee, Hyderabad, India</td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td><strong>32: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results</strong></td>
<td>S. Bloom1, T. Iqbal2, C. Nwokolo3, M. Smith4, D. O'Donoghue5, J. Hall6, B. Dzyngle6</td>
<td>1University College London Hospitals, London, United Kingdom, 2Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, 3University Hospital Coventry &amp; Warwickshire, Coventry, United Kingdom, 4Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, 5St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 6Sublimity Therapeutics, Solana Beach, United States</td>
</tr>
</tbody>
</table>
Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:10</td>
<td><strong>33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies</strong>&lt;br&gt;R. Huang1, H. Irizar2, R. Kosoy3, W.-M. Song3, A. Dinarzo3, K. Hao3, J. Rogers4, A. Arreja2, M. Mahajan1, A. Stojmirovic2, J. Perrigoue2, C. Brodmerkel3, S. Plevy1, J. Friedman2, J.-F. Colombel4, M. Dubinsky3, B. Sands4, E. Schadt1, A. Kasarskis1, B. Losic2, C. Argmann3, M. Suarez-Farinas1,2,3&lt;br&gt;1Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, United States, 2University College of London, London, United Kingdom, 3Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, United States, 4Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, 5Janssen Research &amp; Development, Janssen Biotech, Johnson &amp; Johnson, Spring House, United States</td>
</tr>
<tr>
<td>12:10 - 12:30</td>
<td><strong>34: East meets West: Epidemiology of IBD</strong>&lt;br&gt;Johan Burisch, Copenhagen, Denmark&lt;br&gt;Siew Ng, Hong Kong, China</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>Break / Guided Poster Session (Hall B) &lt;br&gt;See pg. 65</td>
</tr>
<tr>
<td>13:30 - 14:40</td>
<td><strong>Scientific Session 6: New ways of doing endoscopy and imaging in IBD</strong>&lt;br&gt;Hankje Escher, Rotterdam, The Netherlands&lt;br&gt;Christian Maaser, Lüneburg, Germany</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td><strong>35: Assessing bowel damage in CD from adult to childhood</strong>&lt;br&gt;Anne Griffiths, Toronto, Canada</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s Disease: The paediatric Crohn’s Disease adalimumab level-based optimisation treatment (PAILOT) trial</strong>&lt;br&gt;A. Assa1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Reniwi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir10&lt;br&gt;1Schneider Children’s Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children’s medical center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Sheba Medical Center, Pediatric Gastroenterology and Nutrition, Ramat Gan, Israel, 4Sheba Medical Center, Pediatric Gastroenterology and Nutrition, Ramat Gan, Israel, 5Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, 6Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, 7Sheba Zedek Medical Center, Pediatric Gastroenterology and Nutrition, Ramat Gan, Israel, 8Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel, 9Rambam Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s Disease: The paediatric Crohn’s Disease adalimumab level-based optimisation treatment (PAILOT) trial</strong>&lt;br&gt;A. Assa1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Reniwi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir10&lt;br&gt;1Schneider Children’s Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children’s medical center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Sheba Medical Center, Pediatric Gastroenterology and Nutrition, Ramat Gan, Israel, 4Sheba Medical Center, Pediatric Gastroenterology and Nutrition, Ramat Gan, Israel, 5Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, 6Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, 7Sheba Zedek Medical Center, Pediatric Gastroenterology and Nutrition, Ramat Gan, Israel, 8Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel, 9Rambam Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel</td>
</tr>
</tbody>
</table>

**IIS Abstract Award**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:20</td>
<td><strong>37: Best practice in screening for dysplasia</strong>&lt;br&gt;Marietta Iacucci, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>
### Scientific programme day by day (as of February 1, 2019)

**Plenary Hall, Hall A, Bella Center (Session 7 & 8)**

#### 14:20 - 14:30

**38: OP19:** Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis


¹Sheba Medical Center, Tel Hashomer, Israel, ²Cincinnati Children Hospital Medical Center, Cincinnati, United States, ³Broad Institute of MIT and Harvard University, Cambridge, United States, ⁴Georgia Institute of Technology, Atlanta, United States, ⁵University of North Carolina, Chapel Hill, United States, ⁶Emory University, Atlanta, United States, ⁷Hospital For Sick Children, Toronto, Canada, ⁸Harvard School of Public Health, Boston, United States, ⁹Broad Institute of MIT and Harvard University, Boston, United States, ¹⁰Connecticut Children’s Medical Center, Hartford, United States

#### 14:30 - 14:40

**39: OP20:** Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease

A. Lewis¹, R. Jeffrey¹, T. Kumagai¹, C. J. Hawkey², M. M. Clark², M. Allez³, J. Satsangi⁴, G. Rogler⁵, A. Silver⁶, J. O. Lindsay⁶

¹Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, ²Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United Kingdom, ³Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMR 1160, Paris Diderot, Sorbonne Paris-Cité University, Paris, France, ⁴Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ⁵Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, ⁶Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom

#### 14:40 - 15:10 Coffee break

**EITHER:**

#### 15:10 - 15:55

**Scientific Session 7: ECCO Fellowships and Grants**

(Plenary Hall, Hall A, Bella Center)

Janneke van der Woude, Rotterdam, The Netherlands

**15:10 - 15:17**

**40:** Outcomes from the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease

Arie Levine, Tel Aviv, Israel

**15:17 - 15:24**

**41:** Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn’s Disease

Sudharshan Elangovan, Thuwal, Saudi Arabia

**15:24 - 15:31**

**42:** Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease

Sales Ibiza, Lisbon, Portugal

**15:31 - 15:38**

**43:** Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning

Aria Zand, Los Angeles, United States

**15:38 - 15:45**

**44:** Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease

Mathieu Uzzan, Clichy, France

**15:45 - 15:55**

**45:** Announcement of ECCO Fellowships & Grants 2019

**OP = Oral presentation – Best abstracts**
### Scientific Session 8: IBD Horizons

**15:55 - 16:55**

<table>
<thead>
<tr>
<th>15:55 - 16:05</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>46: OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients</strong></td>
</tr>
<tr>
<td>S. Vermeire¹, X. Hébuterne², P. Napora³, M. Wisniewska-Jarosinska⁴, G. Kiss⁵, A. Bourrèlle⁶, Z. Przemyslaw⁷, J. Nitcheu⁸, P. Gineste⁹, <strong>J.-M. Steens</strong>¹⁰, H. Ehrlich¹¹</td>
</tr>
<tr>
<td>¹University Hospitals Leuven, Leuven, Belgium, ²CHU Nice Hospital Archet, Nice, France, ³Piotr Napora Centrum Badań Klinicznych Lekarze Sp., Wrocław, Poland, ⁴SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Lodz, Poland, ⁵Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, ⁶CHU Nantes Hotel Dieu, Nantes, France, ⁷KO-Med, Lublin, Poland, ⁸Abivax, Paris, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16:05 - 16:15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>47: OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis</strong></td>
</tr>
<tr>
<td>M. Barnhoorn¹, L. Plug¹, E. Muller - de Jonge¹, E. Bos², A. van der Meulen-de Jong³, H. Verspaget³, L. Hawinkels¹</td>
</tr>
<tr>
<td>¹Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, ²Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16:15 - 16:25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>48: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models</strong></td>
</tr>
<tr>
<td>J. Shin¹, N. Ha¹, D. Bae¹, D.-h. Suh¹, J.-Y. Baek¹, J. H. Jun¹, Y. J. Lee¹, Y. I. Choi¹, K. H. Ryu¹, G. S. Yoon¹, J. Park², S.-M. Lee³, S.-K. Seo⁴, J. W. Lee⁵, J. S. Kim⁶,⁵</td>
</tr>
<tr>
<td>¹Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, ²Hallym University, Department of Biomedical Science, Chuncheon, South Korea, ³Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, ⁴Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, ⁵Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16:25 - 16:35</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>49: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn’s Disease</strong></td>
</tr>
<tr>
<td>M. Fumery¹, L. Peyrin-Biroulet², S. Nancey³, R. Altweg³, P. Veyraud⁴, G. Bouguen⁵, S. Viennot⁶, F. Poullenot⁶, I. Filippi⁶, A. Buisson⁷, A. Bozon⁸, C. Gilletta⁸, F. Brazier⁸, L. Pouillon⁸, B. Flourie¹⁰, L. Boivin⁹, L. Siproudhis¹⁰, D. Laharie¹, X. Roblin¹¹, X. Treton¹¹</td>
</tr>
<tr>
<td>¹Amiens University Hospital, Gastroenterology, Amiens, France, ²Nancy University Hospital, Gastroenterology, Nancy, France, ³Lyon University Hospital, Lyon, France, ⁴Montpellier University Hospital, Gastroenterology, Montpellier, France, ⁵Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, ⁶Rennes University Hospital, Gastroenterology, Rennes, France, ⁷Caen University Hospital, Gastroenterology, Caen, France, ⁸Bordeaux University Hospital, Gastroenterology, Bordeaux, France, ⁹Nice University Hospital, Gastroenterology, Nice, France, ¹⁰Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, ¹¹Hôpital Beaujon, Gastroenterology, Clichy, France, ¹²Toulouse University Hospital, Gastroenterology, Toulouse, France, ¹³Amiens University Hospital, Gastroenterology, Amiens, France, ¹⁴Lyon University Hospital, Gastroenterology, Lyon, France, ¹⁵Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:35 - 16:45 | **50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's Disease**  
**E. Dreesen**¹, F. Baert¹, D. Laharie², P. Bossuyt³, Y. Bouhnik⁴, A. Buisson⁵, G. Lambrechts⁶, E. Louis⁷, B. Oldenburg⁸, B. Pariente⁹, M. Pierik¹⁰, C. J. van der Woude¹¹, G. D’Haens¹², S. Vermeire¹³, A. Gils¹⁴  
¹University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium  
²AZ Delta, Department of Gastroenterology, Roeselare, Belgium  
³Hôpital Haut-Lévêque, Service d’Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France  
⁴Imelda General Hospital, IBD Clinic, Bonheiden, Belgium  
⁵Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France  
⁶Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France  
⁷AZ Damiaan, Department of Gastroenterology, Oostende, Belgium  
⁸Liège University Hospital, Department of Gastroenterology, Liège, Belgium  
⁹University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, Netherlands  
¹⁰Huriez Hospital, Lille  
¹¹University, Department of Gastroenterology and Hepatology, Lille, France  
¹²University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands  
¹³Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands  
¹⁴Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands  
¹⁵University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium  
¹⁶University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium |
| 16:45 - 16:55 | **51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn’s Disease: Final results from the GEMINI L TS study**  
¹University Hospitals Leuven, Leuven, Belgium  
²Icahn School of Medicine at Mount Sinai, New York, United States  
³Western University, London, Canada  
⁴University of California San Diego, La Jolla, United States  
⁵Humanitas University, Milan, Italy  
⁶Academic Medical Centre, Amsterdam, Netherlands  
⁷University of Calgary, Calgary, Canada  
⁸University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States  
⁹Shafran Gastroenterology Research Center, Winter Park, United States  
¹⁰Takeda Pharmaceuticals, Cambridge, United States  
¹¹Mayo Clinic College of Medicine, Rochester, United States |

**OP** = Oral presentation – Best abstracts
### Scientific Session 9: Basic Science: Immune cells and microbes: A happy marriage? (C1-M4-5, Hall C, Bella Center)

**Scientific Programme**

- **15:10 - 15:30**
  - **52: Metabolic profiling – the new player in microbiome research**
    - Stefan Schreiber, Kiel, Germany

- **15:30 - 15:40**
  - **53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease**
    - V. van Unen¹, N. Li¹, T. Abdelaal¹, ², ³, Y. Kooy-Winkelaar¹, L. Ouboter¹, ⁴, G. Beyrend¹, T. Höllt³, ⁵, L. Mearin⁷, A. Witte⁶, H. Escher⁶, B. Lelieveldt¹⁰, ¹¹, A. van der Meulen - de Jong², F. Koning¹
    - ¹Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, ²Delft University of Technology, Delft Bioinformatics Lab, Delft, Netherlands, ³Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁴Leiden University Medical Center, Department of Gastroenterology, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁶Delft University of Technology, Computer Graphics and Visualization, Delft, Netherlands, ⁷Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁸Alrijne Hospital, Department of Gastroenterology, Leiderdorp, Netherlands, ⁹Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ¹⁰Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, ¹¹Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands

- **15:40 - 15:50**
  - **54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis**
    - M. Neyazi¹, N. Ilott², Oxford IBD Cohort study investigators¹, S. Travis¹, C. Arancibia¹, F. Powrie², A. Geremia¹
    - ¹University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, ²University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom

- **15:50 - 16:10**
  - **55: Using mucosal immune pathways to predict disease outcome**
    - Ahmed Hegazy, Berlin, Germany

- **16:10 - 16:20**
  - **56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer**
    - L. R. Lopetuso¹, C. De Salvo², L. Di Martino², W. Goodman³, F. Scaldaferrí³, A. Armuzzi³, A. Gasbarriii, T. T. Pizarro²
    - ¹Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy, ²Case Western Reserve University, Cleveland, United States, ³Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy

---

**OP = Oral presentation – Best abstracts**
Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
C1-M4-5, Hall C, Bella Center (Session 9)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 16:20 - 16:30 | **57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis**  
K. Machiels¹, M. Ferrante¹, ², N. Davani¹, A. Wolthuis¹, A. D’Hoore³, S. Vermeire¹, ²  
¹KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, ³University Hospitals Leuven, Abdominal surgery, Leuven, Belgium |
| 16:30 - 16:50 | **58: Resolution pathways: Next frontier to control intestinal inflammation**  
Silvia D’Alessio, Milan, Italy |

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 17:05 - 18:05 | **Digital Oral Presentations (Sessions 6 - 10)**  
See pg. 41 |
| 18:35-19:35 | **Industry sponsored satellite symposia 4a & 4c & 4d**  
See pg. 112 |

OP = Oral presentation – Best abstracts
### Scientific Session 10: The cycle of IBD life in clinical practice

**Glen Doherty, Dublin, Ireland**
**Richard Russell, Glasgow, United Kingdom**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:20</td>
<td><strong>Scientific Programme</strong>&lt;br&gt;<strong>Scientific programme day by day (as of February 1, 2019)</strong>&lt;br&gt;<strong>Plenary Hall, Hall A, Bella Center</strong></td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>59: Challenges in managing the elderly&lt;br&gt;Guillaume Savoye, Rouen, France</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>60: OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation&lt;br&gt;K. Tsuchiya, S. Watanabe, T. Shirasaki, R. Nishimura, N. Katsukura, S. Hibiya, R. Okamoto, T. Nakamura, M. Watanabe&lt;br&gt;Tokyo Medical and Dental University and Dental University and, Tokyo, Japan</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>61: OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD&lt;br&gt;R. J. Dart, P. Vantourout, P. M. Irving, A. Hayday&lt;br&gt;1King’s College London, Peter Gorer Dept of Immunobiology, London, United Kingdom, 2Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, 3Guy’s and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom</td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td>62: The reproductive phase: Practical recommendations&lt;br&gt;Ailsa Hart, London, United Kingdom</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td>63: OP33: Late-breaking Abstract</td>
</tr>
<tr>
<td>09:40 - 09:50</td>
<td>64: OP34: Late-breaking abstract</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts

1Amiens University Hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 3IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare, Roeselare, Belgium, 52nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, 6Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 7Cumming School of Medicine, University of Calgary, Calgary, Canada, 8Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 9Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 10Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnitsya, Ukraine, 11Universitatea de Medicina si Farmacie, Timișoara, Romania, 12Translational Gastroenterology, University of Oxford, Oxford, United Kingdom, 13Gastro-Entérologie & Nutrition Clinique, Hopital de l’Archet 2, Nice, France, 14University Hospitals Leuven, Leuven, Belgium, 15Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 16Humanitas University, Istituto Clinico Humanitas, Milan, Italy, 17Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, 18Claude Huriez Hospital, Lille University, Lille, France, 19Skane University Hospital, Lund, Sweden, 20Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, 21Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, 22University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 23Hépato-Gastro-Entérologie, Hôpital de Brabois, Nancy, France, 24Hépato-gastroentérologie et d’oncologie digestive, Hôpital Haut-Lévêque, Pessac, France, 25Kingsbury Hospital, Cape Town, South Africa, 26Hospital Clínico de Zaragoza, ILS Aragón, Zaragoza, Spain, 27Military Medical Academy named after S.M.Kirov, Saint-Petersburg, Russian Federation, 28Department of Internal Medicine I, Kiel University, Kiel, Germany, 29IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 30Uppsala University Hospital, Uppsala, Sweden, 31Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

### 66: Cancer risk in children with IBD, an under-recognised issue

Arie Levine, Tel Aviv, Israel

**OP** = Oral presentation – Best abstracts
### Scientific Session 11: Towards the future of IBD

**Scientific Programme day by day (as of February 1, 2019)**

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 - 11:10</td>
<td>67: Artificial intelligence augmenting medical management</td>
<td>Vishal Nangalia, London, United Kingdom</td>
</tr>
<tr>
<td>11:10 - 11:40</td>
<td>68: OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in Inflammatory Bowel Disease</td>
<td>T. Sato¹, K. Li¹, K. Hayden¹, L. Tomsho¹, F. Baribaud¹, C. Brodmerkel¹, L. E. Greenbaum¹, J. R. Friedman¹, M. Curran¹, Y. Imai², S. E. Telesco¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Janssen Research &amp; Development, LLC, Spring House, United States, ²Janssen Pharmaceutical K.K., Tokyo, Japan</td>
</tr>
<tr>
<td>11:20 - 11:50</td>
<td>69: Robot and surgeon: How will a partnership work?</td>
<td>Antonino Spinelli, Milan, Italy</td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>70: OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI W. J. Sandborn¹, B. E. Sands¹, R. Panaccione¹, C. D. O’Brien¹, H. Zhang¹, J. Johanss¹, L. Peyrin-Biroulet³, G. Van Assche³, S. Danese³, S. R. Targan³, M. T. Abreu³, T. Hisamatsu¹⁴, P. Szapary¹⁴, C. Marano¹⁴</td>
<td>W. J. Sandborn¹, B. E. Sands¹, R. Panaccione¹, C. D. O’Brien¹, H. Zhang¹, J. Johanss¹, L. Peyrin-Biroulet³, G. Van Assche³, S. Danese³, S. R. Targan³, M. T. Abreu³, T. Hisamatsu¹⁴, P. Szapary¹⁴, C. Marano¹⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of California San Diego, La Jolla, United States, Icahn School of Medicine at Mount Sinai, New York, United States, University of Calgary, Calgary, Canada, Janssen Research &amp; Development, LLC, Spring House, United States, Nancy University Hospital, Université de Lorraine, Nancy, France, University of Leuven, Leuven, Belgium, Humanitas Research Hospital, Milan, Italy, Cedars-Sinai Medical Center, Los Angeles, United States, University of Miami Miller School of Medicine, Miami, United States, Kyorin University, Tokyo, Japan</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>71: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis</td>
<td>G. R. D’Haens¹, W. J. Sandborn², M. Ferrante¹, B. R. Bhandari¹, E. Berliba³, T. Hibi³, J. Tuttle³, J. B. Canavan⁴, S. Friedrich⁴, M. Durante⁴, V. Arora⁴, B. Feagan⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amsterdam University Medical Centers, Amsterdam, Netherlands, University of California San Diego, La Jolla, California, United States, UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, Delta Research Partners, LLC, Båstrop, LA, United States, Nicolae Testemiţanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, Eli Lilly and Company, Indianapolis, Indiana, United States, Western University, Robarts Clinical Trials Inc, London, Ontario, Canada</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
**Saturday, March 9, 2019, cont.**

*Scientific programme day by day (as of February 1, 2019)*

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 - 12:50</td>
<td><strong>Scientific Session 12: ECCO Lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Silvio Danese, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td>Laurent Peyrin-Biro, Vandeuvre-Les-Nancy, France</td>
</tr>
<tr>
<td>12:20 - 12:50</td>
<td>73: <strong>ECCO Lecture: Inflammatory cytokines from discoveries to therapies</strong></td>
</tr>
<tr>
<td></td>
<td>Charles Dinarello, Denver, United States</td>
</tr>
<tr>
<td>12:50 - 12:55</td>
<td>74: <strong>Awards and closing remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Silvio Danese, Milan, Italy</td>
</tr>
<tr>
<td>12:55 - 13:00</td>
<td>75: <strong>The ECCO Film</strong></td>
</tr>
</tbody>
</table>

*OP = Oral presentation – Best abstracts*
Thursday, February 15, 2018

*Scientific programme day by day (as of January 15, 2018)*

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:00 - 12:00 | *Industry sponsored satellite symposia 1a & 1b*  
Please refer to pages 104-105 |
| 12:15 - 12:20 | **1: Welcome**  
Rainer Schöfl, Linz, Austria |
| 12:20 - 12:30 | **2: Opening**  
Julián Panés, Barcelona, Spain |
| 12:30 - 14:00 | **Scientific session 1: Exploring IBD over time**  
Axel Dignass, Frankfurt, Germany  
Charlotte Hedin, Stockholm, Sweden |
| 12:30 - 12:50 | **3: Can we diagnose pre-symptomatic IBD?**  
Joana Torres, Lisbon, Portugal |
| 12:50 - 13:00 | **4: OP001: Gut barrier dysfunction – a primary defect in twins with Crohn's Disease predominantly caused by genetic predisposition**  
A. V. Keita1, C.M. Lindqvist2, A. Öst3, C. DL Magana1, I. Schoultz1, J. Halfvarson4  
1Linköping University, Department of Clinical And Experimental Medicine, Linköping, Sweden  
2Örebro University, Department of Medical Sciences, Örebro, Sweden  
3Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden  
4Örebro University, Department of Gastroenterology, Örebro, Sweden |
| 13:00 - 13:20 | **5: Targeting early disease - lessons from rheumatoid arthritis**  
Daniel Aletaha, Vienna, Austria |
| 12:50 - 13:00 | **6: OP002: Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn's Disease cohort shows a quiescent disease course for a substantial proportion of the population**  
D. Wintjens1,2, F. Bergy3, E. Saccenti4, S. Jeuring1,2, M. Romberg-Camps5, L. Oostenbrug1, A. Masclée1,2, D. Jonkers1,2, V. Martins dos Santos1,4, M. Pierik1,2  
1Maastricht University Medical Center +, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands  
2Maastricht University Medical Center +, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands  
3LifeGlimmer GmbH, Berlin, Germany  
4Wageningen University & Research, Laboratory of Systems and Synthetic Biology, Wageningen, The Netherlands  
5Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Authors/Institutions</th>
</tr>
</thead>
</table>
| 13:30 - 13:40 | **7: OP003:** Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics | M. de Bruyn\textsuperscript{1,2}, V. Ballet\textsuperscript{3}, S. Verstockt\textsuperscript{1}, B. Verstockt\textsuperscript{1,3}, G. Van Assche\textsuperscript{1,3}, M. Ferrante\textsuperscript{1,3}, K. Machiels\textsuperscript{1}, S. Vermeire\textsuperscript{1,3}  
\textsuperscript{1}Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, \textsuperscript{2}Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, \textsuperscript{3}University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium,  
| 13:40 - 14:00 | **8: Evolution of disease pathways over time in CD – early versus late disease** | Gerhard Rogler, Zurich, Switzerland                                                  |
| 14:00 - 14:30 | **Coffee break**                                                              |                                                       |
| 14:30 - 16:00 | **Scientific session 2:** Novel treatment strategies \  Matthieu Allez, Paris, France \  Tim Raine, Cambridge, United Kingdom |                                                       |
| 14:30 - 14:50 | **9: Combining new drugs with different mechanisms** | Shomron Ben-Horin, Ramat Gan, Israel                                                   |
| 14:50 - 15:00 | **10: OP004:** The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis | H. Schmitt\textsuperscript{1}, U. Billmeier\textsuperscript{1}, J. Ulmschneider\textsuperscript{1}, C. Admyre\textsuperscript{1}, T. Knittel\textsuperscript{1}, A. Zargar\textsuperscript{1}, M.F. Neurath\textsuperscript{1}, R. Atreya\textsuperscript{1}  
\textsuperscript{1}Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, \textsuperscript{2}InDex Pharmaceuticals AB, Stockholm, Sweden |
| 15:00 - 15:20 | **11: Stem cell therapy for perianal CD – multidisciplinary management**       | Silvio Danese, Milan, Italy  
Damián García-Olmo, Madrid, Spain                                                        |
| 15:20 - 15:30 | **12: OP005:** Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's Disease patients | A. Strik\textsuperscript{1}, M. Löwenberg\textsuperscript{1}, C. Ponsioen\textsuperscript{1}, K. Gecse\textsuperscript{1}, C. Buskens\textsuperscript{1}, W. Bemelman\textsuperscript{1}, G. D'Hae\textsuperscript{1}  
\textsuperscript{1}Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, \textsuperscript{2}Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, \textsuperscript{3}Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands |
| 15:30 - 15:40 | **13: OP006:** Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study | S. Danese\textsuperscript{1}, M. Neurath\textsuperscript{2}, A. Kopon\textsuperscript{1}, S. Zakko\textsuperscript{1}, T. Simmons\textsuperscript{2}, R. Fogel\textsuperscript{2}, J. Maccarchone\textsuperscript{2}, X. Zhan\textsuperscript{1}, K. Usiskin\textsuperscript{2}, D. Chitkara\textsuperscript{1}  
\textsuperscript{1}Istituto Clinico Humanitas, Milan, Italy, \textsuperscript{2}University Erlangen, Nurnberg, Germany, \textsuperscript{3}Torunskie Centrum Gastrologiczne Gastromed, Torun, Poland, \textsuperscript{4}Connecticut Clinical Research Foundation of Bristol Hospital, Bristol, United States, \textsuperscript{5}West Gastroenterology Medical Group, Los Angeles, United States, \textsuperscript{6}Clinical Research Institute of Michigan, Chesterfield, United States, \textsuperscript{7}Celgene Corporation, Summit, United States |
| 15:40 - 16:00 | **14: Small molecules are back**                                               | Laurent Peyrin-Biroulet, Vandeouvre-Les-Nancy, France                                  |

\textsuperscript{OP} = Oral presentation – Best abstracts
### Thursday, February 15, 2018, cont.

**Scientific programme day by day (as of January 15, 2018)**

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:20</td>
<td><strong>15: Sexual dysfunction in IBD patients</strong>&lt;br&gt;Barry Hall, Dublin, Ireland&lt;br&gt;Paula Ministro, Viseu, Portugal</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td><strong>16: How to prevent disability</strong>&lt;br&gt;Jean-Frédéric Colombel, New York City, United States</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td><strong>17: OP007: Detection of mucosal healing with a serum marker panel in adalimumab treated patients with Ulcerative Colitis</strong>&lt;br&gt;M. de Bruyn¹,², R. Ringold¹, E. Martens³, M. Ferrante¹,², G. Van Assche¹,⁴, G. Opdenakker², A. Dukler¹, S. Vermeire¹,²</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td><strong>18: OP008: α4β7 integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages</strong>&lt;br&gt;L. Schleier¹, M. Wiendl¹, M.-T. Binder¹, R. Atrey¹, A. Watson², C. Neufert¹, I. Atrey¹, M.F. Neurath¹, S. Zundler¹</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td><strong>19: Patient perspective on treatment goals</strong>&lt;br&gt;Corey Siegel, Lebanon, United States</td>
</tr>
</tbody>
</table>

**Scientific session 3: Returning to a normal life with IBD**

**Y-ECCO Abstract Award**

**17:30 - 18:30**

**Digital Oral Presentations (Sessions 1-5)**

Please refer to page 43

**18:45 - 19:45**

**Industry sponsored satellite symposia 2a & 2b & 2c**

Please refer to pages 105-106

---

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td><strong>Industry sponsored satellite symposia, 3a &amp; 3b &amp; 3c</strong>&lt;br&gt;Please refer to pages 106-107</td>
</tr>
<tr>
<td>08:30 - 10:30</td>
<td><strong>Scientific session 4: The future of IBD diagnosis and disease prediction</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 08:50</td>
<td>20: <strong>ECCO-ESGAR Guidelines: Present and future of diagnostic techniques for IBD</strong>&lt;br&gt;Christian Maaser, Luneburg, Germany&lt;br&gt;Jaap Stoker, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>21: <strong>OP009: A combination of clinical, serological and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study.</strong>&lt;br&gt;H. Sarter1,2, G. Savoye1, O. Turck3,4, F. Vasseur1, G. Marot1,2, B. Pariente1,8, S. Singh1, J.F. Colombel1,9, C. Gower-Rousseau1,2, M. Fumery1,2&lt;br&gt;1Lille Hospital and University, Public Health, Epidemiology and Economic Health, Epimad registry, Regional house of clinical research, Lille, France, 2Lille University, Lille Inflammation Research International Center LIRIC-UMR 995 Inserm, Lille, France, 3Rouen Hospital and University, Gastroenterology Unit, Epimad registry, Rouen, France, 4Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille, France, 5Lille University and Hospital, Biostatistics Unit, EA 2694, Lille, France, 6Lille University and Hospital, EA 2694 - Santé publique: épidémiologie et qualité des soins, Lille, France, 7Inria Lille Nord Europe, Modal, Lille, France, 8Gastroenterology Unit, Epimad registry, Lille Hospital and University, Lille, France, 9Prometheus Laboratories Inc, San Diego, United States, 10Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 11Amiens Hospital and University, Gastroenterology Unit, EPIMAD Registry, Amiens, France</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>22: <strong>OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative Colitis</strong>&lt;br&gt;I. Al Bakir1,2, K. Curtius1, A.-M. Baker1, T.S.O. Clarke1, M. Moorghen1, M. Jansen1, M. Rodriguez-Justo4, S. Leedham1, T. Graham4, A. Hart4&lt;br&gt;1Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 2St. Mark's Hospital, Inflammatory Bowel Disease Unit, Harrow, United Kingdom, 3St. Mark's Hospital, Pathology Department, Harrow, United Kingdom, 4University College London Hospital, Pathology Department, London, United Kingdom, 5Henry Wellcome Building of Genomic Medicine, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom</td>
</tr>
<tr>
<td>09:10 - 09:20</td>
<td>23: <strong>OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects</strong>&lt;br&gt;R. Barbieri1, W. Uniken Venema1, A. Vich Vila1, Y. Li1, L. Franke1, F. van Dijk1, N. De Klein1, M. Swertz1, S. Sanna1, M.D. Voskuil1, M. Rivas2, R. Xavier2, M. Daly2, G. Dijkstra3, E.A. Festen4, R.K. Weersma1&lt;br&gt;1UMCG, Groningen, The Netherlands, 2The Broad Institute of MIT and Harvard, Cambridge, United States</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:40 - 09:50</td>
<td>25: OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn's Disease patients H. Schmitt1, U. Billmeier1, W. Dieterich1, T. Rath1, S. Sonnewald1, S. Reid2, S. Hirschmann1, K. Hildner1, M.J. Waldner1, J. Mudter1, A. Hartmann1, R. Grützmann1, C. Neufert1, T. Münster1, M.F. Neurath1, R. Atreya1 1Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, 2Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany, 3Sana Kliniken Ostholstein, Eutin, Germany, 4Friedrich-Alexander-University Erlangen-Nürnberg, Department of Pathology, Erlangen, Germany, 5Friedrich-Alexander-University Erlangen-Nürnberg, Department of Surgery, Erlangen, Germany, 6Friedrich-Alexander-University Erlangen-Nürnberg, Department of Anesthesiology, Erlangen, Germany</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td>26: OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease A. Sazonovs1, N.A. Kennedy2, C. Bewshea2, L. Moutsianas1, G.J. Walker2, K. De Lange1, J. Goodhand2, C. Anderson1, J. Barrett1, PANTS Investigator Consortium, T. Ahmad2 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 2University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td>27: OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome A. Vich Vila1, F. Imhann1, V. Collij1, S.A. Jankipersadsing1, T. Gurry2, Z. Mujagic1, A. Kuriishkov1, M.J. Bonder1, J. Xiaofang2, E. Tighelhaar1, J. Dekens1, V. Peters1, M.D. Voskuil1, M.C. Visschedijk1, F. Eleonora A.M.1, G. Dijkstra1, A.A. Masclée1, M.H. Hofker1, R. Xavier1, E.J. Alm1, J. Fu1, C. Wijmenga1, D.M. Jonkers1, A. Zhernakova1, R.K. Weersma1 1University Medical Center Groningen, Groningen, The Netherlands, 2Massachusetts Institute of Technology, Boston, United States, 3Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 4Broad Institute, Boston, United States</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>28: Integration of “omics” and potential for clinical practice Claudio Fiocchi, Cleveland, United States</td>
</tr>
</tbody>
</table>

10:30 - 11:00 Coffee break

11:00 - 12:30 Scientific session 5: New opportunities for IBD care and research Dominik Bettenworth, Münster, Germany James Lindsay, London, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:20</td>
<td>29: Remote monitoring Daniel Baumgart, Berlin, Germany</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>30: Point of care tests Ann Gils, Leuven, Belgium</td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>31: Web-based registries Pascal Juillerat, Bern, Switzerland</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>32: <strong>OP015</strong>: Biomarker correlation with endoscopic outcomes in patients with Crohn’s Disease: Data from CALM</td>
</tr>
<tr>
<td></td>
<td>¹Medical University of Vienna, Vienna, Austria, ²University of Calgary, Calgary, Canada, ³Imelda General Hospital, Bonheiden, Belgium, ⁴“AZ” Delta Roeselare-Menen, Menen, Belgium, ⁵Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, ⁶Oxford University Hospitals, Oxford, United Kingdom, ⁷Istituto Clinico Humanitas, Milan, Italy, ⁸University of California San Diego, La Jolla, United States, ⁹Academic Medical Center, Amsterdam, The Netherlands, ¹⁰AbbVie AB, Solna, Sweden, ¹¹AbbVie Inc., North Chicago, United States, ¹²Icahn School of Medicine at Mount Sinai, New York, United States</td>
</tr>
<tr>
<td>12:10 - 12:30</td>
<td>33: <strong>Can the patient become an investigator?</strong></td>
</tr>
<tr>
<td></td>
<td>Germari Bianchi, Milan, Italy</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>Break / Guided Poster Session</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Scientific session 6: Best perioperative management of IBD</td>
</tr>
<tr>
<td></td>
<td>Yves Panis, Clichy, France</td>
</tr>
<tr>
<td></td>
<td>Walter Reinisch, Vienna, Austria</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>34: <strong>Get your patient fit for surgery</strong></td>
</tr>
<tr>
<td></td>
<td>Peter Irving, London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Paulo Kotze, Curitiba, Brazil; Calgary, Canada</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>35: <strong>OP016</strong>: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014</td>
</tr>
<tr>
<td></td>
<td>D. Kalman³, C. Nordenvall², A. Hallqvist Everhov¹, J.F. Ludvigsson⁴, M.C. Sachs⁵, A. Ekbom⁶, O. Olén⁷, P. Myrelid⁸</td>
</tr>
<tr>
<td></td>
<td>¹Division of surgery, Department of Clinical and Experimental Medicine, Faulty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, ²Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, ³Department of Clinical Science and Education, Södersjukhuset; Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, ⁵Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs’ Children and Youth Hospital, Stockholm, Sweden</td>
</tr>
</tbody>
</table>
Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)
Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:20</td>
<td><strong>36: Enhanced postoperative recovery pathways</strong>&lt;br&gt;Gionata Fiorino, Milan, Italy&lt;br&gt;Antonino Spinelli, Milan, Italy</td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td><strong>37: OP017: Transanal minimally-invasive proctectomy with ileal pouch and anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database</strong>&lt;br&gt;G. Pellino, K. Sahnan, M. Penna, S. Adegbola, P. Chandrasinghe, A. Spinelli, R. Hompes, J. Warusavitarne, on behalf of the International TaTME Registry Collaborative.&lt;br&gt;1Università della Campania, Unit of Colorectal Surgery, Naples, Italy, 2St Mark’s Hospital, Fistula Research Unit, London, United Kingdom, 3Imperial College, Department of Surgery and Cancer, London, United Kingdom, 4Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, United Kingdom, 5Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 6Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, 7Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy</td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td><strong>38: OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling</strong>&lt;br&gt;C. Mascaraque, S. Elangovan, L. Petti, A. Piontini, C. Correale, V. Arena, B. Romano, F. Ungaro, V. Garlatti, S. D'Alessio, G. Fiorino, A. Spinelli, S. Danese, S. Vetrano,&lt;br&gt;1Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy, 2Humanitas University, Department of Biomedical Sciences, Rozzano, Italy, 3Catholic University of Rome, Institute of Pathology, Rome, Italy, 4Humanitas Research Institute, Colon and Rectal Surgery, Rozzano, Italy</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td><strong>39: Preventive strategy after resection surgery in CD</strong>&lt;br&gt;Pierre Michetti, Lausanne, Switzerland</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

EITHER:

<table>
<thead>
<tr>
<th>15:30 - 16:10</th>
<th>Scientific session 7: ECCO Fellowships and Grants (Plenary Hall, Hall D, Messe Wien)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gerhard Rogler, Zurich, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Dino Tarabar, Belgrade, Serbia</td>
</tr>
</tbody>
</table>

15:30 - 15:37

40: Outcomes from the ECCO-IOIBD Fellowship 2016
The interleukin-1 pathway as a putative new target in pediatric inflammatory bowel disease
Sharon Veenbergen, Rotterdam, The Netherlands

15:37 - 15:44

41: Outcomes from the ECCO-IOIBD Fellowship 2017
Precision Medicine for IBD using advanced machine learning
Aria Zand, Los Angeles, United States

15:44 - 15:50

42: Announcement of Fellowships and Grants 2018

15:50 - 16:00

43: OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)
S. Paramsothy1,2, M. Kamm1,4, S. Nielsen1, N. Deshpande1, J. Faith2, J. Clemente2, R. Paramsothy1, A. Walsh4, J. van den Bogarde1, D. Samuel8, R. Leong8, S. Connor3, W. Ng3, E. Lin3, M. Wilkins3, J.-F. Colombel2, T. Borody1, H. Mitchell1, N. Kaakoush1
1University of New South Wales, Sydney, Australia, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3St Vincent’s Hospital, Melbourne, Australia, 4University of Melbourne, Melbourne, Australia, 5Liverpool Hospital, Sydney, Australia, 6St Vincent’s Hospital, Sydney, Australia, 7Nambour General Hospital, Nambour, Australia, 8Bankstown-Lidcombe Hospital, Sydney, Australia, 9Centre for Digestive Diseases, Sydney, Australia

16:00 - 16:10

44: OP020: The clinical determinants affect gut microbial profile of Inflammatory Bowel Disease patients
P. Juillerat1, E. Yilmaz2, R. Wiest1,2, G. Rogler1, A.J. Macpherson1
1Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland, 2University of Bern, Department of Biomedical Research, Bern, Switzerland, 3University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland

OP = Oral presentation – Best abstracts
Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)
Plenary Hall, Hall D, Messe Wien (Session 7 & 8)
Parallel Hall, Hall C, Messe Wien (Session 9)

16:10 - 17:10
Scientific session 8: IBD Horizons
(Plenary Hall, Hall D, Messe Wien)
Filip Baert, Roeselare, Belgium
Gerassimos Mantzaris, Athens, Greece

45: OP021: Autologous haematopoietic stem cell transplantation for Crohn’s Disease: A retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party


1. Oxford University Hospitals, Department of Haematology, Oxford, United Kingdom, 2. Département d’Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France, 3. Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France, 4. Hospital Clinic of Barcelona, Haematology Department, Barcelona, Spain, 5. Hospital Clinic of Barcelona, Gastroenterology Department, Barcelona, Spain, 6. University Hospitals Leuven, Department of Haematology, Leuven, Belgium, 7. University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 8. Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany, 9. University of Freiburg, Department of Gastroenterology, Freiburg, Germany, 10. Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Italy, 11. Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy, 12. Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, 13. Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital, Department of Haematology, London, United Kingdom, 14. Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain, 15. AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d’Île-de-France (site constitutif), Filière FAI2R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France, 16. Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, United Kingdom, 17. Queen’s Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, United Kingdom, 18. Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, United Kingdom

16:20 - 16:30

46: OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study

S. Schreiber1, L. Peyrin-Biroulet2, B. Boland3, P.D. Higgins4, A. Armuzzi5, J. Terdiman6, W. Zhou7, G. Alperovich8, F. Cataldi9, S. Goteti10, A.P. Lacerda11


OP = Oral presentation – Best abstracts
### Scientific Programme 13th Congress of ECCO - Vienna

**Friday, February 16, 2018, cont.**

*Scientific programme day by day (as of January 15, 2018)*

**Plenary Hall, Hall D, Messe Wien (Session 7 & 8)**

**Parallel Hall, Hall C, Messe Wien (Session 9)**

<table>
<thead>
<tr>
<th>OP</th>
<th>Best abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)</td>
</tr>
<tr>
<td>S. Danese¹, B. Feagan², W. Sandborn³, J.-F. Colombel⁴, S. Vermeire⁵, S. Jones⁶, K. Brennan⁷, J. Bornstein⁷</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td></td>
</tr>
</tbody>
</table>

| 48 | OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study |
| G.R. D’Haens¹, W. Reinisch², S.D. Lee³, D. Tarabar⁴, E. Louis⁵, M. Klopotacka⁶, J. Klaus⁷, S. Schreiber⁷, D.I. Park⁸, X. Hébuterne⁹, F. Cataldi¹⁰, A. Banerjee¹¹, K. Gorelick¹², W.J. Sandborn¹³ |
| 16:40 - 16:50 |

| 49 | OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis |
| 16:50 - 17:00 |

**OP** = Oral presentation – Best abstracts
Friday, February 16, 2018, cont.
Scientific programme day by day (as of January 15, 2018)
Plenary Hall, Hall D, Messe Wien (Session 7 & 8)
Parallel Hall, Hall C, Messe Wien (Session 9)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 17:00 - 17:10 | **50: OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score-matched analysis**
|               | D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire5, A. Weiss6, A. Winters7, S. Chabalney8, S. Aniwan9, J.L. Koliangi-Pace10, G. Kochhar3, B. Boland3, S. Singh1, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm6, S. V. Sagi8, M. Fischer8, D. Hudesman8, S. Chang8, D. Lukin1, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen5, W.J. Sandborn1, B.E. Sands1, J.-F. Colombel8, S. Kane6, E.V. Loftus9, P.S. Dulai10
|               | 1Icahn School of Medicine at Mount Sinai, New York, United States, 2Cleveland Clinic Foundation, Cleveland, United States, 3Indiana University, Indianapolis, United States, 4Montefiore Medical Center, New York, United States, 5Mayo Clinic, Rochester, United States, 6Dartmouth-Hitchcock Medical Center, Lebanon, United States, 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, 8New York University (NYU), New York, United States, 9North Shore University Hospital, Manhasset, United States, 10Lenox Hill Hospital, New York, United States, 11University of Mississippi, Jackson, United States |

**OR:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:30 - 17:10 | **51: Pathogenesis of fistulising IBD**
|               | Michael Scharl, Zurich, Switzerland                                      |
| 15:30 - 15:50 | **52: OP027: SUCNR1 receptor mediates intestinal fibrosis**
|               | 1Fisabio, Hospital Dr Peset, Valencia, Spain, 2University of Valencia, Valencia, Spain, 3University of Zurich, Gastroenterology, Zurich, Switzerland |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:00 - 16:10 | **53: OP028: Single cell RNA sequencing of t-cells in Crohn’s Disease identifies tissue specific drug targets**
|               | E. Festen1, R. Weersma2, W.T. Uniken Venema1, M.D. Voskuil2, D. Graham2
|               | 1University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 2The Broad Institute of MIT and Harvard, Cambridge, United States |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:10 - 16:30 | **54: Stress-induced controllers of intestinal inflammatory reactions**
|               | Hermona Soreq, Jerusalem, Israel                                         |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:30 - 16:40 | **55: OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice**
|               | M. Yabal1, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1
|               | 1Technical University Munich, 3Medizinische Klinik, Munich, Germany, 2Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany, 3Technical University Munich, Institut for Pathologie, Munich, Germany |
Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)
Parallel Hall, Hall C, Messe Wien (Session 9)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
</table>
| 16:40 - 16:50 | **56: OP030: Loss of PTPN2 in dendritic cells promotes T cell activation and expression of co-stimulatory molecules**  
L. Hering¹, C. Gottier¹, S. Lang¹, B. Becher², G. Rogler¹, M. Scharl¹, M. Spalinger¹  
¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ²University of Zurich, Institute of Experimental Immunology, Zurich, Switzerland |
| 16:50 - 17:10 | **57: How the gut speaks to the liver: Novel insights from PSC pathogenesis**  
Herbert Tilg, Innsbruck, Austria |

17:20 - 18:20  
**Digital oral presentations (Sessions 6 - 10)**  
Please refer to pages 43-67

18:35-19:35  
**Industry sponsored satellite symposia 4a & 4c & 4d**  
Please refer to pages 108-110
# Scientific Programme

## 13th Congress of ECCO - Vienna

### Saturday, February 17, 2018

**Scientific programme day by day (as of January 15, 2018)**

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
</table>
| 08:30 - 10:20 | **Scientific session 10: Growing up with IBD safely** | **58: Safe use of drugs in paediatric and elderly populations**  
Pieter Hindryckx, Ghent, Belgium  
Gigi Veereman, Brussels, Belgium |
| 08:30 - 08:50 | 59: OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study | N.A. Kennedy1, G. Heap12, B. Hamilton1, G.J. Walker1, C. Bewshea1, S. Bouri1, J. Goodhand1, PANTS Investigator Consortium, T. Ahmad1  
1University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom,  
2AAbbvie, Chicago, United States,  
3St Mark’s Hospital, IBD Unit, London, United Kingdom |
1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium,  
2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium,  
3University Hospitals Leuven, Department of Paediatric Gastroenterology, Leuven, Belgium,  
4Ziekenhuis Oost-Limburg-Campus Sint-Jan, Department of Gastroenterology and Hepatology, Genk, Belgium,  
5CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium,  
6Imelda ziekenhuis, Department of Gastroenterology and Hepatology, Bonheiden, Belgium,  
7Maria ziekheizhuis Noord-Limburg, Department of Gastroenterology and Hepatology, Eperelt, Belgium,  
8Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium,  
9University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium,  
10Sint-Trudo Ziekenhuis, Department of Gastroenterology and Hepatology, Tongeren, Belgium,  
11AZ Velsius, Department of Gastroenterology and Hepatology, Tongeren, Belgium,  
12AZ Klinia, Department of Gastroenterology and Hepatology, Brasschaat, Belgium,  
13AZ Groeninge, Department of Gastroenterology and Hepatology, Kortrijk, Belgium |
| 09:00 - 09:10 | 61: ESPGHAN-ECCO Guidelines: Update on Paediatric UC Treatment | Richard Russell, Glasgow, United Kingdom,  
Dan Turner, Jerusalem, Israel |
1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States,  
2UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, United States,  
3Western University, Robarts Clinical Trials, London, ON, Canada,  
4Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy,  
5Pfizer Inc, Collegeville, PA, United States |

**OP** = Oral presentation – Best abstracts
63: OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the eneida registry


1Hospital Son Llàtzer, Palma, Spain, 2Universitat Autònoma de Barcelona, Barcelona, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 4CIBERehd Instituto de Salud Carlos III, Madrid, Spain, 5Hospital Clínic, Barcelona, Spain, 6Hospital Reina Sofía, Córdoba, Spain, 7Hospital Puerta de Hierro, Majadahonda, Spain, 8Hospital Bellvitge, L’Hospitalet, 9Hospital de Llobregat, Spain, 10Hospital Clínic de Barcelona, Spain, 11Hospital Ramón y Cajal, Madrid, Spain, 12Hospital La Paz, Madrid, Spain, 13Hospital Clínico de Valencia, Valencia, Spain, 14Hospital La Princesa, Madrid, Spain, 15Hospital Universitario Miguel Servet, Zaragoza, Spain, 16Hospital Universitario Central de Asturias, Oviedo, Spain, 17Hospital Clínico Lozano Blesa, Zaragoza, Spain, 18Hospital Parc Taulí, Sabadell, Spain, 19Hospital Santa Creu i Sant Pau, Barcelona, Spain, 20Hospital Universitario Marqués de Valdecilla, Santander, Spain, 21Complexo Hospital Universitario de Vigo, Vigo, Spain, 22Hospital Virgen de la Macarena, Sevilla, Spain, 23Hospital Universitario Burgos, Burgos, Spain, 24Hospital Río Hortega, Valladolid, Spain, 25Hospital Mutua de Terrassa, Terrassa, Spain, 26Hospital del mar, Barcelona, Spain, 27Hospital General Universitario de Alicante, Alicante, Spain, 28Hospital Clínico de Málaga, Málaga, Spain, 29Hospital de octubre, Madrid, Spain, 30Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, 31Hospital Dr Josep Trueta, Girona, Spain, 32Hospital General Universitario de Elche, Elche, Spain, 33Hospital General de Ciudad Real, Ciudad Real, Spain, 34Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, 35Hospital Manises, Manises, Spain, 36Consorci sanitari de Terrassa, Terrassa, Spain, 37Hospital Santa Lucía, Cartagena, Spain, 38Hospital Clínico Universitario Valladolid, Valladolid, Spain, 39CH de Navarra, Pamplona, Spain, 40Hospital Universitario de Salamanca, Salamanca, Spain, 41Hospital de Cruces, Barakaldo, Spain, 42Hospital Galdakao, Galdakao, Spain, 43Instituto Biodonostia UPV/EHU, (Donostia, Spain, 44Hospital San Jorge, Huesca, Spain, 45Hospital Nuestra Sra Candelaria, Sta Cruz Tenerife, Spain, 46Hospital Mancha Centro, Alcazar de San Juan, Spain, 47Hospital General Universitario Valencia, Valencia, Spain, 48Hospital Moisés Broggi, St Joan Despí, Spain, 49CH Santiago, Santiago de Compostela, Spain, 50CH de Palencia, Palencia, Spain, 51Hospital Universitario de Canarias, La Laguna, Spain, 52Hospital Torrejón, Torrejón, Spain, 53CH de Castello, Castelló, Spain, 54Hospital Sant Joan de Déu-Althaia, Manresa, Spain, 55Hospital General de Tomelloso, Tomelloso, Spain, 56Hospital Basurto, Bilbao, Spain, 57Hospital Villadeans, Villadeans, Spain, 58Hospital Royo Vilanova, Zaragoza, Spain, 59Hospital General, Segovia, Spain, 60Hospital Son Espases, Palma, Spain, 61Hospital Arnau de Vilanova, Lleida, Spain, 62Complejo Hospitalario de Jaén, Jaén, Spain

09:40 - 09:50

OP = Oral presentation – Best abstracts
### Scientific programme day by day (as of January 15, 2018)

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker and Affiliations</th>
</tr>
</thead>
</table>
| 09:50 - 10:00 | **64: OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations**  
G. Walker¹,², J. Harrison³, M. Voskuil⁴, G. Heap¹,², N. Heerasing¹,², P. Hendy¹,², J. Koskela¹,², M. Daly¹,², H. Sokol¹,², D. McGovern¹,², R. Weersma⁴, C. Bewshea¹, M. Weedon¹,², J. Goodhand¹,², N. Kennedy¹,², T. Ahmad¹,², IBD Pharmacogenetics Study Group  
¹University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom,  
²Royal Devon & Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom,  
³University of Exeter, Exeter Medical School Bioinformatics Team, Exeter, United Kingdom,  
⁴University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands,  
⁵The Broad Institute of MIT and Harvard, Cambridge, United States,  
⁶Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, United States,  
⁷Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition, Paris, France,  
⁸Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Gastroenterology, Los Angeles, United States | |
| 10:00 - 10:20 | **65: Monitoring and improving safety of new agents**  
Miguel Regueiro, Pittsburgh, United States | |
| 10:20 - 10:50 | **Coffee break** | |
| 10:50 - 12:20 | **Scientific session 11: Colorectal Cancer in IBD**  
Jessica de Bruyn, Amsterdam, The Netherlands,  
Mircea Diculescu, Bucharest, Romania | |
| 10:50 - 11:10 | **66: Molecular basis of dysplasia in IBD – clues for cancer prevention therapies?**  
Laurence Egan, Galway, Ireland | |
| 11:10 - 11:20 | **67: OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study**  
M. de Jong³, S. van Tilburg¹,², L. Nissen³, W. Kievit¹, I. Nagtegaal³, F. Hoentjen¹, L. Derikx¹,²  
¹Radboud University Nijmegen Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands,  
²Jeroen Bosch Hospital, Gastroenterology and hepatology, S Hertogenbosch, The Netherlands,  
³Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, The Netherlands | |
| 11:20 - 11:40 | **68: Serrated lesions in IBD**  
Roger Feakins, London, United Kingdom,  
Maria Pellise, Barcelona, Spain | |
| 11:40 - 11:50 | **69: OP037: Risk of cancer in Inflammatory Bowel Disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors – a cross-sectional and follow-up analysis of the Swiss IBD cohort Study**  
T. Greuter⁴, S. Schärli¹, C. Barthel¹, J.-B. Rossel¹, L. Biedermann¹, B. Misselwitz¹, S. Vavricka¹, G. Rogler¹, M. Schärli¹, on behalf of the Swiss IBD Cohort Study Group  
¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland,  
²University Hospital Lausanne - CHUV, Institute of Social and Preventive Medicine, Lausanne, Switzerland | |

**OP** = Oral presentation – Best abstracts
Saturday, February 17, 2018, cont.
Scientific programme day by day (as of January 15, 2018)
Plenary Hall, Hall D, Messe Wien

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:50 - 12:00 | **70: OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation**  
S. Zundler¹, E. Becker¹, M. Spocinska¹, L. Parga-Vidal¹, R. Stark², R. Atreya¹, T. Rath¹, M. Leppkes¹, C. Neufert¹, I. Atreya¹, K. van Gisbergen², M.F. Neurath¹  
¹University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, ²Academic Medical Center, Department of Hematoepoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands |
| 12:00 - 12:20 | **71: Endoscopic resection of dysplasia – mucosal and submucosal resection**  
Raf Bisschops, Leuven, Belgium |
| 12:20 - 12:50 | **Scientific session 12: ECCO Lecture**  
Silvio Danese, Milan, Italy  
Julián Panés, Barcelona, Spain |
| 12:20 - 12:50 | **72: Is translation the way to treatment personalisation?**  
Yehuda Chowers, Haifa, Israel |
| 12:50 - 12:55 | **73: Awards and closing remarks**  
Julián Panés, Barcelona, Spain |
| 12:55 - 13:00 | **74: The ECCO Film** |

OP = Oral presentation – Best abstracts
Thursday, February 16, 2017

*Scientific programme day by day (as of January 16, 2017)*

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:45 - 11:15 | **Top Tips for chairs (closed session)**  
|             | Laurence Egan, Galway, Ireland                                           |
| 11:30 - 12:30 | **Industry sponsored satellite symposia 1a & 1b**  
|             | Please refer to pages 186-187                                           |
| 12:45 - 12:50 | 1: **Welcome**  
|             | Javier Gisbert, Madrid, Spain                                           |
| 12:50 - 13:00 | 2: **Opening**  
|             | Julián Panés, Barcelona, Spain                                          |
| 13:00 - 14:30 | **Scientific session 1: Pathways of environmental and genetic factors in IBD**  
|             | Stephan Vavricka, Zurich, Switzerland  
|             | Nynne Nyboe Andersen, Copenhagen, Denmark                               |
| 13:00 - 13:20 | 3: **Nutrition and food additives**  
|             | Charlie Lees, Edinburgh, United Kingdom                                 |
| 13:20 - 13:30 | 4: **OP001: Whole genome sequencing and imputation in Inflammatory Bowel Disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights**  
|             | L. Moutsianas¹, K. De Lange², Y. Luo³, J. Lee⁴, L. Jostins⁵, C. Lamb⁶,  
|             | N. Kennedy⁷, J. Mansfield⁸, M. Parkes⁹, J. Barrett¹, C. Anderson¹, UK  
|             | Inflammatory Bowel Disease Genetics Consortium¹  
|             | “Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom,  
|             | “Broad Institute of Harvard and MIT, Program in Medical and Population Genetics, Cambridge, United States,  
|             | “Harvard Medical School, Division of Genetics and Rheumatology, Boston, United States, “Addenbrooke’s Hospital, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom,  
|             | “Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom,  
|             | “Newcastle University, Newcastle upon Tyne, United Kingdom,  
|             | “University of Exeter, Precision Medicine Exeter, Exeter, United Kingdom,  
|             | “University of Newcastle, Human Genetics, Newcastle upon Tyne, United Kingdom,  
|             | “UK IBD Genetics Consortium, Various, United Kingdom”                    |
| 13:30 - 13:50 | 5: **Everyday poisons: Smoking, pollution, stress, sedentary lifestyle**  
|             | Stephan Vavricka, Zurich, Switzerland                                   |
| 13:50 - 14:00 | 6: **OP002: Epigenetic biomarkers to detect UC associated neoplasia: Results from phase I of the ENDCAP-C study**  
|             | T. Iqbal¹, A. Beggs¹, P. Taniere², Y. Wallis², S. Mehta², L. Magill²,  
|             | J. Deeks², G. Matthews², D. Morton², EndCAP-C Consortium²  
|             | “University of Birmingham, Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom,  
|             | “University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom,  
|             | “West Midlands Regional Genetics Centre, Birmingham, United Kingdom,  
|             | “University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom” |

*OP = Oral presentation – Best abstracts*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 - 14:10 | 7: OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study  
J. Kirchgesner1,2, L. Beaugerie1, F. Carrat1,4, N. Nyboe Andersen5, T. Jess1,6, M. Schwarzinger1,6, For the BERENICE Study Group  
1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France,  
2INSERM, University Paris 06, UMR S 1136, Paris, France,  
3Hôpital Saint Antoine, Department of Public Health, Paris, France,  
4INSERM, University Paris 06, UMR S 1136, Paris, France,  
5Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark,  
6Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark,  
7INSERM, UMR 1137, Paris, France,  
8THEN, Translational Health Economics Network, Paris, France |
| 14:10 - 14:30 | 8: Environmental factors as therapy (diet modification, EEN feeding)  
Pierre Ellul, Sliema, Malta  
Arie Levine, Tel Aviv, Israel |
| 14:30 - 15:00 | Coffee break |
| 15:00 - 16:30 | Scientific session 2: Evolving therapeutic algorithms in 2017  
Jane Andrews, Adelaide, Australia  
Jarosław Kierkus, Warsaw, Poland |
| 15:00 - 15:20 | 9: Placing new molecules in the treatment pathway  
Gerhard Rogler, Zurich, Switzerland |
| 15:20 - 15:30 | 10: OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn’s Disease  
L. Le Bourhis1, A. Corraliza2, C. Auzolle1, E. Ricart5, C. Hawkey6, J.O. Lindsay7, M. Clark1, G. Rogler1, J. Satsangi5, D. Haller1, J. Panes2, A. Salas2, M. Allez5  
1Hôpital Saint-Louis INSERM, U1160 - Intestinal Immunity in Inflammation and Cancer, Paris, France,  
2IDIBAPS, Hospital Clinic, Gastroenterology, Barcelona, Spain,  
3University of Nottingham, Gastroenterology, Nottingham, United Kingdom,  
4Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom,  
5University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Swaziland,  
6Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom,  
7Technical University Munich, Department of Nutrition and Immunology, Freising, Germany |
| 15:30 - 15:50 | 11: Maximising the bang for your buck: How to manage IBD on a minimum budget  
Peter Irving, London, United Kingdom |

OP = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Abstract Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:50 - 16:00</td>
<td>12: OP005</td>
<td>The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy</td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td>13: OP006</td>
<td>Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial</td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td>14:</td>
<td>Personalised medicine: Dream or reality?</td>
</tr>
</tbody>
</table>
| 16:30 - 17:30 | Scientific session 3: Vulnerable patients: 10 burning questions in IBD | Pierre Michetti, Lausanne, Switzerland
Triana Lobatón, Barcelona, Spain |

**Thursday, February 16, 2017, cont.**

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB
# Thursday, February 16, 2017, cont.

*Scientific programme day by day (as of January 16, 2017)*

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:42 - 16:54 | **16: Treating the pregnant woman with IBD: Should anti-TNF be stopped during pregnancy? Should vedolizumab be stopped during pregnancy?**  
Janneke van der Woude, Rotterdam, The Netherlands |
| 16:54 - 17:06 | **17: The elderly patient with IBD: Should azathioprine ever be used in the elderly? Should the type of surgery be different in an elderly patient?**  
Jean-Frédéric Colombel, New York, United States |
| 17:06 - 17:18 | **18: The use of IBD medicine in patients with cancer: Which treatment should be stopped when cancer is diagnosed? Which treatment to use in a patient with a prior diagnosis with cancer?**  
Laurent Beaugerie, Paris, France |
| 17:18 - 17:30 | **19: The patient with psychological comorbidities: How to wean off opiates in these patients? Is there any preference in drugs?**  
Jane Andrews, Adelaide, Australia |
| 17:45 - 18:45 | **Industry sponsored satellite symposia 2a & 2b**  
Please refer to pages 187 |
| 17:45 - 18:45 | **Digital oral presentations**  
Please refer to page 43-67 |
**Friday, February 17, 2017**  
*Scientific programme day by day (as of January 16, 2017)  
Plenary Hall, Ground level, CCIB*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:15 - 08:15 | Industry sponsored satellite symposia 3a & 3b  
Please refer to page 188 |
| 08:30 - 10:30 | Scientific session 4: Clinical trials versus real life  
Janneke van der Woude, Rotterdam, The Netherlands  
Pascal Juillerat, Bern, Switzerland |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 08:30 - 08:50 | 20: Trial endpoints vs. therapeutic objectives  
Filip Baert, Roeselare, Belgium |
| 08:50 - 09:00 | 21: OP007 A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis  
I.C. Lawrance¹², A. Baird¹, D. Lightowler¹, G. Radford-Smith¹, J.M. Andrews⁵, S. Connor⁵  
¹University of Western Australia, Medicine and Pharmacology, Perth, Australia, ²Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia, ³University of Queensland School of Medicine, IBD Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia, ⁴University of Adelaide, School of Medicine, Adelaide, Australia, ⁵University of NSW Medicine, South Western Sydney Clinical School, Sydney, Australia |
| 09:00 - 09:10 | 22: OP008: An innovative treatment for refractory perianal fistulas in Crohn’s Disease: Local micro reinjection of autologous fat and adipose derived stromal vascular fraction (ClinicalTrials.gov NCT02520843, Eudract: 2013-002602-31)  
M. Serrero¹, C. Philandrianos⁵, C. Visee¹, J. Veran², P. Orsoni³³, F. Sabatier², J.C. Grimaud¹  
¹Hospital Nord, Gastroenterology, Marseille, France, ²Aix-Marseille, Marseille, France, ³Hospital Nord, Visceral Surgery, Marseille, France |
| 09:10 - 09:20 | 23: OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn’s Disease: 52-week results of a phase III randomised controlled trial  
J. Panes¹, D. García-Olmo⁵, G. Van Assche¹, J.F. Colombel⁵, W. Reinisch⁵, D.C. Baumgart³, M. Nachuryⁱ, M. Ferrante⁵, L. Kazemi-Shirazi⁵, J.C. Grimaud⁵, F. de la Portilla⁵, E. Goldin¹⁰, M.P. Richard¹¹, M.C. Diez¹², S. Danese¹²  
¹Hospital Clinic de Barcelona, Dept of Gastroenterology, Barcelona, Spain, ²Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴Icahn School of Medicine at Mount Sinai, New York, United States, ⁵Medical University of Vienna, Vienna, Austria, ⁶Charité Medical School – Humboldt-University of Berlin, Berlin, Germany, ⁷CHU Lille, Lille, France, ⁸Hospital Nord, Marseille, France, ⁹Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Sharee Zedek MC, Jerusalem, Israel, ¹¹TiGenix, Madrid, Spain, ¹²Istituto Clinico Humanitas, Milano, Italy |
| 09:20 - 09:40 | 24: The long-term efficacy outside clinical trials  
Stefan Schreiber, Kiel, Germany |

*OP = Oral presentation – Best abstracts*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:40 - 09:50</td>
<td><strong>25: OP010: Long term efficacy and safety of Ustekinumab for Crohn's Disease: Results from IM-UNITI long-term extension through 2 years</strong>&lt;br&gt;W. Sandborn¹, P. Rutgeerts³, C. Gasink¹, D. Jacobstein¹, L.-L. Gao¹, J. Johanss¹, B. Sands¹, S.B. Hanauer¹, S. Targan³, S. Ghosh¹, D.V. Willem J.S.¹, J.-F. Colombel³, <strong>B.G. Feagan</strong>⁹&lt;br&gt;¹University of California San Diego, La Jolla, United States, ²University Hospital, Gasthuisberg, Leuven, Belgium, ³Janssen Research &amp; Development, LLC, Spring House, United States, ⁴Icahn School of Medicine at Mt Sinai, New York, United States, ⁵Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶Cedars-Sinai Medical Center, Los Angeles, United States, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Stellenbosch, Stellenbosch, South Africa, ⁹Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td><strong>26: OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study</strong>&lt;br&gt;L. Peyrin-Biroulet¹, B.G. Feagan², J. Mansfield³, D.T. Rubin⁴, U. Arulmani⁵, R. Maciucă⁶, H. Tyrrell⁶, J. Thommes⁶, S. Tole⁶&lt;br&gt;¹Université de Lorraine, Vandoeuvre-lès-Nancy, France, ²University of Western Ontario, London, Canada, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of Chicago Medicine, Chicago, United States, ⁵Genentech, South San Francisco, United States, ⁶Roche, Welwyn Garden City, United Kingdom</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td><strong>27: OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis</strong>&lt;br&gt;M. Ferrante¹, N. Schils¹, A. de Buck van Overstraeten¹, S. Vermeire¹, G. Van Assche¹, A. Wolthuis¹, A. D’Hoore¹&lt;br&gt;¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td><strong>28: The long-term safety outside clinical trials</strong>&lt;br&gt;Gert van Assche, Leuven, Belgium</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td><strong>Scientific session 5: Managing bowel damage in IBD: Surgical or medical treatment?</strong>&lt;br&gt;Antonio Spinelli, Milan, Italy&lt;br&gt;Edyta Zagórowicz, Warsaw, Poland</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td><strong>29: Are we truly changing disease course with current strategies?</strong>&lt;br&gt;Yves Panis, Clichy, France</td>
</tr>
</tbody>
</table>
### Scientific Programme Day by Day (as of January 16, 2017)

**Plenary Hall, Ground level, CCIB**

**Friday, February 17, 2017, cont.**

#### 11:20 - 11:30

30: **OP013: Disease management and outcomes of patients with Crohn's Disease at high risk of recurrence. Results from PRACTICROHN study**

*M. Iborra*1, M.D. Martín Arranz2, E. Domènech3, V. García4, A. Gutiérrez5, M. Barreiro-de Acosta6, L. Cea-Calvo7, C. Romero7, B. Juliá7

1Servicio de Gastroenterología, Hospital La Fe, Valencia, Spain, 2Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 4Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, 5Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain, 6Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 7MSD Spain, Medical Department, Madrid, Spain

#### 11:30 - 11:50

31: **Combined approach for intestinal sparing in CD?**

Paulo Kotze, Curitiba, Brazil

#### 11:50 - 12:00

32: **OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE**


1University of California San Diego, San Diego, United States, 2Robarts Research, London, Canada, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States, 5Feinberg School of Medicine, Chicago, United States, 6Atlanta Gastroenterology Associates, Atlanta, United States, 7University of Leuven, Leuven, Belgium, 8University of Calgary, Calgary, Canada, 9Receptos, a wholly owned subsidiary of Celgene, San Diego, United States

#### 12:00 - 12:10

33: **OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIRIC TRIAL**

J. de Groof1,2, W. Bemelman1, E. Eshuis2, T. Gardenbroek1, P. Bossuyt1, J. Bosmans3, H. van Dongen4, B. van Wageningen2, M. Brink1, E. Consten3, C. Buskens1, G. D’Haens3, P. Stokkers3, C. Ponsioen3, LIRIC study group

1Academic Medical Center, Surgery, Amsterdam, Netherlands, 2Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, 3Academic Medical Center, Epidemiology, Amsterdam, Netherlands, 4VU Medicine, Amsterdam, Netherlands, 5VU University Medical Center, Amsterdam, Netherlands, 6OLVG West, Surgery, Amsterdam, Netherlands, 7Amersfoort Medical Center, Gastroenterology, Amersfoort, Netherlands, 8Meander Medical Center, Gastroenterology, Amersfoort, Netherlands, 9OLVG West, Gastroenterology, Amsterdam, Netherlands

#### 12:10 - 12:30

34: **The ileorectal anastomosis in UC: Time for a comeback?**

Oded Zmora, Tel Aviv, Israel

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:30 - 13:30 | Lunch & Guided Poster Session  
Please refer to page 40  |
| 12:40 - 13:20 | Educational Lunchtime Satellite Symposia  
Please refer to pages 188-189  |

**OP** = Oral presentation – Best abstracts
### Scientific session 6: Intestinal inflammation - not always IBD

**Chairs:** Eugeni Domènech, Badalona, Spain  
Dror Shouval, Tel Aviv, Israel

**Carousel:**  
Epidemiologist – Vito Annese, Florence, Italy  
Basic Science – Britta Siegmund, Berlin, Germany  
Pathologist – Roger Feakins, London, United Kingdom  
Physician – James Lindsay, London, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:50</td>
<td><strong>35: Microscopic colitis</strong></td>
<td>C. Palmela, J. Torres, P. Gomes de Sena, M.P. Costa Santos, C. Gouveia, M.H. Oliveira, C. M. P. Rodrigues, M. Cravo, P. Borralho, Hospital Beatriz Anglo, Gastroenterology Department, Loures, Portugal, Hospital Beatriz Anglo, Pathology Department, Loures, Portugal, Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal, Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal, Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>36: OP016: Potential role of bile acid receptor FXR in microscopic colitis</strong></td>
<td>C. Palmela, J. Torres, P. Gomes de Sena, M.P. Costa Santos, C. Gouveia, M.H. Oliveira, C. M. P. Rodrigues, M. Cravo, P. Borralho, Hospital Beatriz Anglo, Gastroenterology Department, Loures, Portugal, Hospital Beatriz Anglo, Pathology Department, Loures, Portugal, Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal, Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal, Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal</td>
</tr>
<tr>
<td>14:00 - 14:20</td>
<td><strong>37: IBDU</strong></td>
<td>M. de Jong, A. van der Meulen-de Jong, M. Romberg-Camps, M. Becx, M. Cilissen, J. Maljaars, A. van Bodegraven, N. Mahmmod, T. Markus, W. Hameeteman, G. Dijkstra, A. Mascele, D. Boonen, D. Jonkers, A. van Tubergen, M. Pierik, Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands, Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands, St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands, CCUVN, Woerden, Netherlands, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands, Maastricht University Medical Center (MUMC), CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands</td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td><strong>39: OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type</strong></td>
<td>S. Kanis, A. de Lima, C. van der Woude, Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)
Room 111, Level 1, CCIB (Scientific session 9)

EITHER:

<table>
<thead>
<tr>
<th>15:00 - 15:40</th>
<th>Scientific session 7: ECCO Fellowships and Grants</th>
</tr>
</thead>
</table>
| 15:00 - 15:07 | **41: Outcomes from the 2015-2016 Fellowships: Post-genomic application in general, and the establishment of computational approaches relevant to translational medicine**
| | Ferdinando Bonfiglio, Stockholm, Sweden |
| 15:07 - 15:14 | **42: Outcomes from the 2015-2016 Fellowships: Hypoxia, autophagy and inflammasome**
| | Jesús Cosín, Valencia, Spain |
| 15:14 - 15:20 | **43: Announcement of ECCO Fellowships & Grants 2017** |
| | B. Feagan¹, J.-F. Colombel², G. Rossiter³, X. Li³, K. Usiskin³, X. Zhan³, B. Sands² |
| 15:30 - 15:40 | **45: OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease**
| | A. Gils¹, E. Dreesen¹, G. Compernolle¹, M. Peeters¹, E. Brouwers¹, S. Tops¹, V. Ballet¹, M. Noman², M. Ferrante³, G. Van Assche³, S. Vermeire³ |

15:40 - 16:10 Coffee break

16:10 - 17:10 Scientific session 8: IBD Horizons

<table>
<thead>
<tr>
<th>16:10 - 17:10</th>
<th>Scientific session 8: IBD Horizons</th>
</tr>
</thead>
</table>
| 16:10 - 16:20 | **46: OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate-severe flares: A multi-center, randomised, double-blind, sham-controlled trial**
| | P. Dulai¹,², J. Buckey Jr.³, L. Raffals³, J. Swoger³, P. Claus¹, K. O’Toole³, J. Ptak³, M. Gleeson³, C. Widjaja¹, J. Adler², N. Patel³, L. Skinner³, S. Haren³, K. Goldby-Reffner³, K. Thompson², R. Knight¹, J. Chang³, C. Siegel² |

| OP = Oral presentation – Best abstracts |
### 47: OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study

**R. Kalla¹**, S. Vatn², D. Bergemalm³, P. Ricanek⁴, J. Lindstrom², A. Ocklind¹, N. Nordberg¹, N. Kennedy¹, N. Ventham¹, NIBD Character Consortium⁵, M. Vatn², J. Söderholm¹, M. Pierik⁶, L. Törkvist¹, F. Gomollón¹⁰, J. Jahnsen², J. Halfvarson³, J. Satsangi¹

¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²Akershus University Hospital, Department of Gastroenterology, Faculty of Medicine and Health, Ørebro, Sweden, ³Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, ⁴University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁵Olink Proteomics, Uppsala, Sweden, ⁶IBD Character Consortium, Edinburgh, United Kingdom, ⁷Linköping University, Gastroenterology, Linköping, Sweden, ⁸Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁹Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Karolinska, Sweden, ¹⁰HCU “Lozano Blesa”, IIS Aragón, CIBEREHD, Zaragoza, Spain

### 48: OP023: Maintenance of clinical effect in patients with Moderate-to-Severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study


¹University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ²University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³Vivamed, Warsaw, Poland, ⁴Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany, ⁵CHU Nice Hospital l’Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France, ⁶North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France, ⁷NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland, ⁸Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania, ⁹Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland, ¹⁰City Clinical Hospital #31, St. Petersburg, Russian Federation, ¹¹Szent Margit Hospital, Budapest, Hungary, ¹²PSI Pharma Support EO ÖD, Sofia, Bulgaria, ¹³Galapagos NV, Mechelen, Belgium

### 49: OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014

**O. Olén¹²**, J. Asklings¹, P. Frumento¹, M.C. Sachs¹, M. Neovius¹, J. Eriksson¹, K.E. Smedby¹, A. Ekborn¹, P. Malmborg¹², J.F. Ludvigsson¹³, J. Ekbom¹³, N. Nordberg¹³, J. Halfvarson³, J. Jahnsen², J. Satsangi¹

¹Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm, Sweden, ²Sach’s Children’s Hospital, Department of Pediatric Gastroenterology and Nutrition, Stockholm, Sweden, ³Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, ⁴Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁵Orebro University Hospital, Department of pediatrics, Orebro, Sweden, ⁶University of Nottingham, Division of Epidemiology and Public Health, School of Medicine, Nottingham, United Kingdom, ⁷Columbia University College of Physicians and Surgeons, Department of Medicine, New York, Sweden

OP = Oral presentation – Best abstracts
### 16:50 - 17:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>50: OP025</td>
<td>Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naive pediatric patients with Crohn's Disease in clinical practice</td>
<td>S. Steiner¹, E. King², K. Park³, D. Pashankar⁴, H. Shashidhar⁵, B. Sudel⁶, S. Eichner⁷, S. Chen², J. Pratt⁸, R. Colletti⁹, ImproveCareNow Network⁸</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, United States, ²Cincinnati Children's Hospital Medical Center, Cincinnati, United States, ³Lucile Salter Packard Children's Hospital, Stanford University, Palo Alto, United States, ⁴Yale-New Haven Children's Hospital, New Haven, United States, ⁵New Hampshire's Hospital for Children's Hospital, Minneapolis, United States, ⁶University of Minnesota Masonic Children's Hospital, Minneapolis, United States, ⁷AbbVie, North Chicago, United States, ⁸University of Vermont Children's Hospital, Burlington, United States, ⁹ImproveCareNow, Burlington, United States</td>
</tr>
</tbody>
</table>

### 17:00 - 17:10

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>51: OP026</td>
<td>Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease</td>
<td>C. Lahiff¹, L.M. Wang², S.P.L. Travis¹, J.E. East¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Translational Gastroenterology Unit, Experimental Medicine Division, Oxford, United Kingdom, ²John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Department of Cellular Pathology, Oxford, United Kingdom</td>
</tr>
</tbody>
</table>

### OR:

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 17:10</td>
<td>Scientific session 9: Basic Science meets the clinic</td>
<td>Arthur Kaser, Cambridge, United Kingdom, Azucena Salas, Barcelona, Spain</td>
</tr>
</tbody>
</table>

### 15:00 - 15:20

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>52: IL-23 and beyond</td>
<td></td>
<td>Fiona Powrie, Oxford, United Kingdom</td>
</tr>
</tbody>
</table>

### 15:20 - 15:30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>53: OP027</td>
<td>IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer</td>
<td>L.R. Lopetuso¹,², C. De Salvo¹, L. Di Martino¹, W. Goodman¹, F. Scalfarotti¹, A. Gasbarrini¹, T.T. Pizarro¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Catholic University of the Sacred Heart, Internal Medicine, Gastroenterology Division, Rome, Italy, ²Case Western Reserve University, Pathology, Cleveland, United States, ³Case Western Reserve University, Pathology, Cleveland, United States, ⁴Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy</td>
</tr>
</tbody>
</table>

### 15:30 - 15:40

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>54: OP028</td>
<td>Gut specific regulatory T cells – a new frontier for Crohn's Disease therapy</td>
<td>R. Goldberg¹,²,₃, C. Scotta¹,², D. Cooper⁴, E. Eliraz⁵, E. Nir⁵, P. Irving¹, ⁶, J. Sanderson¹,², N. Shipigel¹, F. Marelli-Berg¹, G. Lombardi¹,²,³, G. Lord¹,²,³,⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Guy’s and St Thomas’ NHS Trust, Gastroenterology, London, United Kingdom, ²King’s College London, Experimental Immunobiology, London, United Kingdom, ³King’s College London, Medical Research Council Centre for Transplantation, London, United Kingdom, ⁴Guy’s and St Thomas’ NHS Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom, ⁵King’s College London, Immunoregulation and Immune Intervention, London, United Kingdom, ⁶Barts and the London Queen Mary School of Medicine and Dentistry, William Harvey Research Institute, London, United Kingdom, ⁷Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel, ⁸King’s College London, Diabetes and Nutritional Sciences, London, United Kingdom</td>
</tr>
</tbody>
</table>

OP = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40 - 16:10</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td><strong>55: Genetics and function in IBD: The missing link?</strong></td>
</tr>
<tr>
<td></td>
<td>Sebastian Zeissig, Dresden, Germany</td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td><strong>56: OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn’s Disease</strong></td>
</tr>
<tr>
<td></td>
<td>A. Lewis¹, C. Felice², A. Nihjuis¹, S. Iqbal¹, S. Mehta¹, R. Feakins¹, A. Armuzzi³, A. Silver¹, J. Lindsay⁴</td>
</tr>
<tr>
<td></td>
<td>¹Queen Mary’s University London, Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom, ²Gemelli Hospital Catholic University Foundation, IBD Unit, Presidio Columbus, Rome, Italy, ³The Royal London Hospital, Department of pathology, London, United Kingdom, ⁴Queen Mary’s University</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td><strong>57: OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation</strong></td>
</tr>
<tr>
<td></td>
<td>A. Metwaly¹, L. F. Buttó¹, N. Waldschmitt¹, I. Lagkouvardos², A.M. Corraliza³, A. Mayorgas³, M. Martinez-Medina³, M. Állez³, J. Panes³, A. Salas³, D. Haller¹²</td>
</tr>
<tr>
<td></td>
<td>¹Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany, ²ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany, ³Instituto de Investigaciones Biomédicas de Barcelona CSIC, IDIBAPS, CIBERehd, Department of Experimental Pathology, Barcelona, Spain, ⁴Laboratory of Molecular Microbiology, Universitat de Girona, Biology Department, Girona, Spain, ⁵APHP, Hôpital Saint Louis, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Department of Gastroenterology, Paris, France</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td><strong>58: Epigenetics in complex diseases</strong></td>
</tr>
<tr>
<td></td>
<td>Manel Esteller, Barcelona, Spain</td>
</tr>
<tr>
<td>17:20 - 18:20</td>
<td>Digital oral presentations</td>
</tr>
<tr>
<td></td>
<td>Please refer to pages 43-67</td>
</tr>
<tr>
<td>18:30 - 19:30</td>
<td>Industry sponsored satellite symposia 4a &amp; 4b</td>
</tr>
<tr>
<td></td>
<td>Please refer to page 190</td>
</tr>
<tr>
<td>20:30</td>
<td><strong>ECCO Interaction: Hearts &amp; Minds</strong></td>
</tr>
<tr>
<td></td>
<td>Please refer to page 207</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
### Scientific programme day by day (as of January 16, 2017)

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td><strong>Industry sponsored satellite symposia 5a &amp; 5b</strong>&lt;br&gt;Please refer to page 192</td>
</tr>
<tr>
<td>08:30 - 10:20</td>
<td><strong>Scientific session 10: New compounds in the treatment of IBD</strong></td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td><strong>59: JAK-inhibitors</strong>&lt;br&gt;Séverine Vermeire, Leuven, Belgium</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td><strong>60: OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's Disease: Results from a phase 2 open-label 48-week extension study</strong>&lt;br&gt;J. Panés¹, G.R. D'Haens², P.D.R. Higgins³, L. Mele⁴, M. Moscariello⁵, G. Chan⁶, W. Wang⁷, W. Niezychowski⁵, C. Su⁸, E. Maller⁹&lt;br&gt;¹Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ²Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ³University of Michigan, Ann Arbor, MI, United States, ⁴Pfizer Inc, Collegeville, PA, United States</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td><strong>61: OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial</strong>&lt;br&gt;W.J. Sandborn¹, B.E. Sands², S. Danese³, G.R. D'Haens⁴, S. Vermeire⁵, S. Schreiber⁶, B. Feagan⁷, W. Reinisch⁸, G. Friedman⁹, D. Woodworth¹⁰, H. Zhang¹¹, N. Lavendy¹², W. Niezychowski⁵, C. Su⁸, J. Panés¹¹&lt;br&gt;¹Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States, ²Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ³IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, ⁴Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ⁵Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, ⁶Klinik für Innere Medizin I, Universitätshclinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁷Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Pfizer Inc, Collegeville, PA, United States, ¹¹Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td><strong>62: OP033: Reduction of tissue pSTAT3 in Crohn's Disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor</strong>&lt;br&gt;S. Vermeire¹, G. De Hertogh², G. Chen¹, D. French⁴, E. Huntzicker⁴, A. Van der Aa³, T. Van Kaem³, P. Harrison³, C. Tasset³, R. Gallien³, Y. Pan³, B. Feagan³, W. Sandborn³&lt;br&gt;¹University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ²University Hospitals Leuven, Department of Pathology, Leuven, Belgium, ³Gilead Sciences, Department of Biostatistics, Foster City, United States, ⁴Gilead Sciences, Biomarker Sciences, Foster City, United States, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos SASU, Romainville, France, ⁷Robarts Research Institute, Ontario, Canada, ⁸University of California, Division of Gastroenterology, San Diego, United States</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td><strong>63: S1P modulators</strong>&lt;br&gt;Arthur Kaser, Cambridge, United Kingdom</td>
</tr>
</tbody>
</table>
Saturday, February 18, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

09:40 - 09:50

64: OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study


1University of California San Diego, Department of Gastroenterology, La Jolla, United States, 2Amgen, Thousand Oaks, United States, 3University of Copenhagen, Copenhagen, Denmark, 4Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada, 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, 6Universitätsspital Zurich, Zurich, Switzerland, 7University Hospital Gasthuisberg, Leuven, Netherlands, 8Medical University of Vienna, Vienna, Austria

09:50 - 10:00

65: OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for Moderate to Severe Crohn’s Disease


1University of California San Diego, La Jolla, United States, 2Amgen Inc., Thousand Oaks, United States, 3University of Copenhagen, Copenhagen, Denmark, 4Robarts Research Institute, University of Western Ontario, London, Canada, 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, 6University Hospitals Leuven, Leuven, Belgium, 7Medical University Vienna, Vienna, Austria

10:00 - 10:20

66: Anti IL12/IL23 compounds

Bruce Sands, New York, United States

10:20 - 10:50 Coffee break

10:50 - 12:20 Scientific session 11: Gut luminal content – more than just bacteria

Isabelle Cleynen, Leuven, Belgium

Miquel Gassull, Barcelona, Spain

10:50 - 11:10

67: The forgotten populations in the gut

Patricia Lepage, Jouy-En-Josas, France

11:10 - 11:20

68: OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active Ulcerative Colitis: A randomised controlled trial

S. Costello1,2,3, O. Waters4, R. Bryant5,6, R. Katsikeros7, J. Makanyanga7, M. Schoeman1,2, R. Mountfield7, D. Tee7, S. Howell7, P. Hughes7, M. Conlon7, I. Roberts-Thomson7, J. Andrews1,2

1The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia, 2University of Adelaide, School of Medicine, Adelaide, Australia, 3The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia, 4Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia, 5Flinders Medical Centre, Gastroenterology, Bedford Park, Australia, 6Lyell McEwin Hospital, Gastroenterology, Elizabeth Vale, Australia, 7CSIRO, Health and Biosecurity, Adelaide, Australia

11:20 - 11:40

69: Metabolic activity

Dirk Haller, Freising, Germany
### Saturday, February 18, 2017, cont.

*Scientific programme day by day (as of January 16, 2017)*

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 11:40 - 11:50 | **70: OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life**  
1Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 2Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York, United States, 3Icahn School of Medicine at Mount Sinai, Department of Pediatrics, New York, United States, 4Icahn School of Medicine at Mount Sinai, Obstetrics, Gynecology and Reproductive Science, New York, United States, 5Icahn School of Medicine at Mount Sinai, Immunology, New York, United States. |
| 11:50 - 12:00 | **71: OP038: Impact of ileocecal resection in Crohn’s Disease patients on mucosal microbiota**  
1University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGiD), Leuven, Belgium, 2Vall d’Hebron Research Institute, Barcelona, Spain, 3University Hospitals Leuven, KU Leuven, Leuven, Belgium. |
| 12:00 - 12:20 | **72: Microbiome reality check – looking beyond the hype**  
Jeroen Raes, Ghent, Belgium |
| 12:20 - 12:50 | **Scientific session 12: ECCO Lecture**  
Julian Panés, Barcelona, Spain  
Silvio Danese, Milan, Italy |
| 12:20 - 12:50 | **73: Best individualised IBD care – optimising drugs, psychology, diet and microbes**  
Michael Kamm, Melbourne, Australia |
| 12:50 - 12:55 | **74: Awards and closing remarks**  
Julian Panés, Barcelona, Spain |
| 12:55 - 13:00 | **75: The ECCO Film** |
**Thursday, March 17, 2016**

**Scientific programme day by day (as of February 15, 2016)**

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers, Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:15</td>
<td>Top tips for chairs (closed session)</td>
<td>Laurence Egan, Galway, Ireland</td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td>Industry sponsored satellite symposia 1a &amp; 1b</td>
<td>Please refer to pages 188-189</td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td>1: Welcome</td>
<td>Janneke van der Woude, Rotterdam, The Netherlands Bas Oldenburg, Utrecht, The Netherlands</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>2: Opening</td>
<td>Séverine Vermeire, Leuven, Belgium</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Scientific session 1: Cell therapy: Ready for clinical practice?</td>
<td>Pierre Desreumaux, Lille, France Dominik Bettenworth, Munster, Germany</td>
</tr>
<tr>
<td></td>
<td>3: Haematopoietic stem cell transplantation</td>
<td>Azucena Salas, Barcelona, Spain Elena Ricart, Barcelona, Spain</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>4: Best abstract: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulae in Crohn’s Disease</td>
<td>J. Panés¹, D. García-Olmo², G. van Assche², J.F. Colombel¹, W. Reinisch³, D.C. Baumgart³, M. Nachury⁴, M. Ferrante⁴, L. Kazemi-Shirazi⁴, J.C. Grimaud⁵, F. de la Portilla⁵, E. Goldin⁶, A. Leselbaum⁷¹, M.C. Diez²¹, S. Danese²¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Hospital Clinic Barcelona, Barcelona, Spain ²Hospital U. Fundación Jiménez-Díaz, Madrid, Spain ³University Hospitals Leuven, KU Leuven, Leuven, Belgium ⁴Icahn School of Medicine at Mount Sinai, New York, United States ⁵Medical University of Vienna, Vienna, Austria ⁶Charité Medical School - Humboldt-University of Berlin, Berlin, Germany ⁷CHU Lille, Lille, France ⁸Hôpital Nord, Marseille, France ⁹Hospital Virgen del Rocío, Sevilla, Spain ¹⁰Sharee Zedek MC, Jerusalem, Israel ¹¹TIGenix, Madrid, Spain ¹²Istituto Clinico Humanitas, Milano, Italy</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>6: Best abstract: Histopathological response and remission after dual topical application of the toll-like-receptor 9 agonist DIMSO150 in patients with moderate to severe Ulcerative Colitis</td>
<td>R. Atreyã¹, A. Ostê, C. Admyrne¹, A. Karlsson¹, T. Knittel¹, J. Kowalski¹, F. Scaldaferri¹, M. Neurath¹, C. Hawkey¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany ²Aleris Medlab, Department of Pathology and Cytology, Täby, Sweden ³Index Pharmaceuticals, Stockholm, Sweden ⁴Catholic University of Rome, Internal Medicine Department, Gastroenterology Division, Rome, Italy ⁵Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom</td>
</tr>
</tbody>
</table>
**Thursday, March 17, 2016, cont.**

*Scientific programme day by day (as of February 15, 2016)*

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 14:00 - 14:20 | 7: Mesenchymal stem cells  
Tandem talk:  
Stefania Vetrano, Milan, Italy  
Laurence Egan, Galway, Ireland |
| 14:20 - 14:30 | 8: Best abstract: Predicting short and medium-term efficacy of the biosimilar infliximab: Trough levels/ADAs or clinical/biochemical markers play a more important role?  
P.A. Golovics¹, Z. Végó¹, M. Rutka², K. Gecse³, A. Balint⁴, K. Farkas⁵, J. Banai⁶, L. Bene⁷, B. Gasztonyi⁸, T. Kristof⁹, L. Lakatos¹⁰, P. Miheller¹¹, K. Palatka¹², A. Patai¹³, A. Salamon¹⁴, T. Szamosi¹⁵, Z. Szepes¹⁶, G. T. Toth¹⁷, A. Vincze¹⁸, E. Biro¹⁹, B. Lovasz¹, Z. Kurti¹, F. Nagy²², T. Molnár²³, P. Lakatos²⁴  
¹Semmelweis University, 1st Department of Medicine, Budapest, Hungary, ²University of Szeged, 1st Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, 1st Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, 1st Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, 2nd Department of Medicine, Miskolc, Hungary, ⁷Csolnoky F. Province Hospital, Department of Medicine, Veszprém, Hungary, ⁸Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, ⁹University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁰Markusovszky Hospital, 1st Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹¹Tolna County Teaching Hospital, 1st Department of Gastroenterology, Székszard, Hungary, ¹²University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹³Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁴University of Pecs, 1st Department of Medicine, Pecs, Hungary, ¹⁵Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary |

<table>
<thead>
<tr>
<th>Time</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 15:00</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
### Thursday, March 17, 2016, cont.

*Scientific programme day by day (as of February 15, 2016)*

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

#### 15:00 - 17:00

**Scientific session 2: Application of genetic testing in understanding and managing IBD**

Andre Franke, Kiel, Germany

Thomas Billiet, Heverlee, Belgium

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:20</td>
<td>9: Very early onset IBD – from research to bedside</td>
<td>Holm Uhlig, Oxford, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td>10: Best abstract: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn’s Disease</td>
<td>A. Stojmirovic, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman Janssen R &amp; D, LLC, Spring House, United States</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>11: Genetics in predicting drug response</td>
<td>Tariq Ahmad, Exeter, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>12: Best abstract: A variable number of tandem repeat polymorphism in the promoter region of the neonatal Fc receptor affects anti-TNF serum levels in IBD</td>
<td>T. Billiet1, I. Cleynen1, M. Ferrante2, G. van Assche2, A. Gils3, S. Vermeire2</td>
<td>1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium</td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td>13: Best abstract: Autophagy regulates dendritic cell migration through Rac1 – implications for thiopurine therapy</td>
<td>M. Wildenberg1, P. Koelink2, K. Diederent2, A. te Velde2, V. Nuij3, M. Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude4, G. D’Haens5, G. van den Brink1</td>
<td>1Academic Medical Center, gastroenterology and hepatology, Amsterdam, Netherlands, 2Academic Medical Center, Tytgat Institute, Amsterdam, Netherlands, 3Erasmus Medical Center, department of gastroenterology and hepatology, Rotterdam, Netherlands, 4Beaton Institute for Cancer Research, Glasgow, United Kingdom</td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td>14: The future of genetics in clinical medicine</td>
<td>Rinse Weersma, Groningen, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>15: Best abstract: Comprehensive epigenome-wide DNA methylation profiling in Inflammatory Bowel Disease</td>
<td>N. Ventham1, N. Kennedy2, A. Adams3, R. Kalla3, S. Heath2, K. O’Leary1, H. Drummond4, D. Wilson4, on behalf of the IBD-BIOM Consortium4, on behalf of the IBD-CHARACTER Consortium4, I. Gut5, E.R. Nimmo5, J. Satsangi1</td>
<td>1University of Edinburgh, CGEM, Edinburgh, United Kingdom, 2Centro Nacional de Análisis Genómico, Barcelona, Spain, 3University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom</td>
</tr>
</tbody>
</table>
16: Best abstract: Genotype-phenotype analysis across 130,422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis


1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 3University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, 4Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, 5Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, 6Landspitali University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, 7Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Center, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, 8University of California Davis, Division of Gastroenterology and Hepatology, Davis, United States, 9John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, 10Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, 11University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, 12Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, 13University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, 14Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 15Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, 16University of Padova, Department of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, 17Nordic and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, 18University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, 19University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, 20Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 21University of Munich, Department of Medicine II, Munich, Germany, 22Humanitas Clinical and Research Center, Center for Autoimmune Liver Diseases, Rozzano, Italy, 23Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, 24Mayo Clinic, College of Medicine, Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, United States,
Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:40 - 16:50 cont.

25Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, 26Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 27Karolinska Institute, Stockholm, Sweden, 28Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 29Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, 30Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, 31University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Canada, 32Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, 33Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, 34University of Barcelona, Liver Unit, Hospital Clinic, I.D.I.B.A.P.S., C.I.B.E.Rehd, Barcelona, Spain, 35University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, 36University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, 37University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, 38Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, 39University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, 40University Medical Center Hamburg-Eppendorf, 1st Department of Medicine, Hamburg, Germany, 41Mount Sinai Hospital Toronto, Inflammatory Bowel Disease (IBD) Group, Zane Cohen Centre for Digestive Diseases, Toronto, Canada, 42University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, 43University of Mainz, 1st Department of Medicine, Mainz, Germany, 44Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, 45University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 46University of Thessaly, Department of Internal Medicine, Larissa, Greece

17: Best abstract: Gene-microbiome interactions underlying the onset and the clinical phenotypes of Inflammatory Bowel Disease

F. Imhann1, A. Vich Vila1, M.J. Bonder1, D. Gevers1, J. Fu1, M.C. Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R.W.F. Ter Steege1, C. Huttenhower1, G. Dijkstra1, R.J. Xavier1, C. Wijmenga2, E.A.M. Festen1, A. Zhernakova2, R.K. Weersma1

1University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2University of Groningen and University Medical Center Groningen, Department of Genetics, Groningen, Netherlands, 1The Broad Institute of MIT and Harvard, Cambridge, United States, 4Harvard School of Public Health, Biostatistics Department, Boston, United States

17:15 - 18:15 Digital oral presentations (Sessions 1-5)
Please refer to pages 42-54

17:15 - 18:15 Industry sponsored satellite symposia 2a & 2b
Please refer to pages 189-190
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:15 - 08:15 | Industry sponsored satellite symposia 3a & 3b  
Please refer to pages 190-191 |
| 08:30 - 09:30 | Scientific session 3: Resolution of inflammation  
Javier Gisbert, Madrid, Spain  
Giovanni Monteleone, Rome, Italy |
| 08:30 - 08:50 | 18: Mechanisms by which inflammation resolves  
Silvio Danese, Milan, Italy |
| 08:50 - 09:10 | 19: Stopping drugs  
Charlie Lees, Edinburgh, United Kingdom |
| 09:10 - 09:20 | 20: Best abstract: Azathioprine dose reduction in Inflammatory Bowel Disease patients on combination therapy: A prospective study  
E. Del Tedesco¹, S. Paul², H. Marotte³, C. Jarlot⁴, N. Williet⁵, J.M. Phelip⁶, L. Peyrin-Biroulet⁷, J.F. Colombel⁸, X. Roblin⁹  
¹University Hospital, Gastroenterology, Saint Etienne, France,  
²University of Saint Etienne, Immunology, Saint Etienne, France,  
³University Hospital, Rheumatology, Saint Etienne, France,  
⁴CHU Saint Etienne, Saint Etienne, France,  
⁵CHU de Nancy, Department of Gastroenterology, Vandoeuvre-Lès-Nancy, France,  
⁶Mount Sinai Hospital, New York, United States |
| 09:20 - 09:30 | 21: Best abstract: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s Disease: A prospective, multicentre, open-labelled clinical trial (DIAMOND study)  
¹Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan,  
²Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan,  
³Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan,  
⁴Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan,  
⁵Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan,  
⁶Tokyo Yamate Medical Center, Department of Medicine, Division of Gastroenterology, Tokyo, Japan,  
⁷Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan,  
⁸Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan,  
⁹Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan,  
¹⁰Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan,  
¹¹Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan,  
¹²Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan,  
¹³Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan,  
¹⁴Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan,  
¹⁵Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan,  
¹⁶The Institute of Medical Science Hospital, The University of Tokyo, Center for Translational Research, Tokyo, Japan,  
¹⁷Kitsato University Kitsato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 10:30</td>
<td>Scientific session 4: Viruses and IBD</td>
</tr>
<tr>
<td></td>
<td>Laurent Beaugerie, Paris, France</td>
</tr>
<tr>
<td></td>
<td>Marina Shapina, Moscow, Russia</td>
</tr>
<tr>
<td>09:30 - 09:50</td>
<td>22: Should we treat CMV in patients with UC?</td>
</tr>
<tr>
<td></td>
<td>Britta Siegmund, Berlin, Germany</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td>23: Best abstract: Risk factors for colorectal neoplasia in Ulcerative Colitis:</td>
</tr>
<tr>
<td></td>
<td>Results from the largest and longest-running colonoscopical surveillance programme</td>
</tr>
<tr>
<td></td>
<td>C.H.R. Choi, I. Al Bakir, N.S.J. Ding, M. Moorghen, S. Thomas-Gibson, B.</td>
</tr>
<tr>
<td></td>
<td>Saunders, M. Rutter, T. Graham, A. Hart</td>
</tr>
<tr>
<td></td>
<td>1St. Mark's Hospital, London, United Kingdom, 2Barts Cancer Institute, Tumour</td>
</tr>
<tr>
<td></td>
<td>Biology, London, United Kingdom, 3University Hospital of North Tees, Department</td>
</tr>
<tr>
<td></td>
<td>of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td>24: Best abstract: Evolution of corticosteroid use in Crohn's Disease patients</td>
</tr>
<tr>
<td></td>
<td>between 1991 and 2014: Results from the Dutch population-based IBDSL cohort</td>
</tr>
<tr>
<td></td>
<td>S. Jeuring, V. Biemans, L. Liu, T. van den Heuvel, M. Zeegers, W. Hameeteman,</td>
</tr>
<tr>
<td></td>
<td>M. Romberg-Camps, L. Oostenbrug, A. Mascele, D. Jonkers, M. Pierik</td>
</tr>
<tr>
<td></td>
<td>1Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, 4University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>25: Other viral complications in clinical practice</td>
</tr>
<tr>
<td></td>
<td>Jonas Halfvarsson, Örebro, Sweden</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

11:00 - 12:20

Scientific session 5: Challenging dogmas – from clinical trials to clinical practice
Torsten Kucharzik, Lüneburg, Germany
Maria Chaparro, Madrid, Spain

11:00 - 11:20
26: Mucosal healing – Is it the holy grail?
Geert D’Haens, Amsterdam, The Netherlands

11:20 - 11:30
27: Best abstract: A multicentre, double-blind, placebo-controlled phase3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s Disease refractory to anti-TNFα: UNITI-1
1University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 2Janssen R & D, LLC, Spring House, United States, 3Janssen Scientific Affairs, LLC., Horsham, United States, 4Mount Sinai Medical Center, New York, United States, 5Northwestern University Feinberg School of Medicine, Chicago, United States, 6Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada, 7Cedars-Sinai Medical Center, Division of Gastroenterology, Los Angeles, United States, 8University of Calgary, Department of Gastroenterology, Calgary, Canada, 9Universite Stellenbosch University, Stellenbosch, South Africa, 10Mount Sinai, Icahn School of Medicine, New York, United States, 11University of Washington, Seattle, United States, 12University of Lille, Lille, France, 13Mayo Clinic Rochester, Depart-ment of Gastroenterology, Rochester, United States, 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 15University of California San Diego, Division of Gastroenterology, La Jolla, United States

11:30 - 11:40
28: Best abstract: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn’s Disease who are anti-TNF inadequate responders
1Humanitas University Clinical and Research Hospital, Rozzano, Milan, Italy, 2University Hospitals Leuven, Leuven, Belgium, 3Nature Coast Clinical Research, Inverness, United States, 4University of Calgary, Calgary, Canada, 5University of Zürich, Zürich, Switzerland, 6Rabin Medical Centre and University of Tel-Aviv, Petah Tikva, Israel, 7AO San Camillo Forlanini, Rome, Italy, 8University of Lille, Inserm U995, Lille, France, 9Concord Hospital, Sydney, New South Wales, Australia, 10Pfizer Inc, Cambridge, United States, 11Pfizer Inc, Collegeville, United States, 12Christian-Albrechts University, Kiel, Germany

11:40 - 12:00
29: Patient-reported outcomes
William Sandborn, San Diego, United States

12:00 - 12:20
30: Should clinical trials in children be different?
Dan Turner, Jerusalem, Israel

12:20 - 13:20
Lunch break and guided poster session in the exhibition hall
Please refer to pages 38-39

12:30 - 13:10
Industry sponsored educational lunchtime satellite symposia LS1-4
Please refer to pages 191-192
## Scientific Programme day by day (as of February 15, 2016)

### Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Organizers</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:20 - 14:50</td>
<td>6</td>
<td><strong>Bugs and drugs in IBD</strong></td>
<td>Philippe Seksik, Paris, France, Barry Hall, Dublin, Ireland</td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td></td>
<td><strong>31: The microbiome and geographical spread of IBD</strong></td>
<td>Philip Rosenstiel, Kiel, Germany</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td></td>
<td><strong>32: Best abstract: Development and validation of diagnostic criteria for IBD-Unclassified (IBDU) in children: A multicentre longitudinal study from the Paediatric IBD Porto group of ESPGHAN</strong></td>
<td>L. Birimberg Schwartz¹, D. Zucker², A. Akriv³, C. Salvatore³, F. Cameron⁴, I. Lazowska⁵, L. Yianni⁶, P. Siba⁷, S. Kolacek⁸, C. Romano⁹, S. Buderus¹⁰, A. Pærregaard¹¹, J. C. Escher¹², <strong>D. Turner</strong>¹³, ¹Shaare Zedek Medical Center, Paediatrics, Jerusalem, Israel, ²The Hebrew University, Jerusalem, Israel, ³Sapienza University of Rome, Rome, Italy, ⁴Yorkhill Children’s Hospital, Glasgow, United Kingdom, ⁵Medical University of Warsaw, Warsaw, Poland, ⁶University Hospital Southampton, Hampshire, United Kingdom, ⁷University of Dundee, Scotland, United Kingdom, ⁸Zagreb University Medical School, Zagreb, Croatia, ⁹University of Messina, Messina, Italy, ¹⁰St. Marien Hospital, Bonn, Germany, ¹¹Hvidovre University Hospital, Copenhagen, Denmark, ¹²Erasmus Medical Center, Netherlands, ¹³Shaare Zedek Medical Center, Jerusalem, Israel</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td></td>
<td><strong>33: Manipulating the microbiota in everyday practice</strong></td>
<td>Francisco Guarner, Barcelona, Spain</td>
</tr>
<tr>
<td>14:10 - 14:20</td>
<td></td>
<td><strong>34: Best abstract: Multi donor intense faecal microbiota transplantation is an effective treatment for resistant Ulcerative Colitis: A randomised placebo-controlled trial</strong></td>
<td>S. Paramsothy¹, M. Kamm²,³, A. Walsh⁴, J. van den Bogaerde⁵, D. Samuel⁶, R. Leong⁶, S. Connor⁷, W. Ng⁷, R. Paramsothy⁷, N. Kaakoush⁸, H. Mitchell⁸, W. Xuan⁹, E. Lin¹⁰, T. Borody¹⁰, ¹University of New South Wales, St Vincent’s Clinical School, Sydney, Australia, ²St Vincent’s Hospital, Melbourne, Australia, ³Imperial College London, London, United Kingdom, ⁴St Vincent’s Hospital, Sydney, Australia, ⁵Nambour General Hospital, Nambour, Australia, ⁶Bankstown-Lidcombe Hospital, Sydney, Australia, ⁷Liverpool Hospital, Sydney, Australia, ⁸University of New South Wales, School of Biotechnology &amp; Biomolecular Sciences, Sydney, Australia, ⁹Ingham Institute, Sydney, Australia, ¹⁰Centre for Digestive Diseases, Sydney, Australia</td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td></td>
<td><strong>35: Best abstract: The impact of “Crohn’s Disease-TReatment-with-EATing” diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolism</strong></td>
<td>V. Svolos¹, R. Hansen², K. Hughes³, U.Z. Ijaz³, C. Quince⁴, D. Gaya⁵, R. Russell⁶, K. Gerasimidis⁶, ¹Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, ²Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, ³School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁴Warwick Medical School, University of Warwick, Warwick, United Kingdom, ⁵Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td></td>
<td><strong>36: Future strategies to change the flora</strong></td>
<td>Harry Sokol, Paris, France</td>
</tr>
</tbody>
</table>

14:50 - 15:20 **Coffee break**
**Scientific programme day by day (as of February 15, 2016)**

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>15:20 - 16:00</th>
<th><strong>Scientific session 7: ECCO Fellowships &amp; Grants</strong> Gerhard Rogler, Zürich, Switzerland Noortje Festen, Groningen, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20 - 15:27</td>
<td><strong>37: Outcomes from the 2015 Fellowships – Part 1</strong> Selective histone deacetylase inhibitors: A potential new treatment of Inflammatory Bowel Diseases Carla Felice, Rome, Italy</td>
</tr>
<tr>
<td>15:27 - 15:34</td>
<td><strong>38: Outcomes from the 2015 Fellowships – Part 2</strong> Sphingosine 1-phosphate (S1P)/S1PR3 axis a novel therapeutic target for intestinal fibrosis in Crohn's Disease Cristina Mascaraque, Granada, Spain</td>
</tr>
<tr>
<td>15:34 - 15:40</td>
<td><strong>39: Announcement of ECCO Fellowships &amp; Grants 2016</strong> Gerhard Rogler, Zürich, Switzerland</td>
</tr>
<tr>
<td>15:40 - 15:50</td>
<td>1Division of Gastroenterology, University of California, San Diego, United States, 2Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, 3Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, 4Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 5Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, 6IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, 7Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 8Robarts Research Institute, London, Canada, 9McMaster University, Hamilton, Canada, 10Pfizer Inc, Collegeville, United States, 11Pfizer Inc, Groton, United States</td>
</tr>
<tr>
<td>15:40 - 15:50</td>
<td>1UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, 2University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, 3Vivamed, Warsaw, Poland, 4Asklepios Hospital West Hamburg, Department of Internal Medicine, Gastroenterology, Hamburg, Germany, 5Archet 2 Hospital, Department of Gastroenterology, Nice, France, 6Saint Etienne Hospital, Department of Gastroenterology, Saint Priest en Jarez, France, 7University Hospital Nr. 2 im. Biziela, Department of Gastroenterology, Bydgoszcz, Poland, 8Policlinica Algomed, Department of Gastroenterology, Timisoara, Romania, 9Saint Family Hospital Medical Center, Department of Gastroenterology and Endoscopy, Lodz, Poland, 10City Clinical Hospital #31, St Petersburg, Russian Federation, 11Szent Margit Hospital, Department of Internal Medicine and Gastroenterology III, Budapest, Hungary, 12Galapagos NV, Department of Development, Mechelen, Belgium</td>
</tr>
</tbody>
</table>
### Scientific programme day by day (as of February 15, 2016)

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 8: Challenging Cases</th>
</tr>
</thead>
</table>
| 16:00 - 17:00 | Peter Irving, London, United Kingdom  
Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France |

<table>
<thead>
<tr>
<th>Session 8: Challenging Cases</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>42: Case 1: Challenges during pregnancy: Anti-TNF treatment during pregnancy</strong></td>
<td>16:00 - 16:20</td>
</tr>
<tr>
<td>Shannon Kanis, Rotterdam, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 8: Challenging Cases</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>43: Case 2: Refractory upper gut Crohn’s Disease: Refractory upper gut Crohn’s Disease with fatal outcome</strong></td>
<td>16:20 - 16:40</td>
</tr>
<tr>
<td>Miquel Cusachs, Barcelona, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 8: Challenging Cases</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>44: Case 3: When extra-intestinal symptoms dominate: Severe arthralgia in Crohn’s Disease – disease or drug-related?</strong></td>
<td>16:40 - 17:00</td>
</tr>
<tr>
<td>Donata Lissner, Berlin, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 9: What’s new on the Guidelines front?</th>
</tr>
</thead>
</table>
| 17:00 - 17:50 | Oded Zmora, Tel Aviv, Israel  
Loris Lopetuso, Rome, Italy |

<table>
<thead>
<tr>
<th>Session 9: What’s new on the Guidelines front?</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>45: ECCO Guidelines: Surgical CD</strong></td>
<td>17:00 - 17:10</td>
</tr>
<tr>
<td>Willem Bemelman, Amsterdam, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 9: What’s new on the Guidelines front?</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>46: Best abstract: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn’s Disease: Results of a Phase 2b randomised placebo-controlled trial</strong></td>
<td>17:10 - 17:20</td>
</tr>
</tbody>
</table>
| G. D’Haens¹, R. Pannaccione², P.D.R. Higgins³, J.-F. Colombel³, B.G. Feagan¹, M. Moscariello¹, G. Chan¹, P. Healey¹, W. Niezychowski¹, W. Wang¹, A. Marren², E. Maller³  
¹Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ²University of Calgary, Calgary, Canada, ³University of Michigan, Ann Arbor, United States, ⁴Robarts Research Institute, London, Canada, ⁵Pfizer Inc, Collegeville, United States, ⁶Pfizer Inc, Groton, United States |

<table>
<thead>
<tr>
<th>Session 9: What’s new on the Guidelines front?</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>47: Best abstract: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate to severe Crohn’s Disease: Results of a Phase 2b randomised placebo-controlled trial</strong></td>
<td>17:20 - 17:30</td>
</tr>
</tbody>
</table>
| J. Panés¹, W.I. Sandborn², S. Schreiber³, B.E. Sands³, S. Vermeire³, G. Chan³, M. Moscariello³, W. Wang³, W. Niezychowski³, A. Marren³, P. Healey³, E. Maller³  
¹Hospital Clinicas de Barcelona, IDIBAPS, CIBERErh, Barcelona, Spain, ²Division of Gastroenterology, University of California, San Diego, United States, ³Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁴Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ⁵Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁶Pfizer Inc, Collegeville, United States, ⁷Pfizer Inc, Groton, United States |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 10: What’s new on the Guidelines front?</th>
</tr>
</thead>
</table>
| 18:05 - 19:05 | Digital oral presentations (Sessions 6-10)  
Please refer to pages 56-66 |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 10: What’s new on the Guidelines front?</th>
</tr>
</thead>
</table>
| 18:05 - 19:05 | Industry sponsored satellite symposia 4a & 4b  
Please refer to page 193 |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 10: What’s new on the Guidelines front?</th>
</tr>
</thead>
</table>
| 20:00   | ECCO Interaction: Hearts & Minds  
Beurs van Berlage, Damrak 243, 1012 ZJ Amsterdam  
(Please refer to page 207) |
Saturday, March 19, 2016
Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td>Industry sponsored satellite symposia 5a &amp; 5b</td>
</tr>
<tr>
<td>08:30 - 10:20</td>
<td>Scientific session 10: Surgical and endoscopic FAQs in IBD</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td><strong>51: Case 1 – Preparing your patient for optimal surgery</strong></td>
</tr>
<tr>
<td></td>
<td>Richard Fedorak, Edmonton, Canada</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td><strong>52: Best abstract: Comparison between newly-developed NBI and panchroendoendoscopy for surveillance colonoscopy in patients with Ulcerative Colitis: A prospective multicentre randomised controlled trial, Navigator Study</strong></td>
</tr>
<tr>
<td></td>
<td>K. Watanabe¹, M. Nishishita², F. Shimamoto³, T. Fukuchi⁴, M. Esaki⁵, Y. Okamoto⁵, Y. Maehata⁵, S. Oka⁵, S. Nishiyama⁵, S. Fujii⁵, F. Hirai⁵, T. Inoue⁵, N. Hida¹⁰, R. Nozaki¹⁵, T. Sakurai¹⁵, K. Takeuchi¹⁵, M. Saruta¹⁴, S. Saito¹⁵, Y. Saito¹⁵, N. Ohmuya¹⁵, H. Kashiha¹⁵, S. Tanaka⁵, T. Matsui⁵, Y. Suzuki¹⁵, Y. Ajioka¹⁵, H. Tajiri¹⁵</td>
</tr>
<tr>
<td></td>
<td>¹Osaka City General Hospital, Gastroenterology, Osaka, Japan,</td>
</tr>
<tr>
<td></td>
<td>²Nishishita Gastrointestinal Hospital, Osaka, Japan,</td>
</tr>
<tr>
<td></td>
<td>³Faculty of Human Culture and Science Prefectural University of Hiroshima, Hiroshima, Japan,</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td><strong>53: Best abstract: Mucosal healing and dysplasia surveillance in a large referral centre cohort of patients with Crohn’s Disease and Ulcerative Colitis treated with vedolizumab</strong></td>
</tr>
<tr>
<td></td>
<td>M. Noman¹, M. Ferrante¹, R. Bisschops¹, G. De Hertogh², K. van den Broeck¹, K. Rans¹, P. Rutgeerts¹, S. Vermeire¹, G. van Assche²</td>
</tr>
<tr>
<td></td>
<td>¹UZ Leuven, Gastroenterology, Leuven, Belgium, ²UZ Leuven, Campus Gastrohuisberg, Pathology, Leuven, Belgium</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 09:10 - 09:20 | **54: Best abstract: Escalation of medical therapy decreases need for repeat dilatation in Crohn's anastomotic strictures**  
N.S. Ding\(^1\), W. Yip\(^1\), R. Choi\(^1\), B. Saunders\(^1\), S. Thomas-Gibson\(^1\), N. Arebi\(^1\), A. Humphries\(^1\), A. Hart\(^1\)  
\(^1\)St Mark's Hospital, IBD, London, United Kingdom, \(^2\)Imperial College London, Department of Surgery and Cancer, London, United Kingdom, \(^3\)St Mark's Hospital, Wolfson Unit For Endoscopy, Department of Gastroenterology, Harrow, United Kingdom |
| 09:20 - 09:40 | **55: Case 2 – Post-surgery prevention**  
Marc Ferrante, Leuven, Belgium |
| 09:40 - 09:50 | **56: Best abstract: The TOPPIC trial: A randomised, double-blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's Disease following surgical resection in 240 patients**  
I. Arnott\(^1\), C. Mowat\(^2\), H. Ennis\(^3\), C. Keerie\(^4\), S. Lewis\(^5\), N. Kennedy\(^4\), A. Cahir\(^2\), A. Morris\(^6\), M. Dunlop\(^7\), S. Bloom\(^7\), J. Lindsay\(^8\), S. Subramanian\(^9\), J. Satsangi\(^9\), on behalf of the Toppic Trial Study Group\(^10\)  
\(^1\)NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, \(^2\)NHS Tayside, Gastroenterology, Dundee, United Kingdom, \(^3\)University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom, \(^4\)University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, \(^5\)NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, \(^6\)University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, \(^7\)University College Hospital, Department of Gastroenterology, London, United Kingdom, \(^8\)Bart's Health NHS Trust, Newham University Hospital, Department of Gastroenterology, London, United Kingdom, \(^9\)Royal Liverpool University Hospital, Gastroenterology, Liverpool, United Kingdom, \(^10\)Toppic Trial Study Group, UK, United Kingdom |
| 09:50 - 10:00 | **57: Best abstract: Anti-TNF therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn's Disease: Outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group**  
A. Brouquet\(^1\), L. Maggiori\(^2\), P. Zerbib\(^3\), J. Lefèvre\(^4\), Q. Denost\(^5\), A. Germain\(^6\), E. Cotte\(^7\), L. Beyer-Berjot\(^8\), N. Munoz-Bongrand\(^9\), V. Desfournes\(^10\), A. Rahili\(^11\), J.-P. Duffas\(^12\), K. Pautrat\(^13\), C. Denet\(^14\), V. Bridoux\(^15\), G. Meurette\(^16\), J.-L. Faucheron\(^17\), J. Loría\(^18\), F. Guillon\(^19\), E. Vicaut\(^20\), S. Benoist\(^2\), Y. Panis\(^2\)  
\(^1\)Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive Surgery, Le Kremlin Bicêtre, France, \(^2\)Beaun Hospital, Colorectal Surgery, Cluny, France, \(^3\)CHU Lille, Digestive Surgery, Lille, France, \(^4\)Saint Antoine Hospital, Digestive Surgery, Paris, France, \(^5\)CHU Bordeaux, Digestive Surgery, Bordeaux, France, \(^6\)CHU Nancy, Digestive Surgery, Nancy, France, \(^7\)CHU Lyon-Sud, Digestive Surgery, Lyon, France, \(^8\)CHU Marseille, Digestive Surgery, Marseille, France, \(^9\)Saint Louis Hospital, Digestive Surgery, Paris, France, \(^10\)CHU Rennes, Digestive Surgery, Rennes, France, \(^11\)CHU Nice, Digestive Surgery, Nice, France, \(^12\)CHU Toulouse, Digestive Surgery, Toulouse, France, \(^13\) Lariboisière Hospital, Digestive Surgery, Paris, France, \(^14\)Montsouris Institute, Digestive Surgery, Paris, France, \(^15\)CHU Rouen, Digestive Surgery, Rouen, France, \(^16\)CHU Nantes, Digestive Surgery, Nantes, France, \(^17\)CHU Grenoble, Digestive Surgery, Grenoble, France, \(^18\)Saint-Joseph Hospital, Digestive Surgery, Paris, France, \(^19\)CHU Montpellier, Digestive Surgery, Montpellier, France, \(^20\)Fernand Widal Hospital, Clinical Research, Paris, France |
### Scientific Programme day by day (as of February 15, 2016)

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:20</td>
<td><strong>58: Case 3 – Dealing with a problematic pouch</strong></td>
</tr>
<tr>
<td></td>
<td>Michael Kamm, Melbourne, Australia</td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>10:50 - 12:20</td>
<td><strong>Scientific session 11: Right time, right drug, right strategy</strong></td>
</tr>
<tr>
<td></td>
<td>Marieke Pierik, Maastricht, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Nik Ding, London, United Kingdom</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td><strong>59: Molecular stratification of the patient</strong></td>
</tr>
<tr>
<td></td>
<td>Miles Parkes, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>11:10 - 12:00</td>
<td><strong>60: Best abstract: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s Disease: Results from the UNITI-1 and UNITI-2 studies</strong></td>
</tr>
<tr>
<td></td>
<td>O.J. Adedokun1, Z. Xu1, C. Gasink1, J. Friedman1, P. Szapary1, Y. Lang1,</td>
</tr>
<tr>
<td></td>
<td>J. Johans1, L-L. Gao1, Y. Miao1, H. Davis1, S. Hanauer1, B. Feagan1, W. Sandborn1</td>
</tr>
<tr>
<td></td>
<td>1Janssen R &amp; D, LLC, Spring House, United States, 2Northwestern University Feinberg School of Medicine, Chicago, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Canada, 4UCSD, Medicine, La Jolla, United States</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td><strong>61: Choosing the right drug</strong></td>
</tr>
<tr>
<td></td>
<td>Iris Dotan, Tel Aviv, Israel</td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td><strong>62: Best abstract: Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn’s Disease: A prospective, randomised, multicentre trial (Tailorix)</strong></td>
</tr>
<tr>
<td></td>
<td>G. D’Haens1, S. Vermeire1, G. Lambrecht1, F. Baert1, P. Bossuyt1, M. Nachury1, A. Buisson1,</td>
</tr>
<tr>
<td></td>
<td>Y. Bouhnik1, J. Filippi1, J. van der Woude1, P. van Hootegem1, J. Moreau1, E. Louis1,</td>
</tr>
<tr>
<td></td>
<td>D. Franchimont1, M. De Vos1, F. Man1, L. Peyrin-Biroulet1, H. Brix1, M. Allez1, P. Caenepeel1,</td>
</tr>
<tr>
<td></td>
<td>A. Aubourg1, B. Oldenburg1, M. Pierik1, A. Gils1, S. Chevret2, D. Laharie24</td>
</tr>
<tr>
<td></td>
<td>1Academic Medical Centre, Gastroenterology, Amsterdam, Netherlands, 2University Hospitals Gasthuisberg, Gastroenterology, Leuven, Belgium, 3AZ Darniaan, Oostende, Belgium, 4AZ Delta, Roeselare, Belgium, 5Imelda GI Clinical Research Centre, Bonheiden, Belgium, 6Hospital Claude Huriez, Lille, France, 7Hospital Estaiing, Clermont-Ferrand, France, 8Hospital Beaujon, Clichy, France, 9Hospital Archet, Nice, France, 10Erasmus Medical Centre, Rotterdam, Netherlands, 11St Lukas Hospital, Bruges, Belgium, 12Hospital Rangueil, Toulouse, France, 13Hospital Sart Tilman, Liège, Belgium, 14Hospital Erasme, Brussels, Belgium, 15University of Ghent, Ghent, Belgium, 16Free University of Brussels, Brussels, Belgium, 17Hospital Brabois, Nancy, France, 18Hospital Robert Debre, Reims, France, 19Hospital St Louis, Paris, France, 20Ziekenhuis Oost Limburg, Genk, Belgium, 21Hospital Trousseau, Tours, France, 22University of Utrecht, Utrecht, Netherlands, 23University Hospital Maastricht, Maastricht, Netherlands, 24University of Leuven, Leuven, Belgium, 25Department Biostatistique St Louis, Paris, France, 26Haut-Leveque, Pessac, France</td>
</tr>
</tbody>
</table>
Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

11:50 - 12:00

63: Best abstract: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in Ulcerative Colitis

1Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 2Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, 3Sapporo-kosei General Hospital, Inflammatory Bowel Diseases Center, Sapporo, Japan, 4Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 5Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan, 6Kitano Hospital The Tazuke Kofukai Medical Research Institute, Digestive Disease Center, Osaka, Japan, 7Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 8Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan

12:00 - 12:20

64: Care or action plans for patients

Jane Andrews, Adelaide, Australia
Karen Kemp, Manchester, United Kingdom

12:20 - 12:50

Scientific session 12: ECCO Lecture

Séverine Vermeire, Leuven, Belgium
Julián Panés, Barcelona, Spain

12:20 - 12:50

65: Future of IBD healthcare in Europe

Daniel Hommes, Los Angeles, United States

12:50 - 12:55

66: Awards and closing remarks

Julián Panés, Barcelona, Spain
on behalf of the Organising Committee

12:55 - 13:00

The ECCO Film 2016
“Bringing science, therapy & quality to patients”

February 18-21, 2015, Barcelona, Spain

**Opening & welcome:**
Eugeni Domènech (ES) and Séverine Vermeire (BE)

**Scientific session 1: The exposome in the pathogenesis of IBD**

13:00 – 14:30

Arie Levine (IL) and Isabelle Cleynen (BE)

- How food triggers inflammation: Marc Veldhoen (UK)
- Best abstract: Transmissive Crohn’s disease-like ileitis is caused by functional dysbiosis in the intestinal microbiota independent of inflammation-driven Paneth cell failure: Monika Schaubock (DE)
- Impact of lifestyle changes on disease course: Gerhard Rogler (CH)
- Best abstract: UK IBD twin and multiplex registry: Concordance and environmental risk factors of twins with IBD: Hannah Gordon (UK)
- Best abstract: Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial: N.G.M. Rossen (NL)
- Epigenetics of IBD: Jack Satsangi (UK)

**Scientific session 2: Pharmacokinetics in clinical practice: Does it matter?**

15:00-17:00

Geert D’Haens (NL) and Eugeni Domènech (ES)

- Influence of the inflammatory burden on pharmacokinetics of biologicals: Diane Mould, (US)
- Best abstract: Adalimumab and infliximab levels in neonates (ERA study): Mette Jølsgaard (DK)
- Understanding pharmacokinetics and immunogenicity of anti-TNFs: Ann Gils (BE)
- Best abstract: Infliximab trough level thresholds vary depending on the efficacy criterion chosen in IBD patients: Xavier Roblin (FR)
- Best abstract: Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn’s Disease patients: Thomas Billiet (BE)
- Applying pharmacokinetics in the daily care of patients: from combination therapy to therapeutic drug monitoring: Barrett Levesque (US)
- Best abstract: Complete remission in Crohn’s Disease does not prevent disease relapse after withdrawal of anti-TNF α therapy: Martin Bortlik (CZ)
- Applying the lessons learnt from anti-TNF strategies to novel biologics: Yehuda Chowers (IL)

**Friday, February 20, 2015**

**Scientific session 3: Optimal use of resources**

08:30-09:30

Anna Kohn (IT) and John Mansfield (UK)

- The true cost of IBD care: Keith Bodger (UK)
- Best abstract: The first prospective Australian population-based study of newly diagnosed IBD identifies frequent use of immunomodulators, low surgery rates and high cost from medications and investigations: Olga Niewiadomska (AUS)
Scientific Programme
10th Congress of ECCO - Barcelona

- Best abstract: Unchanged surgery and hospitalization rates in an East-West European inception cohort despite differences in use of biologicals - 3-year follow-up of the ECCO-EpiCom cohort: Johan Burisch (DK)
- Surgical alternatives to biological therapy: Omar Faiz (UK)

Scientific session 4: The gut barrier under attack: Therapeutic implications 09:30-10:30
Silvio Danese (IT) and Philippe Marteau (FR)

- Mechanisms of damage and repair: Gijs van den Brink (NL)
- Best abstract: Medication-induced microscopic colitis: Do recency and duration of use matter? Bas P.M. Verhaegh (NL)
- Best abstract: Budesonide MMX® 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs: David T. Rubin (US)
- The microbiome in the pathogenesis and therapy of IBD: Allsa Hart (UK)

Scientific session 5: Delivering quality to the patients 11:00-12:20
Simon Travis (UK) and Philippe Marteau (FR)

- The central role of the IBD nurse in the multidisciplinary management: Marian O'Connor (UK)
- Best abstract: Information needs and concerns of patients with Inflammatory Bowel Disease: What can we learn from participants of a national clinical cohort? Valérie Pittet (CH)
- Measuring the quality performance of your centre: Xavier Calvet Calvo (ES)
- Best abstract: Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years? Andreas Stallmach (DE)
- Panel discussion: Simon Travis (UK) and Ronan O’Connell (IE) and Zuzana Zelinkova (SK) and Hankje Escher (NL) and Marian O’Connor (UK)

Scientific session 6: Anti-TNF: Originators & Biosimilars 13:30-15:00
Gerassimos Mantzaris (GR) and Gronata Fiorino (IT)

- The science behind biosimilars: Gonzalez Calvo (ES)
- Best abstract: Use of anti-TNF-α agents in relation to first-time surgery for ulcerative colitis and Crohn’s disease during childhood: Michael Due Larsen (DK)
- Experience with biosimilars from rheumatology: Ulf Müller-Ladner (DE)
- Best abstract: Multicentre clinical trial with topical administration of the Toll-Like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis: Raja Atreya (DE)
- Best abstract: Treatment strategy during the first year after diagnosis in patients with inflammatory bowel diseases from the 2011 ECCO-EpiCom inception cohort: Zsuzsanna Vegh (HU)
- Unanswered questions on biosimilars in IBD: Stefan Schreiber (DE)

Scientific session 7: ECCO Fellowships & Grants 15:30-16:10
Edouard Louis (BE) and Pieter Hindryckx (BE)

- Outcomes from the 2013-14 Fellowships: The effect of vitamin D on the intestinal microbiome in patients with Ulcerative Colitis: Mayur Garg (AUS)
- Outcomes from the 2013-14 Fellowships: Mechanisms of primary non response to anti-TNFα therapy in Inflammatory Bowel Disease: Konstantinos Papamichael (GR)
- Announcement of ECCO Fellowships and Grants 2015: Edouard Louis (BE)
• Best abstract: Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab: David Laharie (FR)
• Best abstract: Prolonged Deep Remission of Ileocolonic Crohn’s Disease following Autologous Haemopoietic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists: Chris Hawkey (UK)

Scientific session 8: Challenging Cases
16:10-17:10
Edouard Louis (BE) and Pierre Michetti (CH) and Frank Ruemmele (FR)
• Case 1: Risk of cancer in chronic perianal disease: Stephan Vavricka (CH)
• Case 2: Risk of infection occurring under biological treatment: Thomas Billet (BE)
• Case 3: Loss of response to anti-TNF in paediatrics: Malgorzata Sladek (PL)

Scientific session 9: What’s new on the Guidelines front?
17:10-17:50
Vito Annese (IT) and Tiago Nunes (DE/BR)
• Malignancy: Rami Elisafim (IL)
• Best abstract: Forty-Year Analysis of Colonoscopic Surveillance for Ulcerative Colitis Reveals Decreasing Risk of Interval and Advanced Cancer and Reducing Colectomy Rate for Dysplasia: Chang Ho Ryan Choi (UK)
• Best abstract: Patients with Inflammatory Bowel Disease and a history of cancer: The risk of cancer following exposure to immunosuppression: Jordan Axelrad (US)
• Extra-intestinal manifestations: Franck Carbonnel (FR) & Marcus Harbord (UK)

Saturday, February 21, 2015

Scientific session 10: New therapies and strategies
08:30-10:20
Laurent Peyrin-Biroulet (FR) and Krzysztof Gocse (HU)
• New algorithms for treating IBD: Gert van Assche (BE)
• Best abstract: TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of Anti-MACAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC): Sverre Vermeire (BE)
• Best abstract: Anti-MACAM-1 Antibody (PF-00547659) for Active Refractory Crohn’s Disease: Results of the OPERA study: Geert D’Haens (NL)
• Best abstract: Methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial: Franck Carbonnel (FR)
• Positioning of the new molecules in practice: Brian Feagan (CA)
• Best abstract: A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC 1063) in moderate to severe Ulcerative Colitis: Results of the TOUCHSTONE study: William Sandborn (US)
• Best abstract: A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: Bruce E. Sands (US)
• New surgical techniques: Willem Bemelman (NL)

Scientific session 11: Managing the manageable: Chronic pain and fatigue
10:50-12:20
Eduard Cabré (ES) and Igor Khalif (RU)
• Joint pain: arthritis and arthralgias: Juan Jesús Gómez Heinó (ES)
• Algorithm for abdominal pain management: Andreas Sturm (DE)
• Algorithm for the management of fatigue: Janneke van der Woude (NL)
• Best abstract: Post-operative use of anti-TNF agents in patients with Crohn’s disease and risk of re-operation - a nationwide cohort study: Jens Kjeldsen (DK)
- Best abstract: Oral delivery of a new class of non-antibody protein scaffold Nanofilins targeting TNF-alpha shows a strong preventive and curative anti-inflammatory effect in models of inflammatory bowel disease. Mathieu Clinier (FR)

**Scientific session 12: ECCO Lecture**

Séverine Vermeire (BE) and Julián Panés (ES)
- The science which will impact our IBD clinic: Maria Abreu (US)
- Awards and closing remarks: Séverine Vermeire (BE)
- The ECCO Film 2015

12:20-12:50
"The causes, consequences and quality of care for IBD"

February 20-22, 2014, Copenhagen, Denmark

Thursday, February 20, 2014

Top tips for chairs (closed session): 10:45 – 11:15
Geert D’Haens (NL)

Opening & welcome: 12:45 – 13:00
Simon Travis (UK) and Ole Hamberg (DK)

Scientific session 1: Neglected cells as potential target 13:00 – 14:30
Eduard Stange

(DE) and James Lee (UK)
- Lymphatic endothelial cells as mediators and targets: Silvio Danese (IT)
- Best abstract: Innate lymphoid cells accumulate in IBD. Geremia, A. (UK)
- Mast cells at the leading edge: Guy Boeckxstaens (BE)
- Best abstract: The GCN2/eIF2alpha/ATF4 signaling pathway is necessary for autophagy response to infection with Crohn’s Disease-associated adherentive Escherichia coli: Nguyen, H. (FR)
- Best abstract: Circadian clock function maintains mucosal architecture and protects against intestinal inflammation in mice: Sina, C. (DE)
- Stromal cells: Innocent bystanders or regulators? Ben Owens (UK)

Scientific session 2: Optimisation of therapy 15:00 – 17:00
Jean-Frédéric Colombel (US) and Dirk van Asseldorik (NL)
- Defining quality: Gil Melmed (US)
- Best abstract: Early combined immunosuppression for the management of Crohn’s Disease: A community-based cluster randomized trial: Feagan, B.G. (CA)
- Maintaining quality when choice is limited: Vineet Ahuja (IN)
- Best abstract: Is elderly-onset Ulcerative Colitis a different entity? Natural disease course and treatment response compared to adult-onset disease in the population-based IBDSL cohort: Jeuring, S. (NL)
- Best abstract: Personalised thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients; Results from a randomized trial in the Netherlands: Coenen, M. (NL)
- Biologic drug levels in practice: Shomron Ben-Horin (IL)
- Best abstract: Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn’s Disease patients who are anti-TNF inadequate responders: Results from the TOSCA study: D’Haens, G. (NL)
- Travel with IBD: Climb high; dive deep: Stephan Vavricka (CH)
Friday, February 21, 2014

Scientific session 3: Cost of therapy, burden of care

Pia Munkholm (DK) and Irl Monstad (NO)
- Biosimilars – straight ahead or off at a tangent? Pierre Michetti (CH)
- Best abstract: The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study. Burisch, J. (DK)
- Best abstract: Long-term safety and efficacy of golimumab in patients with moderately to severely active Ulcerative Colitis: Results from the PURSUIT-SC maintenance study extension. Reinisch, W. (CA)
- Exit strategies: James Lindsay (UK)

Scientific session 4: Tomorrow’s therapy

Herbert Tilg (AT) and Pär Myrelid (SE)
- It’s decision time: Anti-TNF vs anti-integrin therapy. Julian Panés (ES)
- Tomorrow’s surgery: Antonio Spinielli (IT)

Scientific session 5: Fibrosis as a complication

Gerhard Rogler (CH) and Tim Raine (UK)
- ECCO-DigestScience Research funding 2014 – Award ceremony
- Intestinal fibrogenesis: Claudio Fiocchi (US)
- Imaging: inflammation vs. Fibrosis: Andrea Laghi (IT)
- Tandem Talk: Strictureysis: potential and practice: Iris Dotan (IL) and Willem Bernelmaan (NL)

Scientific session 6: Intestinal failure

Laurence Egan (IRE) and Aurelien Amiot (FR)
- Physiology and consequences of short bowel syndrome. Palle Jeppesen (DK)
- Best abstract: Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric Ulcerative Colitis. Turner, D. (IL)
- Surgical quality: timing of decision-making. Iain Anderson (UK)
- Best abstract: Gut homing markers in perianal Crohn’s fistulae. Yassin, N.A. (UK)
- Intestinal transplantation: Just the end, or the end of the beginning? Peter Friend (UK)
Scientific session 7: ECCO Fellowships and Grants

Michael Kamm (AUS) and Pierre Michetti (CH)
- Outcomes from 2012 – 13 Fellowships: Nathalie Aoun (LEB) and Markus Tschurtschenthaler (AT)
- Announcement of ECCO Fellowships and Grants 2014: Edouard Louis (BE)
- Best abstract: Transethnic association study of IBD identifies 14 new disease loci and demonstrates pervasive sharing of genetic risk factors and phenotypic features between five seronegative autoinflammatory disease: Weersma, R.K. (NL)
- Best abstract: Cross-disease study determines extent of sharing of associated loci between five seronegative autoinflammatory disease: Ellinghaus, D. (DE)
- Best abstract: Optimising the use of faecal calprotectin for early diagnosis of IBD in primary care: R. P. H. Logan (UK)

Scientific session 8: Challenging Cases

Michael Kamm (AUS) and Pierre Michetti (CH) and Yves Panis (FR)
- Case 1: Ileal Crohn’s disease (is therapeutic choice making decisions more complex?): Marc Ferrante (BE)
- Case 2: Acute severe colitis (the stakes are high): Maria Nachury (FR)
- Case 3: Dealing active Crohn’s in pregnancy: Jaqueline Paterson (UK)

Scientific session 9: What’s new on the guideline front

Axel Dignass (DE) and Rami Eliakim (IL)
- ECCO Guidelines: Reproduction and IBD: Janneke van der Woude (NL)
- ECCO Guidelines: P-ECO/ESGPHAN Guidelines in Paediatric CD: Frank Ruemmele (FR)
- ECCO Guidelines: The Crohn’s Disease Consensus: Axel Dignass (DE)

Saturday, February 22, 2014

Scientific session 10: Colitis under the microscope

Gerassimou Mantzaris (GR) and Signe Wildt (DK)
- Is microscopic colitis IBD? Cord Langner (AT)
- Best abstract: Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a deficient commensal bacteria implicated in Crohn’s Disease: Seksil, P. (FR)
- Best abstract: Hypoxia responsive elements methylation status governs adherent-invasive Escherichia coli-receptor CEACAM6 expression in Crohn’s Disease: Barnich, N. (FR)
- Best abstract: 16S rRNA gene pyrosequencing indicate that siblings of Crohn’s Disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities: Hedlin, C. (UK)
- Treatment-refractory microscopic colitis: Andreas Munch (SE)
- ECCO Guidelines on Anaemia in IBD: Konstantinos Katsanos (GR)
- Best abstract: Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn’s Disease in the IMAGINE 1 trial: Griffiths, A. (CA)
- ECCO Guidelines on Surgery in Ulcerative Colitis: André D’Hoore (BE)
Scientific session 11: Challenging current practice: Value-based healthcare for IBD

10:50 – 12:20

Zuzana Serclova (CZ) and Marilia Cravo (PT)

- What triggers relapse? Charles Bernstein (CA)
- Best abstract: Low microbial gene diversity and depletion of Akkermansia muciniphila is associated with a relapsing course of Ulcerative Colitis: Casellas, F (ES)
- Post-operative prevention - offence or defence? Paul Rutgeerts (BE)
- Best abstract: Optimising post-operative Crohn’s Disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring: The POCER study: Kamm, M.A. (AU)
- Best abstract: Agreement among central readers in the evaluation of endoscopic disease activity in Crohn’s Disease: Khanna, R. (CA)
- Challenging conventional pathways of care: Daan Hommes (US)

Scientific session 12: ECCO Lecture

12:20 – 12:50

Séverine Vermeire (BE) and Simon Travis (UK)

- The causes of Crohn’s Disease? Tony Segal FRS (UK)
- Awards and closing remarks: Séverine Vermeire (BE)
- The ECCO Film 2014
“New concepts and current challenges in IBD”
February 14-16, 2013, Vienna, Austria

Thursday, February 14, 2013

Top tips for chairs (closed session): Geert D’Haens (NL) 10:15 – 10:45

Join the fight against IBD 2013: “Crohn’s and Colitis in Europe: The burden of disease in young people:
Helmut Brand (NL) 12:15 – 12:45

Opening & welcome:
Simon Travis (UK) and Wolfgang Petritsch (AT) 12:45 – 13:00

Scientific session 1: Early stage IBD Oliver Brain (UK) and
Silvio Danese (IT) 13:00 – 14:30

- Does the pathogenesis change over the course of the disease?: Matthieu Allez (FR)
- Best abstract: Functional consequences of a novel IL-10 receptor alpha mutation on innate and adaptive immunity in early-onset Inflammatory Bowel Disease: J. N. Samsom (NL)
- Is there a therapeutic window of opportunity?: Gert van Assche (BE)
- Best abstract: A novel FOXO3-driven pathway determines prognosis in Crohn’s Disease, rheumatoid arthritis and malaria: J. Lee (UK)
- Best abstract: Anti-TNF in patients with an early course of Crohn’s Disease - a prospective observational study in Germany: B. Bokemeyer (GER)

Scientific session 2: Preventing progression in IBD 15:00 – 17:00

Arthur Kaser (UK) and Alexander Moschen (AT)

- Fat and inflammation: Britta Siegmund (GER)
- Best abstract: Caspase 8 maintains epithelial cell adhesion and intestinal homeostasis in vivo through regulation of clathrin-dependent endocytosis and autophagy: G. Pineton de Chambrun (FR)
- Inflammation in IBD: Tissue repair or despair: Florian Rieder (US)
- Best abstract: Prep 1: A new player in the development of IBD-associated fibrosis: S. D’Alessio (IT)
- Best abstract: Development of the Crohn’s Disease (CD) digestive damage score: The Lémann score: B. Pariente (FR)
- Best abstract: ER stress transcription factor Xbp1 suppresses intestinal tumourigenesis: L. Niederreiter (UK)
- Preventing cancer: Ian Lawrance (AU)
- ECCO: ESP Histopathology Guidelines in IBD: Arzu Ensari (TR) and Fernando Magro (PT)
Friday, February 15, 2013

Scientific session 3: What is on the horizon? 08:30 – 09:30
Siew Ng (CN) and Herbert Tilg (AT)
- Genomics in IBD: Who gets what and when? Stefan Schreiber (GER)
- Best abstract: Characterization of the ~40,000 patient cohort of the International Inflammatory Bowel Disease Genetics Consortium (IBDGC): C. W. Lees (UK)
- Best abstract: Clinical and endoscopic improvement following haemopoietic stem cell transplantation in the ASTIC trial: C. Hawkey (UK)
- Therapeutic targets to hit or miss: Jean-Frédéric Colombel (US)

Scientific session 4: Clinical trials in Ulcerative Colitis 09:30 – 10:30
Franck Carbonnel (FR) and Alexander Eser (AT)
- Pitfalls in design and practice: Brian Feagan (CA)
- Best abstract: Indigenous Australians (IA) have a distinctive gut microbial profile compared to patients with Inflammatory Bowel Disease (IBD) and non Indigenous control: G. Iyngkaran (AU)
- Best abstract: Videlizumab induction therapy for patients with Crohn’s Disease and prior anti-tumour necrosis factor antagonist failure: A randomised, placebo-controlled, double-blind, multicentre trial: P. Rutgeerts (BE)
- Long-term outcomes: Sandro Ardizzone (IT)

Scientific session 5: Reproduction and IBD 11:00 – 12:20
Monica Cesarini (IT) and Sanja Kolacek (HR)
- Pharmacokinetics in pregnancy and location: Implications for drug efficacy & safety: Zuzana Zelinkova (SK)
- Best abstract: Pre-existing IgG antibodies to the Fab region of infliximab predict efficacy and safety in IBD patients naïve to anti-TNF agents: C. Steenholt (DK)
- Care from conception to delivery: Janneke van der Woude (NL)
- Best abstract: Prevalence of anemia in patients with Inflammatory Bowel Disease during the first ten years from diagnosis-results from a population-based inception cohort, the IBSEN Study: M. L. Helvik (NO)
- Neonatal safety: Saskia de Wildt (NL)

Scientific session 6: Adolescents with IBD 13:30 – 14:50
Kajsa-Leena Kolho (FI) and Frank Ruemmele (FR)
- The adolescent phenotype: Gabor Veres (HU)
- Best abstract: Incidence and phenotype at diagnosis in paediatric IBD patients –An ECCO-EpiCom study: J. Bursch (DK)
- Organising care: Hankje Escher (NL)
- Best abstract: Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with Inflammatory Bowel Disease: DEVELOP registry data: J. Escher (NL)
- Therapeutic strategies: Richard Russell (UK)

Scientific session 7: ECCO Fellowships and Grants 15:20 – 16:05
Marie Joossens (BE) and Andreas Sturm (GER)
- Outcomes from 2011/12 Fellowships: Timon Erik Adolph (AT) and Jessica Claire Wilson (IE)
- Announcement of ECCO Fellowships and Grants 2013: Andreas Sturm (GER)
- Best abstract: Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn’s Disease: Analyses from the SONIC trial: L. Peyrin-Biroulet (FR)
- Best abstract: Optimising the use of faecal calprotectin for early diagnosis of IBD in primary care: P. H. Logan (UK)
Saturday, February 16, 2013

Scientific session 9: Course and treatment of IBD in the elderly 08:30 – 10:30

Mircea Diculescu (RO) and Konstantinos Papadakis (GR)
- The natural history of IBD in the elderly: Corinne Gower-Rousseau (FR)
- Best abstract: The quality of care for inpatients with Inflammatory Bowel Disease in the UK over a six year period: L. Alrubay (UK)
- Medical management of IBD in the elderly: David Binion (US)
- Best abstract: Tumour necrosis factor-alpha antagonists and cardiovascular disease in Inflammatory Bowel Disease: N. Nyboe Andersen (DK)
- Best abstract: Mortality and causes of death in Ulcerative Colitis: Results from a Norwegian population based study during a twenty years period of follow-up (the IBSEN study): I. L. K. Monstad (NO)
- Minimising damage: Single incision surgery and enhanced recovery: Tonia Young-Fadok (US)
- First N-ECCO Consensus on caring for patients with IBD: Marian O’Connor (UK)
- Opportunistic Infection Guidelines: The update: Jean-François Rahier (BE)

Scientific session 10: Treating IBD in patients with past or current malignancy 11:00 – 12:20

Dino Tarabar (RS) and Ricardo Veloso (PT)
- The risk of extra-intestinal cancer in IBD: Tine Jess (DK)
- Best abstract: Risk of cervical dysplasia and cancer in patients with Inflammatory Bowel Disease: C. Runge (DK)
- Lessons from rheumatology: Georg Schett (GER)
- Best abstract: When to stop therapy in Crohn’s Disease? Results of the EPACT-2 Update panel: V. Pittet (SH)
- Practical management of IBD with past or current malignancy: David Laharie (FR) and Jean-Frédéric Blanc (FR)

Scientific session 11: ECCO Lecture 12:20 – 12:50

Simon Travis (UK) and Séverine Vermeire (BE)
- Where it all started and where it’s going to: Biological therapy for IBD: Sander van Deventer (NL)

Closing remarks 12:50 – 13:00

Organising Committee Members and Simon Travis (UK)
“Breaking down barriers in IBD”

February 16-18, 2012, Barcelona, Spain

Thursday, February 16, 2012

Top tips for chairs (closed session): Geert D’Haens (NL) 10:45 – 11:15

Opening & welcome:
Miquel Gassull (ES) and Daniel Hommes (US) 12:45 – 13:00

Scientific session 1: Common ground across inflammatory disorders 13:00 – 14:20
Miquel Sans (ES) and Jan Wehkamp (GER)
- Tandem talk: Shared pathways in inflammation: Maria Abreu (US) and Fiona Powrie (UK)
- Best abstract: Card9 is a crucial adapter protein for gastro-intestinal immune response: Harry Sokol (FR)
- Best abstract: Identification of Glycoprotein 2 as an immunomodulator of innate and adaptive immune responses: Lael Weiner (GER)
- Best abstract: Induction of autophagy upon DC-T cell contact is mediated by LKB1-AMPK-mTOR signaling: Manon Wildenberg (NL)
- Inflammatory side-effects of biological therapy: François Aubin (FR)

Scientific session 2: Measuring success and failure in IBD Dana Duricova (CZ) 14:50 – 16:10
and Pierre Michetti (CH)
- Predicting disease outcome: Siw Ng (HK)
- Best abstract: Mortality and cancer in paediatric Inflammatory Bowel Disease: A population-based study: Guillaume Savoye (FR)
- Tandem talk: Scoring disease damage and disability: Benjamin Pariente (FR) and Laurent Peyrin-Biroulet (FR)
- Best abstract: Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s Disease: Edouard Louis (BE)
- Assessing endoscopic and disease activity in practice: Gert van Assche (BE)

Scientific session 3: Preliminary results from the 3rd Scientific Workshop 16:10 – 16:30
Dana Duricova (CZ) and Pierre Michetti (CH)
- Malignancy in IBD: Laurent Beaugerie (FR), Silvio Danese (IT) and Laurence Egan (IRE)

Mini-session 3: ECCO-ESPghan Paediatric Guidelines on UC Dan Turner (IL) 16:30 – 17:00
Friday, February 17, 2012

Scientific session 4: Imaging in IBD

08:30 – 09:30
Simon Jackson (UK), André D’Hoore (BE) and Janneke van der Woude (NL)
- Medical or surgical therapy for obstruction: Is imaging the key? Casper Gjjsbert Noomen (NL)
- IBDU facing surgery - Are you sure the small bowel is normal? Alisa Hart (UK)
- ECCO-ESGAR Imaging Guidelines: Julián Panés (ES)
- Case resolution
- Best abstract: Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD - A pilot study: Helmut Neumann (GER)
- Best abstract: Use of fecal calprotectin as marker of disease activity in patients under maintenance treatment with infliximab for ulcerative colitis: Martine De Vos (BE)

Scientific session 5: Complications carousel: Management tips and tricks

09:30 – 10:30
Simon Jackson (UK), André D’Hoore (BE) and Janneke van der Woude (NL)
- Anaemia: Christoph Gasche (AT)
- Osteoporosis: Ad Van Bodegraven (NL)
- Renal: Satish Keshav (UK)
- Ocular: Luis Pablo (ES)
- Pulmonary: Franck Carbonnel (FR)
- Thromboembolism: Gerassimos Mantzaris (GR)
- Discussion

Scientific session 6: Impact of IBD on daily life

11:00 – 12:20
Fermin Mearin (ES) and Fernando Magro (PT)
- Debate: IBD and IBS - Marriage or divorce? Giovanni Barbara (IT) and Michael Kamm (AUS)
- Best abstract: SPARC modifies colonic tissue healing and inflammation by regulating collagen and MMP expression: Ian Lawrence (AUS)
- Best abstract: Anti-TNF-alpha Therapy is a major cost driver in Inflammatory Bowel Disease: Results from the COIN study: Mirthe Van der Valk (NL)
- The patient perspective: Ben Wilson (UK)

Guided poster session
Poster award ceremony

Scientific session 7: Organising care in IBD Mircea

13:30 – 14:30
Dicleuvs (RO) and Francesc Casellas (PT)
- E-Health and home-testing: Ready for prime time? Pia Munkholm (DK)
- Best abstract: Importance of trough levels and antibodies on the long-term efficacy of Infliximab therapy in Ulcerative Colitis: Maria Teresa Arias Santander (ES)
- Best abstract: Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled trough level adapted infliximab treatment (TAXIT) trial: Niels Vande Casteele (BE)
- The IBD care pathway: Daniel Hommes (US)
Scientific session 8: ECCO Fellowships and Grants

Andreas Sturm (GER)
- Fellowship 1: Bénédicte Brounais-Le Royer (CH)
- Fellowship 2: Lael Werner (GER)
- Announcement of ECCO Fellowships and Grants 2012: Andreas Sturm (GER)
- The role of proteases in IBD: Daniel Lottaz (CH)
- Best abstract: Multiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium: Isabelle Cleynen (BE)
- Best abstract: TLR4 signaling activates the WNT pathway in a mouse model of colitis-associated neoplasia: Rebeca Santaló alla (US)

Scientific session 9: Challenging Cases

Schömerich (GER), Peter Irving (UK), Manuel Barreiro (ES) and Antonino Spinelli (IT)
- Life-threatening restrictive TBC – Pericarditis affecting a Crohn’s patient while on treatment with an anti-TNF 42: Xavier Aldeguer (ES)
- The troubled journey of a young colitis patient: Shaji Sebastian (UK)
- Crohn's Disease, Anti-TNF & surgery: Paulo Kotze (BRA)
- Best abstract: Adenomas in patients with Inflammatory Bowel Disease: Increased risk of advanced neoplasia: Fiona van Schaik (NLD)
- Best abstract: Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn’s disease (CD): Catherine Reenaers (BE)
- How I manage abnormal LFTs in IBD: Maria Esteve (ES)

Saturday, February 18, 2012

Scientific session 10: Surgery in IBD

Daniel Hommes (US) and Bjorn Moun (NOR)
- Perianal CD: Bruce George (UK)
- Best abstract: Adding ciprofloxacin to adalimumab results in a higher fistula closure rate in perianal fistulizing Crohn’s disease: Peter Dewint (NLD)
- Tandem talk: Find the best timing for surgery: Sandro Ardizzone (IT) and Antonino Spinelli (IT)
- Best abstract: Risk of colectomy in patients with ulcerative colitis under thiopurine treatment: Study of prevalence and predictive factors: ENEIDA project: Alex Cañas-Ventura (ES)
- Best abstract: Long-term outcome after first intestinal resection in paediatric-onset Crohn’s disease: A population-based study: Medina Bouallit (FR)
- Managing complications: Emmanuel Tret (FR)

Scientific session 11: Where are we heading?

Antonio Lopez San Roman (ES) and Simon Travis (UK)
- Are gene hunting days over? Miles Parkes (UK)
- Best abstract: Genetic and functional evidence for a role for CYLD in Crohn’s disease: Results from a European consortium: Isabelle Cleynen (BE)
- Are stem cells ready for clinical practice? Gijs van den Brink (NLD)
- Best abstract: TNF and MDP induce epithelial-to-mesenchymal transition in human intestinal cells: Implications for the pathogenesis of Crohn’s disease-associated fistulae and the use of anti-TNF antibodies: Michael Scharl (CH)
- Are we ready to manage the microbiome? Arlette Darfeuille-Michaud (FR)
Scientific session 12: ECCO Lecture

11:50 – 12:20

Antonio Lopez San Roman (ES) and Simon Travis (UK)

- Translating evidence from clinical trials into personalised medicine: Stephen Hanauer (US)

Closing remarks:

12:20 – 12:30

Simon Travis (UK)
“Embracing diversity in IBD”

February 24-26, 2011, Dublin, Ireland

Thursday, February 24, 2011

Top tips for chairs (closed session): Geert D’Haens (NL) 10:45 – 11:15

Opening & welcome: Daniel Hommes (NL) and Colm O’Morain 12:45 – 13:00

Scientific session 1: Where are we heading? 13:00 – 14:40
Jean-Frédéric Colombel (FR) and Laurence Egan (IRE)
- Concept and importance of mucosa-associated bacteria: Arlette Darfeuille-Michaud (FR)
- Best abstract: Autophagy contributes to immune regulation through destabilization of the immunological synapse: Manon Widenberg (NL)
- Metabolic functions as sensor for the microbiome: Dirk Haller (GER)
- Best abstract: Gene expression profiling in CD8 T cells predicts disease course in Crohn’s Disease and Ulcerative Colitis: James Lee (UK)
- Stressed out! Arthur Kaser (AT)
- Best abstract: Crohn’s Disease-associated dysbiosis as a predictive factor of clinical relapse: A microbiological substudy of the GETAID-STORI cohort: Sylvie Rajca (FR)
- Microbial manipulation for IBD in practice: Eamonn Quigley (IRE)

Scientific session 2: Intestinal Healing: 2nd ECCO Pathogenesis Workshop 15:10 – 16:40
Florian Rieder (US) and Gigi Veereman (BE)
- Overview: Andreas Sturm (GER)
- Mechanisms of intestinal healing: Miquel Sans (ES)
- Measures and markers for monitoring intestinal healing: Marco Daperno (IT)
- Impact of intestinal healing on the course of IBD: Laurent Peyrin-Biroulet (FR)
- Therapeutic strategies to enhance intestinal healing: Geert D’Haens (NL)
- Best abstract: Pro-fibrogenic action of Toll-like receptor and NOD-like receptor ligands on human intestinal myofibroblasts: Florian Rieder
- Best abstract: Depth of remission may not predict outcome of UC over 2 year: Daniel Burger (UK)

Mini-session 2: ECCO Guidelines 1: The ECCO Consensus process and future prospects 16:40 – 17:00
Gert van Assche (BE)

Friday, February 25, 2011

Scientific session 3: The age of innocence: IBD in children 08:30 – 10:00
Sanja Kolaček (CRO) and Tom Øresland (NO)
- IBD in the very young - insights into pathogenesis: Frank Ruemmele (FR)
Scientific Programme
6th Congress of ECCO - Dublin

- Best abstract: Paediatric modification of the Montréal Classification for Inflammatory Bowel Disease - the Paris classification; Arie Levine (IL)
- IBD Surgery in children: indications and outcome; Paolo Lionetti (IT)
- Best abstract: Induction and maintenance Adalimumab therapy for the treatment of Moderate to Severe Crohn's Disease in children; Anne Griffiths (CAN)
- Best abstract: Bronchopulmonary manifestations in Inflammatory Bowel Diseases: a retrospective study from the GETAID; Matthieu Allez (FR)
- Management of IBD in adolescence; Robert Heuschkel (UK)

Mini-session 3: ECCO Guidelines 2: Paediatric acute severe colitis

Dan Turner (IL)

Scientific session 4: Targets in IBD: Lost and Found

Silvio Danese (IT) and Charlie Lees (UK)
- TLRs as therapeutic targets; Luke O'Neill (IRE)
- Best abstract: Phase I-II safety, immunogenicity and clinical results of TNFα-kinoid immunotherapeutic immunization in Crohn's Disease patients; Pierre Vandepapellere (FR)
- Past and future of T cell-directed therapies; Yehuda Chowers (IL)
- Best abstract: Inhibition of IL17A by Secukinumab is ineffective for Crohn's Disease; CD: Simon Travis (UK)
- Best abstract: NKG2D activation drives Th17 response in Crohn's Disease; Benjamin Patiente (FR)
- Therapeutic implications of autophagy and apoptosis; Stefan Schreiber (GER)

Guided poster session
Poster award ceremony

Scientific session 5: Optimising surgical outcomes in IBD

Johan D. Soderholm Linkoping (SWE) and Antonino Spinelli (IT)
- Nutrition and medication preparation for surgery; John Hyland
- Best abstract: Ciclosporin versus Infliximab in acute severe ulcerative colitis refractory to intravenous steroids: A randomized study; David Laharie
- Tandem Talk: Treating ileocaecal Crohn's disease: resect or medicate? Julian Panes (ES) and André D'Hoore (BE)
- Best abstract: Infliximab, Azathioprine, or Infliximab + Azathioprine for treatment of Moderate to Severe Ulcerative Colitis: the UC SUCCESS trial; Remo Panaccione (CAN)
- Best abstract: Infliximab for Severe IV steroid-refractory Ulcerative Colitis: Can Infliximab trough levels guide our management? Marc Ferrante (BE)
- Improving outcomes of pouch surgery: raising the bar; John Nicholls (UK)

Scientific session 6: Daily challenges in IBD

Hülya Özyer-Hamzaoglu (TR), Martine De Vos (BE)
- Report of the ECCO Consensus on reproduction and IBD37; Janineke van der Woude (NL)
- Best abstract: Risk of squamous and basal cell carcinomas in patients with Inflammatory Bowel Disorders exposed to thiopurines: The Caesme National Cohort Study; Laurent Peyrin-Biroulet (FR)
- Optimising conventional therapies for IBD; Peter Irving (UK)
Scientific Programme
6th Congress of ECCO - Dublin

Mini-session 6:
Hülya Över-Hanızoğlu (TR)

- Imaging in IBD: Simon Jackson (UK)

Saturday, February 26, 2012

Scientific Session 7: Challenging Cases
08:30 – 10.00 Willem
Bemelman (NL), Eugene Domenech (ES), Michael Kamm (AT), Joseph Keane (IE), Siew Ng (CN)

- Challenging Case 1: Tuberculosis: Séverine Vermeire (BE)
- Challenging Case 2: Transplantation: Elena Ricart (ES)
- Challenging Case 3: Hermann Schulze (DE)

Scientific Session 8: Cancer and IBD
Dino Tarabar
10:30 – 12.00
(RS), Gijs van den Brink (NL)

- Inflammation and Cancer: Partners in crime: Florian Greten (DE)
- Best abstract: Junctional adhesion molecule-a is a new key regulator in Colitis associated colorectal cancer: Stefania Vetrano (IT)
- Needle in a haystack: strategies to detect cancer: Ralf Kießlich (DE)
- Best abstract: Incidence of dysplasia and colorectal cancer in patients with Ulcerative Colitis included in the Spanish ENEIDA registry: Jordi Gordillo (ES)
- Best abstract: Risk factors for Inflammatory Bowel Disease associated colorectal carcinoma: Maurice Lutgens (NL)
- Extraintestinal cancer in IBD: Corey Siegel (USA)

Scientific Session 9: ECCO Lecture
Daan
12:00 – 13.10
Homes (NL), Simon Travis (UK)

- ECCO Fellowships 2010: Presentation 1: Emanuela Sala (IT)
- ECCO Fellowships 2010: Presentation 2: Caterina Strisciuglio (IT)
- Announcement of ECCO Fellowships & Grants 2011: Matthieu Allez (FR)
- Marc Lémann Lecture: Understanding clinical trials in IBD: Jean-Frédéric Colombel (FR)

Closing remarks
Daan
13.00 – 13.10
Homes (NL)
February 25-27, 2010, Prague, Czech Republic

Thursday, February 25, 2010

Opening and welcome
Petr Dite (CZ), Jean-Fred Colombel (FR) 13:00 – 13:10

Scientific Session 1: Fibrogenesis and its consequences
Franco Scaldaferri 13:00 – 14:40

(TI, Martin Zeitz (DE)
- Mechanisms of intestinal fibrogenesis: Miquel Sans (ES)
- Best abstract: Smad7 expression in T cells protects from colitis-associated colorectal cancer: Massimo Fantini (IT)
- Markers of fibrosis in practice: Is this stricture inflammatory?: Gerhard Rogler (CH)
- Best abstract: IRF-4 drives experimental colitis through direct activation of IL-17 promoter: Jonas Mudter (DE)
- Best abstract: Oxygen sensor inhibition attenuates TNF-α-induced intestinal epithelial damage by hypoxia-inducible factor (HIF)-1-dependent repression of fas-associated death domain protein (FADD): Pieter Hindryckx (BE)
- Therapeutic opportunities for modifying fibrosis: lessons from the liver: Massimo Pinzani (IT)

Scientific Session 2: Extraintestinal manifestations
15:10 – 16:50

Martin Bortlik (CZ), Republic Gerard Dijkstra (NL)
- Communication between the gut and liver: Pierre Desreumaux (FR)
- Best abstract: Modulation of gut immune homeostasis via the Toll-interacting protein: Michel H Mailard (CH)
- PSC and prognosis: Roger Chapman (UK)
- Best abstract: Genetic variants that predispose to early complications in Crohn's disease identified by re-analysing genome-wide association study data from 3 consortia: James Lee (UK)
- Best abstract: Decreased expression of ATG16L1 and IRGM results in pro-inflammatory dendritic cells: Manon Wildenberg (NL)
- Best abstract: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Walter Reinish (AT)
- When the skin causes problems in IBD: Emmanuel Laffitte (CH)

Scientific Session 3: Therapeutic opportunity: Leukocyte Trafficking
08:30 – 10:00

Maria Papp (HU), Andreas Sturm (DE)
- Mechanisms in intestinal inflammation: Jesús Rivera Nieves (USA)
- Best abstract: Phase I results of intravenous autologous bone marrow derived mesenchymal stromal cell treatment in refractory Crohn's disease: Marjolijn Duijvestein (NL)
- Policing the traffic - safety first?: Brian Feagan (CA)
Scientific Programme
5th Congress of ECCO - Prague

- Best abstract: The pharmacologic and toxicologic profile of the gastrointestinal-selective, anti-inflammatory drug vedoluzumab in cynomolgus macaques: Eric Fedyk (USA)
- Best abstract: Oral treatment using Parabacteroides distasonis components attenuates dextran sodium sulphate induced colitis by modulation of immunity and microbiota composition: Miloslav Kverka (CZ)
- Future present: Traffic control: Konstantinos Papadakis (GR)

Scientific Session 4: Endpoints and outcomes of therapy
10:30 – 12:00

Milan Lukas (CZ), Gottfried Novacek (AT)
- Predicting the course of disease: Andreas Stalimach (DE)
- Best abstract: Predictors of poor outcome in paediatric Crohn's disease: Guillaume Savoye (FR)
- Mucosal healing and its relevance: Gert van Assche (BE)
- Best abstract: Mucosal healing in Crohn's disease is associated with high infliximab trough levels: Wouter Van Moerkercke (BE)
- Future perfect-endpoints and damage scores: Laurent Peyrin-Biroulet (FR)

Guided poster session
Award ceremony

Scientific Session 5: It's not always IBD
13:30 – 15:00

Andrea Cassinotti (IT), Denis Franchimont (BE)
- Chronic granulomatous disease: Edward Loftus (USA)
- Best abstract: Clinical and biological efficacy to anti-TNF therapy relates to reciprocally modulating blood and intestinal mucosa Foxp3 expression: Zhe Li (BE)
- TB or not TB? Gerassimos Mantzaris (GR)
- Best abstract: Endoscopic response to placebo therapy in Crohn's disease: Marc Ferrante (BE)
- Best abstract: Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: Results from EXTEND: Jean-Frédéric Colombel (FR)
- Intestinal Behçet's disease: Aykut Ferhat Celik (TR)

Scientific Session 6: Safety in IBD therapy
15:30 – 17:00

Iris Dotan (IL), Zusana Zelinkova (SK)
- Immunomodulation and lymphomas: Laurent Beaugerie (FR)
- Best abstract: Liver histology of IBD patients who are treated with 6-thioguanine due to failure of conventional thiopurines: Dirk van Asseldonk (NL)
- Pregnancy: Janneke van der Woude (NL)
- Best abstract: Severe auto-immune driven arthralgia as a new side effect in anti-TNFα treated IBD patients: Wouter Van Moerkercke (BE)
- Best abstract: Long-term outcome of treatment with infliximab in paediatric Crohn's disease: a population-based study: Jean-Frédéric Colombel (FR)
- Travelling with IBD: Shomron Ben-Horin (IL)
Saturday, February 27, 2010

Scientific Session 7: Intestinal failure
08:30 – 10:00

Ana-Maria Catuneanu (RO), Miquel Gassull (ES)
- Physiology of short bowel syndrome: Palle Bekker Jeppesen (DK)
- Best abstract: Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study: Prevost Jantchou (FR)
- Managing high output stomas and enterocutaneous fistulae: Simon Gabe (UK)
- Best abstract: Effects of dietary and systemic iron on chronic ileitis targeting endoplasmic reticulum stress responses and apoptosis in the epithelium: Stefan Wagner (DE)
- Best abstract: Predictors of intestinal failure in inflammatory bowel disease: Richard Garry (NZ)
- Intestinal transplantation: Olivier Goulet (FR)

Scientific Session 8: Challenging Cases
10:00 – 11:00

Francisco (PT), Grazyna Rydzewska (PL), Severine Vermeire (BE), Alastair Windsor (UK)
- Case 1: Hide and seek - CMV in IBD: Johannes Merer (DE)
- Case 2: An unusual mediastinal complication during anti-TNF treatment: Harald Peeters (BE)
- Case 3: Severe hypoalbuminemia in a patient with long duration Crohn's disease treated with Infliximab: Catarina Andrade Fidalgo (PT)

Scientific Session 9:
Pathogenesis Workshop: Loss of response to anti-TNF monoclonal antibodies
11:30 – 12:15

Mathieu Allez (FR), Yehuda Chowers (IL)

Scientific Session 10: ECCO Lecture
12:15 – 13:00

Jean-Frederic Colombel (FR), Daan Hommes (NL)
- ECCO Fellowship 2009: The impact of anti-TNF therapy of the faecal microbiota in inflammatory bowel disease: Francesca Fava (IT)
- Announcement of ECCO Fellowships & Grants 2010: Matthieu Allez (FR)
- Science at the bench - what will impact on clinical practice? Claudio Fiocchi (USA)
- ECCO's road 2010-2012: Daan Hommes (NL)
“Unmet therapeutic needs in IBD”

February 5-7, 2009, Hamburg, Germany

Thursday, February 5, 2009

Scientific Session 1

Axel Dignass (DE), Tibor Hlavaty (SK)

- Welcome: Jean – Frederic Colombel (FR)
- IBD: An inflammatory barrier disease? (Tandem talk part 1): Pierre Michetti (CH)
- IBD: An inflammatory barrier disease? (Tandem talk part 2): Stefan Schreiber (DE)
- Best Abstract: Colonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatment: Ingrid Arijis (BE)
- Best abstract: targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits Th1 cytokine production and T-bet in inflammatory bowel disease: Antonio Di Sabatino (IT)
- The unmet therapeutic need in IBD: the Japanese perspective: Toshifumi Hibi (JP)

Scientific Session 2

Charlie Lees (UK), Giovanni Monteleone (IT)

- How do anti-inflammatory therapies work? – Back from the bedside to the bench (Tandem Talk part 1: Clinical): Julian Panes (ES)
- Best abstract: Azathioprine modulates human monocyte function via the pak-2 signalling pathway: Lu Zhou (NL)
- Best Abstract: The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6: Stefania Vetran (IT)
- Changing gut flora: aetologic & therapeutic implications (Tandem talk part1): Patricia Lepage (AT)
- Changing gut flora: aetologic & therapeutic implications (Tandem talk part2): Herbert Tilg (AT)
- Best abstract: neutrophil accumulation and bacterial clearance are delayed in patients with crohn’s disease: Buhussain Hayee (UK)
- Best abstract: Temporal stability of faecal microbiota by inter spacer rDNA bacterial profiling (15-pro): Mathijs Grasman (NL)
Friday, February 6, 2009

Scientific Session 3
08:30 – 10:30
Laurence Egan (IE), marc Lemann (FR), Markus Neurath (DE), Tomi Oresland (NO), Stefan Schreiber (DE)

- Live Endoscopy: Live Demonstration via Satellite from Kiel to Hamburg: Marco Deparno (IT), Stephan Hellmig (DE), Tanja Kühbacher (DE), Susanna Nikolaus (DE), Marcus Seeger (DE), Andrea Sturm (DE)

Scientific Session 4
11:00 – 1400
Jean-Frederic Colombel (FR), Andre van Gossum (BE)

- OMEC-ECCO consensus report: small bowel endoscopy in IBD (Part 1): Arnaud Bourreille (FR)
- OMEC-ECCO consensus report: small bowel endoscopy in IBD (Part 2): Ana Ingjatovic (UK), Chairs: Matthieu Allez (FR), Willem Remelman (NL), Lloyd Mayer (USA), Simon Travis (UK)
- Difficult cases in IBD: Yehuda Chowers (IL)
- State of the art lecture (endoscopy): Optimal endoscopic techniques in 2009: Ralf Kiesslich (DE)

Guided poster Session

Scientific Session 5
14:00 – 15:20
Elena Belousova (RU), Konstantinos Papadakis (GR)

- Immunomodulators in IBD: is there a price to pay?: Gert van Assche (BE)
- Best abstract: Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: The cesame prospective data: Laurent Beaugerie (FR)
- Best abstract: Azathioprine/biological therapy does prevent surgery but not recoperaion in smokers with crohn’s disease: Tamás Szamosi (HU)
- Stress in IBD: the overlooked villain: David Rampton (UK)
- Best abstract: Geographic distribution of inflammatory bowel disease (IBD) in France is influenced by sunlight exposure: V. Nenich (FR)
- Best abstract: Patterns and predictors of dosage increase in patients treated with adalimumab for crohn’s disease in the United States: Jingdong Chao (USA)

Scientific Session 6
15:50 – 1700
Simon Travis (UK)

- ECCO Fellowship 2008: Alessia R. Grillo (IT)
- Announcement of ECCO Fellowship & Grants 2009: Simon Travis (UK), Chairs: Jens Dahlerup (DK), Laurent Payrin-Biroulet (FR)
- The right use of diagnostics: How not to harm: patient: Edouard Louis (BE)
Scientific Programme
4th Congress of ECCO - Hamburg

- Best Abstract: Lack of usefulness of systematic determination of azathioprine (AZA) metabolites during follow-up of inflammatory bowel disease (IBD) patients under thiopurinic therapy: Final results of the metasa study. Y. Gonzalez Lama (ES)
- Best abstract: Immunosuppressive (IS) therapy impacts the results of quantiferon® and tuberculin skin in routine screening for latent tuberculosis (LTB) in patients with inflammatory bowel disease (IBD): Palov Papay (AT)

Saturday, February 7, 2009

Scientific Session 7
08:30 – 09:40

Michael Kamm (AU), Miquel Sans (ES)
- Crohn’s disease: Where it all started and where it’s all going: Lloyd Mayer (USA)
- The unmet therapeutic need in IBD: a European regulatory view: Sif Ormarsdottir (IS)
- Best abstract: Welcome: A randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn’s disease with secondary failure to infliximab: Paul Rutgeerts (BE)
- Best abstract: Clinical course and cost of care in ulcerative colitis: Markov chain analysis of a European prospective population-based cohort: Selwyn Oides (DK)

Scientific Session 8
09:40 – 11:40 Laurent
Beaumerie (FR), Geert D’Heans (BE), Sanja Kolacek (HR), Alastair Windsor (UK), Oded Zmora (IL)
- Optimizing IBD management: Case-based discussion: Limited ileoceleal crohn’s disease with a simple perianal fistula at presentation: Gianluca Sampietro (IT)
- Optimizing IBD management: Case-based discussion: Fistulizing CD: Dario Sorrentino (IT)
- Optimizing IBD management: Case-based discussion: Acute severe UC in 16 yr old female: Franck Carbonnel (FR)
- Best abstract: Laparoscopic-assisted versus open ileocolic resection for crohn’s disease: Long term results of a prospective randomized trial: E. J. Eshuis (NL)

Scientific Session 9
11:40 – 12:50
Jean-Frederic Colombel (FR), Eduard Stange (DE)
- CD Consensus update presentation (Part 1): Alex Dignass (DE)
- CD Consensus update presentation (Part 2): Gert van Assche (BE)
- CD Consensus update presentation (Part 3): James Lindsay (UK)
- ECCO lecture: The unmet therapeutic need in IBD: Michael Kamm (AU)
- Concluding remarks: Jean-Frederic Colombel (FR)
3rd Congress of ECCO

February 28 – March 1, 2008, Lyon, France

Thursday, February 28, 2008

Welcome
Miquel Gassull (ES), Jean-Frédéric Colombel (FR)

13:00 - 13:10

Scientific Session 1: Pathogenesis of IBD: What's New and What's the Relevance to Clinical Practice?

13:10 – 17:00

Stefan Schreiber (DE), Christian Mottet (CH)

- New Discoveries in IBD Genetics and insights into Therapeutic Development: Miles Parkes (UK), Severine Vermeire (BE)
- Of Mice and Men: Relevance of Animal Studies to Human Research: Fabio Cominelli (USA, Silvio Danese (IT)
- Best Abstract: Selective Influence of Tcf-4 Mediated Wnt Signaling on Intestinal Innate and Adaptive Immunity of Ileal Crohn’s Disease: Maureen Koslowski (DE)
- Defensins: What’s their Role in Crohn’s Disease? Eduard Stange (DE)

Scientific Session 1 continued: Pathogenesis of IBD: What's New and What's the Relevance to Clinical Practice?

Daan Hommes (NL), Shomron Ben-Horin (IL)

- T-Cell Co-stimulation and Therapeutic Implications: Markus Neurath (DE)
- Best Abstract: Lymphoneogenesis: A New Component In Inflammatory Bowel Disease Pathogenesis: Silvio Danese (IT)
- Best Abstract: Probiotic E. Coli (Symbioflor® 2) Treatment Mediates Antimicrobial β-Defensin (hBD-2) Synthesis and Fecal Excretion in Humans: Jan Wehkamp (DE)

Friday, February 29, 2008

Scientific Session 2: Live Endoscopy

08:30 - 12:00

Guido Tytgat (NL), Geert D’Haens (BE), Jean-Frédéric Colombel (FR), Gert de Hertogh (BE)

- Live Demonstrations via Satellite from Lille to Lyon (1): Brian Saunders (UK), Markus Neurath (DE), Gert Van Assche (BE), Jean-Marie Reimund (FR), Bernard Duclos (FR), Yoram Bouhnik (FR), Philippe Marteau (FR), Philippe Bullois, Jeanne Boizard, Vincent Maunoury
- Live Demonstrations via Satellite from Lille to Lyon (2)

Current Concepts on Cancer in Ulcerative Colitis

12:00-12:30
Guido Tytgat (NL)

Scientific Session 3 - Panel Discussion: Pathology, Radiology and Surgery in Adult and Paediatric IBD: What the Gastroenterologist Needs to Know

14:00 - 17:00

Marc Lemann (FR)
- Panel: Robert Loffler (SE)
- Panel: Gert de Hertogh (BE)
- Panel: Andre D'Hoore (BE)
- Panel: Andreas Schreyer (DE)
- Panel: Robert Heuschkel (UK)
- Case presentation 1: Longstanding UC with Dysplasia: Stephan Vavricka (CH)
- Case presentation 2: Refractory Pouchitis: Marc Ferrante (BE)
- Case presentation 3: Extensive Small Bowel in Crohn's Disease in an Adolescent: Laurent Peyrin-Biroulet (FR)
- Talk: Europe-wide perspectives, improving the lives of people with IBD: Rod Mitchell (UK)
- ECCO Fellowships & Grants: Miquel Gassull (ES), Simon Travis (UK)
- ECCO Fellowships 2007: Kostas Karmiris (GR)
- Announcement of ECCO Fellowships and Grants 2008:
- Historical Perspectives of the Management of Severe Colitis: Renzo Caprilli (IT), Miquel Gassull (ES), Simon Travis (UK)

Saturday, March 1, 2008

Scientific Session 4: Risks Associated with IBD

08:30 – 11:00

Boris Vucelic (HR), Martin Bortlik (CZ)
- Malignancy and Lymphoma in IBD: Larry Egan (UK)
- Best Abstract: Colonoscopic Surveillance in Inflammatory Bowel Disease improves Survival after Colorectal Cancer Diagnosis: Maurice Lutgens (NL)
- Best Abstract: Inflammatory Bowel Disease and Pregnancy: Preliminary Results of an European Multicenter Prospective Case-Control Study: Aurora Bortoli (IT)
- Opportunistic Infections in IBD: Diagnosis and Prevention (or if ready title should be changed into: ECCO consensus on opportunistic infections): Jean-Frédéric Colombel (FR), Jean-Francois Rahier (FR)
- Best Abstract: Long-term Efficacy of Infliximab and Colectomy-free Survival in Outpatients with Refractory Ulcerative Colitis: Marc Ferrante (BE)
- Best Abstract: Maintenance Therapy with Azathioprine (aza)/6-mercaptopurine (6-mp) in Crohn's Disease (cd) reduces the Risk of Re-operation particularly in Smokers: Pavol Papay (AT)

Scientific Session 5: Management of IBD

11:00 - 13:00

Pierre Michetti (CH), Walter Reinisch (AT)
- Complex Fistulizing Crohn's Disease: Marijana Protić (RS)
- The Evaluation of Fistulizing Perianal Crohn's Disease: André D'Hoore (BE)
- The Combined Management of Fistulizing Perianal Crohn's Disease: Remo Panaccione (CA)
- Best Abstract: Assessment of Certolizumab Pegol in the Treatment of Crohn's Disease in Patients for Whom Infliximab Treatment was not Successful: Open-Label Induction Preliminary Results from the WELCOME Study: Séverine Vermeire (BE)
- Best Abstract: Long Term Outcome and Quality of Life after Restorative Proctocolectomy in a Cohort of 955 Canadian Patients: Marco Scarpa (IT)
- Flexible Therapy in IBD: Is It Possible?: Paul Rutgeerts (BE)
- Concluding Remarks: Jean-Frédéric Colombel (FR)